var title_f34_3_34864="Palpation of popliteal fossa";
var content_f34_3_34864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the popliteal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAWEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDpFgjT5duVbnn1qleaTaXBJ8ryn/vd/wAK0mDb8IMHH3uopTGo4Y5Pc1+cqVj6txTOZk026ticN58ft96oQ4zgk7umK6maMgDBz9KoXNrDK/zABux9DW0KnQ554dPWJlAjv0p4bnFJdWskA3D5kz2piuDnacj+VbXvsckouLsycNTgeO2ahU9O9PUjrxn607EkgPFOB45zUYPHrTs1QEgJpyjcHQ/xqUP48VEDjkZp6MFZW9wfyNUroDwnwGf7P8f39ieN7ug9OGyK9n0Nv3JycGvG/Gkf/CPfFGC6UYSUxzccfeGDXsOiMuDtIK9Rj6V6ONXM4VF1SOelonHsba09SO9Qqeev41KDmuaJTJB+Ge1PU+tRA8dRTgeK1SYiYGng5qIGnKfxrREslXipFPpxUK+3AqRSc9eK0RJKDjg1ICeOahBzT1NbIhkyn3p6nP1qJTjNOGPpWsSGTA46U4Eds1Gp6frSg81qtCWSil78U1TSitESyQHPB61DqNytlpd7dtnbDC5P4qRUitgj9a5j4r3psvhxrrg4aSHy1PvkVpBCR8vWbM8YYn5izEn/AIEauJI6t8pOR3xVS2wiEHoCf510PhuTwiI9/ii61Au3Agt7cOF992evtSfmguV7XVLi3YmOYqfcCuj0zxddRAb23gHrj/61W7b4cWXiOH7T4G8SQXwXJNrehbeUewXkntXO3umXfh6/Nrrdo1vcKA2w9GB5BHrS+rwqbWZoqjR6XoXjyQNGvmyJ0GFUf4V6Bo/ii1vLu3s2cPdzxmRVTk7RwWbjpmvnGyuDc3ZaNQi5wAK9S+EVubjx1rV63KWdsbVD1xuXdV0sPyNtPQyqzv01PYcckelKM4PvTFpw9c10pGI9Tmg9P8KaPeo7q4itIGnuZFiiHc9z6D1NUIkc7Y5WXgqmQfxFfOb3rf2jdSSPuJmf5ux+avRvE/i2W/WS2sQYbQ5VmyQ0gz39K851CzDMQgGQM8HqKmUk1ymsI23LP9ox/wDPOP8AM0Vi/Z1/vSUVPIyj3vZ0bOM0xiARtw2T6U6YNgjIAzuxjr7Uh4jBVNp9DX5tc+wsNCIf7wGabKqnghceuKmfcIwWGB7VCWDcDBA6g96pMViq6s6MuzjpnPaqM9gpy0fDegrXcMQMLgY79qikiyMglW9PWrjOxMoKSsznJA0TgSKVIp6nAGcVt3NuJI/nUNWRNbNGCUBZRzzW8alziqYdx1Wo0HjFPB9etQb8kjuDTwTjng1qmcxKDz1pajByeBTgRzjrVIR5h8cbAvY2GpRr80T+W59BgY/lXS/DfUPt+hWcpIL7Ar/XJq5470/+1PCmo24GZDGHQ+hXJ/pXA/BLUfmuLFj91hIM/Q16cf3mE84v8GYP3anqeyofbFSrx3qBCCFqQGuRMtkw5xinDpUanHHanLxg1tF3JJc9xTx29aiU59BTwRzWqIZKpqQHpUIOPTFPQnFaxJZMp4608dajXr9aep555HvWsWQyQVIMYqMEU9SPoK0juQPFPByKjByKcp9egrYRKD3pw9e1M96XJzmtIkEleaftDXpt/Alrbj711dNH+Sg16Uo3Ngc84rwv4/8AiDTr++07SoLgTGwkMk4jI4cqBtz+VaR3A8nlby7csTjdwvvVa2NoYJzcq7XB/wBWytgD6+tSnF1KN2Ao4VfQUurWsVtaK6S4lJxsz2rVRcthPsVrLVLjTruK6sJDb3UJDK8fy5x64r2fx7rg8Z/DTSPENz/yEreV7eY+rBce/HIrwbJ610+k6vcSaAmkEYtluGnY/wB4sAP6VasncT8jp/DcKi6gVh/Fk/ka9i+B0GPD+pagwOb25DZ9QFK145pEv2e1ubk/8sYwwPvnH9a+gvhjYnTvh9okDjDmIu+fUsT/ACNTD4Uu7/L/AIcie51K9KUU1etUNa1my0a3829fLHAWJT8zf4VpsTvsaLukcMkszbIowWZz0AxXkniXxC+t6sSATZIT9njA7Z+8ffirPinxRcasqwBTb2QblBgl/wDeI6iseNo1j8xdvoSOKzm29EawjbVkkdvvLKxGQOR/9eiSyhKh1fa2CCOuau2C2w3NdM2CPkjQ4LD1zTNRdbv5YlWIr90IMce/rUxj3KbsZX2Mf88l/wC+qKk8ub+61FXyCueov8wUbdxzyKjlUEZIIHXNXCvORx3+bjAquzFGYFchjxX5sfYojT5487Tj3qBo9r5bg9aus2RhAuT15qNos8qQCRjI5pXAgJJAKcYOCTTdzAHOwY9OgqUDad5O0/3e1VrlJYzuj25PBAPaq5gsI8qhcsyAHjnrUDMpUkhV56nvUgKeUEZCG5zkdah8xQ4Rhsz0zVxkLlKV3apKx2naSM7uxqg7GGQK4OT0PatUsUmICKARkHPDCqtxtmTZKjFT0IFawq9zmq0FLUrrICc54qQMSPbtVWaKS1A43xDqe/409X+UMOQea3jI4ZRcXZk0qrLC8bjO5WX8wR/WvDPCZbQfiRLZHgGZoT275Fe5owJGT3rxH4iQ/wBk/EmO7XgTMk/HucGvVy9qXPTfVHNW0tLse6QtlAR3GanUjBrN0qbzbCBx3RT+gq+vTNcyfQpkoI9DT1PrUQOOT0pysp71pFkk4OD/AEp/0qFeOtPHFbIhsmUnFSLxyKgUmpQa1iSyX2xT1PPoKjXkU5TjHtWyMyUH0qRT71Ep96eCMjitY2JJgc/WnCo1P0NPBrVEskGOgpw6VH1HWnKePetESc18T9cufDngPUtRsTtuRshRv7u8lSa+RvtcrTtLM5mZjli5J3H3r6u+L76b/wAK91GDV7nyVnKeQoGWkdSSAo784zXy3qdnBYw26eaJLl0DyqOkZP8ACfet4LQBt1PF8klqSueqnqp/wpsKz6jMkUSNNcSHaqjkmqFer/Bfw8v24axqChY9rLAjgfP6sPpWsVzOyIm1FXMm9+F2tWmlG9ZoZSi7pIUyWQe/5VzumJwCM/N2r6P8PRX0txf/ANpMGjkLLGnUKvf8wa8Kv4Iotd1CKLGyOdlXA7cVvXhCEbxMqc5T3NO0gabT1tk5a8lWDA+oP9K+prKJbeyt4FACxxIBj/dFfOngeCKbxZ4cguJEjgjnFzK7nCquCOa9o1TxUsWVsEI7CaQEZA4ynY1zOSja/Yqzk9DW8Tam+kaPLPAqPdsMQIT1PrXlkOtS39yF1TdHfuuJGk6HjoPYVavp576UPdXLy3C5K7jjg+orkPEPiQaZdpYNY+dJLtYM+Vx3O0jrU83PsjVR5UdetttIC5kxwfQ/Sqs2noWLIfJGMYTqT71pWrefZ2+dylow4Djae/B96fC/lTJOV3Mv8JHehSaAzbOCa3Qz3hZ7EcK/+12FTTFionhUFPTtirt/dtektckMMYCgYA/Cs+1jkt3zuJhb/lmapagyH7enotFX9w/59R+VFMLHpJ2hSTnj25qMZ3lmA6gAegpxkO9mKERqOTnPNPhIJboox82e9fmh9gRBcsxCgEfeH+FRbyo2J948jj+fpUzqWdgCBwNuep/GmgtGPmQsSTj3pFIryxiQr5nrzg9qhnVVRiWMb9fXmppkkwEOFDeg5qFdkszhwSc9T0P4UyvMpySokRZzuQ8cDkVXlSW4i/cqrL1XJ/rWhPDGq7VBwTyOv1qmkbpuUZGTkY4pJ2ZJnlx5R3A56MM85qKU4GYyqyLx874BPtV+aFWYMSBzu+hqre2aTcuPbPXB9apSHuVXumnBVl3kclj8o/8Ar1BK4ji8xBmPoVHODVCaBrS4kDySFWI25yQKR7hlUhMZUHcBxu/Ct4zdzCpRUlqaEEu9FKsCcdBXlvxtg/0vS7wddnlkg+gBruldiglSNo1x03jkVyXxVC3nhq3dEO+K4JxnJxtAr1cuqcteJ5eKouMGdl4IvRc+H7VuSRGB+lbqTq928JJxGBx7muA+FV1nRI4iTlVxzx2rodXlNnrENwc+VcDnHQEcVGKi1KUV3NcCoyqR5jppUaOAuhJXPII6VWWQqwIYZq1p92skaq5BznrV82sM6j5Ap9VGK5efbyOyvgm23EqwzI6jnmpwc4qGbTGQ/ISPQ9c1Aba8jXhSR9a64Ym3xHnVMJNbGgtPB/WqMLXfAMDGrsMV03JtyPqa66eJpvqc7ozWyJgcH3p4Peq07TQAl4GwO4OaqDVkBwUI9jWyxNJdTKVKa3RsKT37U9e1ULbUIZe+PYmrqsDjac/jXVTnGavFmUk47kwOM+9OB9KYPT/Ip3A+lbxM2SZqnr2sWPh7SJtV1eQpZw46DJdj0UfXpViSWOC3muLmVYreFDJJK7ABVHU8/XpXzN8RvFd58QfE8dlpUco0+I+XbwDnPJy5x19fYVpHu9hblLxDrWufErxQzxDcI0YwwkhUhjUZye2cd65AohZvMfeSfvbuvvX1T8NvBlv4S0fZIiS30wImcqec/wAP09qzvE3wk8N6uGkskOmTtk5jJ8sHH90VpSlzq+y6BKy0Pmu12280cyYZ423AMMg49RXoulfEK2ubuyfXrQxtbDCzWxIAHp5YOKh8TfCPX9HDS2jR6laqCTJEChAz6Gs/QPAGoXaLc6kxsrbJ4Kks3twOK2c3S1bIcVU0O7HxK/4k08Nmz6jrVwzrCI4sCOI8LnB64rC0HwZdSFZ9ZkSNXO5lVwxY+/oeOlWrfS9QsNtnoOlpYxudr3UuJJGHc7hyK7nTdL8iJYQXmKdXY7mb3rnq4iU1ZFU6SgQ6TYWliES3tlDgYWRjuwPTB61PNFIxXJBkQ9e2Pp2q4EySpxkdx6UxFDtuLYzweKzUerLvYqLbRq7b8nIzgHv9aim0a1vL2G5u4BKsYwnOCjY4PvzWz5I4O0Ar1BGdwqZQsikhcJ3raKtqK5RsT9pP2W5dUuIvuyH5QB61aMFggc3Ny7ekSp1/4F2qq8W69EbqpLKBkjt2p0SC2mCTKH3fdbt9Kvl7E3K+oT2cbs+Fs4B91XfJPuM9amWNCoZMtuX731HXFYes+E7PVJ3e4nuhKMmMmQlFPptx710EMZ+zQ7DtKKI2I74GKq1thXuVPsb+p/Oir3l/7Rop6BZnblSRsJ2EHj3pwUH5lbI6D39aROjbg33gF/LrTwgCMMDPfHSvzWx9gmNWPa+GG8EdDQ8jRkM4URZ4yKc5K4AXOMdadIrNuHCYHHoaB31Ks6ytGWKruToFqJ1aNsCMbmI5NWGBVcbFYkfdaoJt8rFQoVlPOe/0pFojTG75gcg9+9VLmTy8lCNrHGT0+lSGFXicsxZs/K/pVd4wSilF3ck7u4qHdj8yExr5rbQjNjovpUMse1j5THDDOG6fjUscUiO7R7RGx+7np9KbIDul8tmjD9aED1MbUY7nyHGzzI0GSqdh7VmR2MsiMZEBITKnHOCOh966B4pUj3RsyrjofX1qK3k8uHdtG0nLZ9utaRm0rBymE1nJHAN/Pyjp2H+NYerWLNEySxyFG5OOg967q7CuiPEh2SAEnHFVJ7eGSM7x8uOeOhranVcJXM5Q5lqeeaI39l3GIyzR9x6V1U4h1bTmijkJckNGQejjoPzrP1PRleV2VQG6giqdnI9hKAWJA6r613+0VT3k9TinRcHeJpaFqpjHkXR2TRsVYHsfWu/0rVoDEVyjHbwPWvPNS06LVkF1aTLa32MLIThWA7NWNFq91o9x5epo0RzhXJOx/cH0pxpc75ofcdsMVGpHlnoz2+3ni+zIW5b1qwj20keXXLDpnsa4HRPECXMKfvDjjvXTW13HKMoAeOT601DWzIqXua0l1HCAEI3nmpbeUzElyDgZwKwNVzHatNEct1I9qh0zUzcxrtYooAye9P2epK96J0ysshyASTxgdqqajo8FxyeJj/c+9S29wBtTlQR+VaNsy42qOe49ar2ZjUSRxl3o17bkskTSp6r1FQwXtxathkbHuK70whyd7Biex6CopbdCrAxqVHsOacYSi7xdjklTjI5611iGRSHbawOPSryXsLnCuMketLdaHZzlQ0ChyOo61gan4avDbXSaXfG3mOUjkY4KHFdsMZVjpJJnPLB3+E8v+N/jdtSu18NaDJ5lrGdty8YyZpM8KCO2McetdZ8HfAi6DZrqWpLnUZlOA38C4GAOfrWDonwsn0LUf7SurqK7lTLIDg4P9489a7eCO8uw080riJvlVRxn1rpq46m5cq1S/EUMvrNbWOjv9Zt7MNvkQsKx5PE090hFnbBAP4nHP1FJHo8CqGMf7wnr6YqxJZx4xFtXA5NYVMfUl8Gn5nVSy6nDWpr+RgXttqt5ExW8ZS3VB0P6dKltQQArcgDBx6+tdAFYJ5aEFsYJP9KoXECpc+YT8soxz0Hanh6spTtN3uZ4rDxULwVrFeOIbcKO+TT0le1lSSIYI7nuP/1VKy4bHQDg/wBKcsQbgAZHQGvVjHoeU2QMPMYmFP3atlQeuPerV3axkJc24xFJjco6IemKYinB5wFGdvqtWIpvLtpoAoML/MC38LdiKpRsIgjwGUNxngZqHUraaW1mhtpXgnI3Iy8HjkipYo2O11PzKchz1zWpeKtzELoHa3CSKOxHAb8TWydmSzlfD1pcLp8k91cSzX+8kCQ5IXsBVyZDcR/O4jBOUHcGr8pCD5lxIh2v23e9V5VUTfdUMxyGPar8xFeGbzYiWURyDhs/ep0gdA0gyCcbgep+lPgtJnuTdW8ZkU/LJKfuIfUn0qa88mO2kELie4bjzR9xR32n3p3QjP8AtDf7X50VX+x/7bfpRV2iTqekIQGQ43D1qVG/dknIHPA5qpHtLGLJUEcHtipBLtGNpx/M1+Yn2aRPK4VAcnA29vWpJc7cqR7D1qKRv3YYkEEc+1JHnYqK4Zev0oKQlxn5OSAe46ioWgYquXJftxjmpZZcRN3cHAGOpplw7NGFj4KkHntUNFJXIWjSPPUhuox0qCaPZ86Hn1xnAq4PuEv94DP1qEnzEG0fMeStLlHcz5UKupHMe3BAP61VmwFBRs8f5zU98eVB3Kjccd6hlhZbMJDjJbaM9aSRSHRzpNEP7g9uc+9Z7HZNJDLnY4+UqvT1qxEkyxEbRkkdsZqaCAM7bx0weveqK0RQj03EG5XckHIB6U1opI4z+5DOB0z0HrWzFGRuBlyG4xjGKieFRHIo35C4znr+NWkS2cxqYjit2uZ8QxoeSf4vYep9qxltG1CQNbWYWLHMkx2MfoK1ks38Qa1J5jbra0bbHGR8pPJya61tMErBZSUcADCnjFdMUoLuzJ6nms2h3UBLWxUr6B87fwrPllkibbqADoeDvUHP59K9blsoIIjleR1GcE1i6lpFvdoWSMMWydpGeMfpWsajMZUkzh7TQrS4RZ9PuGspiMkR/OP16Vajk1nSh84E6D+OJtxP1AqVtDntZFmsyyY5aNqtadqRnkeKT91IvGDxmuhVn11RzSdSl6FrTtea9tvs9xGUmY/xZ5FS20qwTlVbjP8AWoLi1W5QgAJKvzIw46dvxqNSVVXYY/vexrS6eqOqjUjNXR2dsSyAlhwMVqWc5QnJ6DrXM6VdYTa3rWmr7ZQV5VvU1rFXFON9DorZyXLE5B6Z4q2FD7gF54xmsqyYtjB4PStm0OwnbgkcnPatlG5yyVtypdq0e1B99uSfSq1vErRS7jk7936VqSRhlMj9WJP4VWiiBTavVuSfek4jjLoZ0lsrMyMud1RLpoZAq8BTwBittos3AO3HGOKckfLhe/Ss+Q15zGNgx2lDnHJ4FVHtgjuH9c8Cumjt8OCOnqTilFnGG3kZJ6g1rGlzbGcptbnM/ZWAlEQ3KejAZxUzaMs0RRsbGHysOdrV0aKqx7V2rjnAGKaqqwIiVsHpitI0lF3ZLqcyskcDJDsLZAEkeVYZ69gagUljnGSn8q6fxDpjBPtiYBGBIgOcjsfwrl5VdZRJEQF6+u4f0r1qMueJ4tan7OVuhMwzh0UHHXmmvtyF2lu4zwBTkkRWypOxx6dKqawbtdPmNiyrMvzDcu7jjjFbqN3YxZaDOpI2n1xjGKkgkkjWTZjEowwPcf0rivCt/fQ37krLcw3A/es2flYdMeldjCkW8m6nNvGOuBuJ9q05baMi9yTcJYhFEpllQYKKNzNUUlpIsyQTlS2eApzt/H1p51A27+VZRCCHorE7nPvu6iqkmRkyMwRjuU5+b8e9NXC4839zeQtHJceYsfyOqKF+nAqmWWKMqRgEjnPSoJ1Ef72DK9nQd/eql9dfuTk5Xgg4x+FVy9hXRrYH99PzorlP7WX/AJ4/rRRysOZHrAIbAJOCflB6VaVShDM2ecVRhmJjIPIHQ+lWSWaIbDhgRlj6V+ZH2XkFz/x9L02c8GnQlVJ2rtwMjHSmjEgyT0HbvSqwRfnyABzQl3LWxO0eVOTuY85Bpv8Ayxkzg5GM+tMKFFRc/Kx2qD0ApJXUQHoBg9O3vUsEQyPjJD5U4GD/AA1HbvlDnLMSRkHtUbskj7WJYspHHTFVbR2gBt1BzklWHTHvSLsGoiTa4bc0SfMuD0PpSFyWRxhflwN/IBp5nRmaGUHcRnPaq13+8tS0av8AMM8dvely31GVpJzHLJh2kjXjP1qS1u91wVGXwARiprS2dIsqVxjgmrFlaL5rSbEVcdurGqUWNyRYt4dwZ3zwc7WOakmgBQ7Cwz2z0NTqAgDf3uTViFBJjZtGa2SM2zL0PSBp0TQM+6TduLKCDW0lsNhaP5ufvHtSWuBu5DHv9anjf5SGbHs3U1qo3Zk2Z01oZnxJtPXnFVmt/KUgDGRjIrdKqI9zbdv+1VC4tmljOSFJPBXpitEieYwHgjaQxsWaXPIzx+NYPiDRUuJfkURzdVdfXtmu58hFjXCYJOAfSql9aDDER4JHT1961jEm6Z5zbTTJOlre4jlBwGHG7FWrhSJJUcfKxPPvWprOhR3kI4Mc6sGWReq81jWjSLLJb30m6QH5Sf4uetOL5XqaUYRSdixp0hikCyHAHeuhtZV2gMfm7Guemi8mTkjBOQatWVw0YUNk9s13RM5S6nZWMnHyntWnBIMgR5wevvXO2NwJHCgHp1rXgl8vgE9eneuhI5+a+h0JI8gEAYxgCoBGEeIoMgfNmq9tdvcMFX7qHp71ptEDEAOuOTWjipaozu4bkMpZAuwA8/N608oA25QcEdKmijVrdhIcN1U+9QrJtYJuJf8AkKTS6k3d9BJnJX7oGO9RxGSZyuVB/nUksHzZkLMPbtUQZd4EQYMB0Hemotg5W3HiKGIfOSzE5K96crzum2NFiT2+8alhRfJLAYHv1PtSMu0hnVK2jBLVIy5r6FaS2j2MGyS42kk5+tcTqdgbS5aFvkixuVj0I7D613ksqBTwAfX1rE1yBLyxZQNsy5ZH98c1vSbT1MqsOePmcfhFDKMhW6ZOcGonby/m3e2f61BcNcGMtZmP7Rv27J84HsMVn32qXWnWz3Goac0kKD5jb9D9M13pX2PNfZmlCxhj8q3QRxcnPYZ608PEyFWOSR19KrxzSXvkiJGG5A+JeiKRnJqZoLOF8Iy3dx1Of9SR7d6pLuT6CpKksRibqnAPr71DNJkZcjenBz3qK5eWT94ZhF5f3UT7oHpVZpJZHJjhlkPTcuMVaiTcklkJGXZYoj1yMk/SuevJCkUkcbh42OVPc1d1CO8DgSK0DPwpk/8ArVkXjW9tE2bgzSj7zk/IvsO+a0iiSnuPpLRUH9qr/t0VXKO67HuUDbZCR3HPvSST7clOT6DvUUHCu27OBj6UW7FpdrAYWvys+0WhOkvyhlwCx6579xVxSFB4xzz7VnZVCFQDhskE1cklYKWTBU9R3pjTuJM5kysTfMfu4qJrTYrKZWZWGSx7U5CXctGRjG1eKdLKVBLDG77wx0pWLUmtCtHElvKBGDsIJzTLhCkYlxxnPFWDJvT5hkYIOPSmNIrAIoJUD5h/Kk10Ku9ysSGfe4BOwYI7mpooxGgCjGRwevNK67kX5flU9u9EcgZMMCMDAHc0xX0FgjEKSbVG08gE8D1psDqZF3/eHb0FOYLIS4GUPBXdiqcyRRuVVX5BPBPb3poReiuVNwdwwOzVeQhk35OcdDxWNb4W2HPzPjaMckVpxy8YYY2nGfat4ol73NFJRhdo+vHT2FWY3yWJXJ/hBHFZ8BXzH2nK98nH5Vdj4wykhfetkiGSHdGu7Cknkljx+FRKwOSO4zxzTiWd3DdCBhv/AK1RsoXcFb7o6AdKtLuSkmMl2/MV+Zx1qjIWER2qxOD+Aq0DlAR1J5B4xRIdgGcAt0rZRJcTPMSnkgLkDg9aw9U0yO8YoUCsBuBHbiuju4g6Dbx3Y+uKzbotIArZHYdvzquRPRi1WqOJlmltCbW+C7f4Js8fjT4icLuycjINXbq5t5dTudKvcSRpFnzAOjZxisaNXsbvyJ8mJ+YWBzkZpq9PR7D+NabnRWV35YODzWtBqO4qoB3N39BXJRTFJCWxuPABNaMM3luNnzynrjoK6oybWoRpJM7KyulQAKTweK2be8aVAm7GPSuVsIWdd03BJz6VrWgVGwvJ781Sm0tBuEXudDAzONvzBR3xT3Qb98K5YdxUETbUUL1zzk1KJWzkH8hVxXU5pK70LMzxyWhcsA6du9VYmG3zMYf0AqO7CW2LgtlT95QOtNjnHyzMpCnt7V0K1jBxbJBI8ku5l2L2X3pLhnYY5zRNIM5B4qKS4BGRyfpitEyeSxXlWTYcEqQe3OaqzZx8/JPrU9xeAITJx7YrFub/AMwMEJHuQeKpJjZk6/ZiCR7iMkxTcOF/hP8AernLyBr68sYZiBbxsLh+erKcBT9RWn4p8VWNhCbcS+dMRt2IM8++K5/w3qzanbyGVNt5HkDdwGXrnHrXbTqJWUt2ebiaevMjpSse05/doOR2I9Kz541nYCMkL1BHUVWmjmdWYy5B6gc4+prMknunby4mGwenr9a6ox8zjbNOS1SOXzlmPmA5Pp+NV7xyh3yXnmbuSeBj8qy1u57eRzfYaBhhscFR68da5nXXla4NvZP5wYbhLuwoXPT61dlFc03ZCWrsixrevJbho4H89yeFDEnPv6ViCC5vT5t47RhsfIDzV3S9J3yAQRCa4J656V6P4Y8CvJIk+pDIHO3dn09q86eMqVnyYZadzo9lGC5qv3Hl39lRf3JKK+hv+Eb07/ngP8/hRU/VsX/z8ZP1ij/IU3fy58dVJ59MVJHxH5jtgk9Qe1Vrh/8ARdw6odxPtUkLBYlBGVxk18Bax9huWbbHmMWBAOBzUyx7CzBvkJwfaqu8pE3BzkEY7ipopPMjIJ68+9NXYFiTiP8AdcAjCkDpSuCwZWfOVx0qBZWIKjaSvQ4psMjuo3YXPpTsNE6/u+d2AB07VXuiGUGNir9gOuKmkXK9T7c1WuNsW1mGc8BvSlbUpDw/lx5kJBU8nPBpHyI9+doB61EQLhFAHfkj+dDFkgO5gQxwM0boZJCxwxxnJDY9qq3kxRQ2dztuXA4xmpy5ilVDna3f+7Vacp9o27RjPAHc+tUuwXRbs1YohBG5F28jPPSpAZFKq/JXqAeh96jtY5EbDEqxYnK1pJEigNgFieW75reKRmySDaVUkbQPWrKy4Kg8kA8VXQb5NzZOxSCOxqdWXJdwdg6D1NbxM2TKZTJuLBfT2/xqwkYMe5R1+ZifWq0CtIA8iHPO0DtVtfMVMqylR971b2reKJbsVpU3SeXs+YDJNVxtDBGUscHGe1XIo2ciT7kjcEjgGqk4ZZCzAhiwye2K0SBNNlG/AgkEjuwUcEDvmud1rWLe0cW6O0k8nAUDdsz0J+v6VpXa61fTTRxpBbWrcNMynzCP9k0210GKyU/Z90khGWml5c+2atRtqZSdzG0vRkhVp7kYmf8AebWOfzqS+s4b63Nuz7COFccFT61fnk3hBIjIT1z3Hp9ai+zxmV5NxOzr9aJ+8KPumRpkaoz2t1H+/Tjc3Vh61cWPyJY1VQCSc+tV9ZguJo47yIbZYTlNv8Qz0pdL1eG/UzSLslT5TnGM96y9o4rlkdCfNqdRaMdu1uT0rTsoljOT36Vjae24KdwK+3ety2YEAdDjg1vFtjloaUZGQO9LI/lrncAPYVXSTbuJPTvWbeaguSpfap9+tdUGc0omkzq2TK4ZeoFUGvdkhUncvY57ViT3ksYLBjs6Asawda8Q/YoSZSgA5yDzW8KbkxNxWh6Ab2NYSXxuHuKyrzxDbRWxaR0UA45YD+teWP4m1bU4l+xwCGE/8tXHX6cVXg0ibULnFxNNc5/hJyoNOVelTdt35HJOSN/WfGYmcpYxSTvzjHArEJ1nUQEeZlDdoxtI/HFdfpnhgIi+b06AdhXR2emW1tyqLx7VrGlXq/3F+JxTxSWiOE0fwYdweUZYnO5gd34nFdbY+G7eFQGHbG4ZyK3VwOgx9KXdzz+ddlLCU6b5rXfc4p1py3Z51r1nPo90Y7p82z5MbIMbh7muauNUEl0trp0Ek07cKkY3D8xnFex6lZW+pWEtneLuhkUjjqp9R71V8O6Fp/h61EWmw/PjDTvzI31Oa7U1YxbPFdY0zVI5lGsK8O77sS9fxIFa3h/wtd6kVxGYIOD0I4/KvWtQ0u2v5EMyA7TkE1fghjhjCRqABXHWwbr1OapL3exssRyRtFa9zI0Hw7aaVCu2NS5HJx14rb6LgDA9qM+9ISM+9dsIRgrRVkczfM7sPxopMiiruKxyMJ3QbvvBu3qKWF/kZTyAO9VbFwIij5zj8qkZh5mR3/UV+WXufek6lpmUKDsFWTK4dVQ/j6VVtZdkhTsf0qZiY5A6HjPIpXuBcVMHjg57U0yFZFwPlA5xTY5RuJHIB6ZpigGQZY5PXFNMC0jBoNw46/jUEoMqgbvmPTH604qVnTn90QQw9+1JsHmv1woGCKFtYa0IC6w8Zw7dPakuXYhdp4Azx61OQjZXGccZxTY4AZWbJJxg+lPQrzFG1nUnpjOfeokRWLgIc9gf1qdkRSVxgDnIpLJlmdtq5QHhjx9auL1J2RNpsKRE4OWrT4yxONvvVSOH5hjIXPT1q2sZztIBHfmtoqyIb6iwAldw+XdUi4JOMcUpxt5cYxggUkaKYiWzleff2raKIZaWQRbZGbanAwOoqyHtj/Gp7nnnNZqRq4DuzSHH3QOlWYVUgeWoUkY9T+I7V0QMZ7k4fDoJl3MeVA7VBeSZjd1XkdB6097Z44xhyEYZAP8AjVWWZnhxGDnODuGM1skRcihkLBcg+6kc0sykBudq8g0kKxhSzMWlbg8dKVINxJLHAB61SBsxbiMSKEB467vSnSWpNttZc5HQdWNPaOPzoZWzuB2hfX61eikV16HcBzx0pbsTZj/ZZJECP0/u1xXiSxk0m6W6tA2HOHA7fSvUmj+YMMY7VmajYJc7vNVSWHIrKcb6GsJuLuYXhy+aaIAHeOpXPzCushkRow2QOOlea6na3Wiz+ZayYts8YP3Pauj8O6xNfxbXdWdR06E0UJ2917nRNprmR0OoXrRW/XPp6msxIRLlnkZJCMkjtUN2Wvr6K3hztA3OTx0pdbuksYDHH8pXqetepThzHnVaz5rRMHxLqA062ZmnjwB0J+YnHSuNhtZb+UXWqEkdY7c9F9z78U3Mms6s1zc5a1gOEB6O3/1q1Ml3A/iJ4rmxeJs/ZU/mZSk2WrG1e9ukiQcE4JAHFd5pOmQ2MKgKC/riqXhnThZW29wPMfn9K3Afzr0MvwipR55LVnmV6rm7X0Jc+mPxpR696jBp2TXpo5GOzSjmm5980o/yfWrQh+cdqd24qMH1p2Tjg1aIY8U9TnqKjFOzjvWiJeopOG6npSUhNISOnemSLkUUzNFHMgscHazAqBjJ24NWomUquOSDz9K5uG42SFWPQfmK1rKfDk7gVPH51+WuLR99Y0o3Tzd3pkVbkbEGVAyKzoZFNwyPjawwKtRH5WVj8pO0k+3eptcLWLcRUMABt3cmmRAwsMHocetJljICDgjv61MQJAuOMc8VQiZXLMRjGRxzTnLEIARnPzD0qIDERXocHBqSNGCgsO3NCQDnAXOFB55OetTwgRpluNxznNQFgnzPkYOfwqTdHIP3ZJz3NWkNvuNmjWUAKTnvjiltwY5cqoVDx09PapomVdygqWPX1qTZmT5shcdPWtFEm5NFkvuLAke1SAHzck4U8CoY2zztAOO3GBSLIJERF4ycfWtVqyCaRC2woowW57CluN5CFASAwDDp1pFMgkCOvyN0FWXYNGQQ2MjH+NaxSIlKxJCoAJQgY6jPIpTeoH2omXYYA6EmqlzBKRvQEPwCx6NUlrBJHIZWTLjo7HNbwu9DN23NNHGwbl3NjpngVVnlZ8LHHg5weKZJOIgRjbu+XGOTTDeKmYwW3E8KecVumluzJ7kflhZCdwyRz7U+4T5V2E4I6etSW8SeaTI2SeoAqxLGBJtHLMMAelVZCuYWshf7N87y+R90qeTT9IVHsDMxOX6+o9qlukCbw/DI+dvYCktkME0iY/cj5g3cVDWpfQsBdyHacpweR+lVrleGx0A7+9X8fuPlIKZ+X/GoGBMZVsn+tXy3VwUzBltUkhdJFDKRznvXD67o0+nMbzT5HGG+ZVz09a9MS3CREydM81RksmnN2g/1iksmehHpWModivaOLOG8Ka/JbRTy3gV3c/eyFK8elct8RPFPmxPb2jZaQYOOuOc966PxFoRYN9mBjlYED0bnnNeVavYXFpdOl1G0c3Qlu456V3YOrryyOLEx5U5R6jtA1+9sQsDKJrdeq8A/nXd+HddspbqKXIJU/NG5x+RPWvMVkERCqflJ60/zl3g9GHII613yy6nVfPDR/wBdDxXi50nyy1R9L2Oo214gaBxngbSeelXlJr5y0rxJeWMqg4kUEEHjd+del+HvHHm2yNcBXiwQWAGVOO9aurOhpiFbzW3/AABwcKv8J/LqeihueKcDmqtvOs0Ec0Z3I4yCPSpck11xs1dEPzJd3OKXPGc1EDTgeeatIklzzS9utRBiSacD39KtIlsnBFL16VED6U7JHQVaJaH596aTwfSm5qOeVYraeZ2ASGJpWJOOFGapInclyKK8v/4W1oP96f8A7+LRRobewZjzz4TzV4OMGtS0uAH3I2VkAOfTArnWk3ZQ8A9f8avW0u1QC3AGPavzedPQ+1jPpc6eObBAyS3UHNadvPvXkcAdO9cjHKwZST0Oc561uWc6kYBwTzXM48uxe5swne2PusBVpZFwGAIAGCBWVC4+Ug4Ze/rVgTqx29MilYLGmGTaQOOOv1pY2wAjZDD171RZsjIzkEcVIzDKsOMdauwkjQGGGxgP60+PdGrjILn171TWTaAVPBqbzQiZPYZqrWJZMrhmChMn07UI0jISzE4bAJ7CoxON464PfHSptwQkocg9VrSOoi0IlKgDLZ5yal2gSKcZHXjsPaqVg7RybCSVJJyf5VdbYT5vJ2/wjqRWqRLJ5kC4Zl5UjHrU/CbBkbzyMVR3ubsEgrGoyPc+lXbRN0kskmD/AEFXFMxexcWLKDGC7HnNQ3MEqAbmJi74qRZQOFGfYfpVGaXzywO7n72OmfrW0WRZkLuJrptrkhTge59qtWVkw38jc3Bc9aZpkeV3CNN4GBzyfrWtHCsAxt5UZznqa2h3ZL7EcCAQ4AKlQc56mnLF5zL8uSiBlz+tSgbssP8AVkZ54GfSk8oQsFk3BJxlRjoetVqQ2YOqxPPMptyVEv3Sehb/APVViJGYTK6sjj+EfSrEqHEnyl1U7iAOSPan2+6dllDAODtG7jI9DRbUfNoVYnkCFJOXTjj3qSGLbJlCShHIPY1PdWjSpI64EqDBC9SD2qCKOcxiW1LswwCAOmKpCuOFujrIAR9O31qmkYMsuW24+6f6mpXmnQu4iJDD94p4b/eAqOSRfLLqGeN1yvHLLmoegGL4gs1ykuwGGRgjLjhWPQ1yXinwrBqNkXaMMowNwHzL7ivSNUTMD4yY5k81SwxhxgBaoWUIk0+Nj3yrA+tRb3hp6anyz4s0G90oGVXaa2zjzlHK+zVz0N9uYJK2D/ePQ19Oa1oKubgIgKsDujZRhxg14r4z8DTW8AvtIhaeDkSQbRvjwMnAHJFetg8c01Cr9552LwMWuaBzKscgjrXVeE3b+x5w2eWOPyrgobgxlByR/L6123g6ZpNOuMHKBgB+IrszKfPh38jzsJTdOqe8+H5N+h2ZPUrjj8K0wSPSuZ8FTs+iRBzyrMAPbiuiUjAIz+Na4WXNRi/IKitJom3DNKDxmogaUYrpRmyXP509T61Fn0pQT0rREkwb9aUGog3FPBwOv41SRLY7PFcz8TZZovh/q7W/+s+Rf+AnOf0roifpmsvxTALzwvqsBH3rdz+SmtaekkJPU+O/l9DRVv8As6X/AGfzoqfq1Xsdl0dZY+JZl2LfR+Yo/jHB/Kus0/UILtP9HkVs9m4P5VxV1pUsOcjGPbtXV+DPh3e6rCt7eztY2h5QKCHfjsQOK+OxUMPyc9+X+ux7OFnXnLlSubP2krIvt1z2rVtbqMj76gZyMmuh0/wZYQxL5nnuF/iebk/gea0o/D2mqM+Swx2Zs8V4U5weiR7Cg09WjAjuUyPnHAzVqO4UhcFc9Sc1tR6dZhsJbgY7mrR0u1YYMSjjqOOKxu1sjTlsY0EgI4bHoatRycfN9MVPPoqhS1vIQOwJzVRrO8hJ3JvX1H+FXGWmpEkWEkAGPQ5p3n7gwcCs+abyEIKtn3BpUcHuD6+9aoi3c0LdiFQZG0fjmrQfIO3h/WsmK5w+1RnFWBcqGw/GRwOmatIGakLNtZWwGB+9V23lzKcncpHUDqaxI3PVT16A84q1BMEkjw23n8q2ijKTubEf30ZzyTnHpU3mqoy5IBPygVlNdpI4UEcHaaW5fbEsgbCjPU9KtIixqXVwocIoO4gdPSm+S0jCAnZGTuOOSRVeykWWHenzEn72MVp7lReDy56d/wA60ir6kN2J12QEAcgcDHX6UgfzR1dBI2MEZJ/wqkHkeaTaMKPug8kn61opGyfM5LOBgEf09K2irmZbkG+JYD8qjqO59KdcK80PkhSQgyGzzUIk+ZC44bgHHNW4n8i5WNjnf0Pp9a2irmT0M1IPOWSJiQwHJB5C5qZbY/ZBOOHX7ydvrmnQSIdXuYwCNvG4fwn0NaNspCGMr14znimo3JbM2NwJMrKEkxwW/iHpVkLG7eZattnUfMoPX14q5cWEFym0qAwHJ7j6VjXNlNAFktmy6nHufr60pRaJTTFuQJT50RAZRyhPI/xqgyQiRDa5EUjbQh6xmtKK4juZMOix3ecbTwD75rM1aBlcyK2ws+HAH3D/AHiah66lrR2JZk+YW2QyN80ZPZuwFZ1qGEEgZdsquRLHngDPBrVZRNaoBhHXDJgdMd6rNi4cSxgLN9xsjh+3Sjk1HzFa9tftNoxAHmIMqQeornLrSRJGs6ghpMnKngHuCK620Uss1uTtlU5AI7H+dRTWxSKQwj5+rIeh9x6Gla+402tDwHx18OYb15rzS0EFyuSyZAV+fpgd65nw3Zy6bpht7hCs+8ll7ivpW4tIbmAsqnzMfODmuA8VeHTKplh+WYnCuc/Nz0NaSqTdP2bd0YzpRb5luc94e1r7FiJuErvtNv0uYwVOfbFeOzh4JjHKCsinBGK3vDF7em7jighmfc2M7CAOfXFdWDxbhaEtjir0b6o9SVifWpFz3zUIt7pLdTKVBPUKeR+VVzagJ5n2iQN3ySR+Ve2qi6HDyM0M4FKCeKqW0iBGWaORh03Ke9TQiDchSKdxnH3/AEqlVQOkycyKBksB+NVpL+JDjcKluoIp2X7OrFjxtP8AD/jTYdFE0yx3RWHcOMjv6Zp+100RPsyA6nH6io31GGRWRiNjjYwzjIPBp9/oVvaTbJy67vukEkVnzWFqx2QiR26cEkGj2z7B7Ig/4R/wr/z52/8A4Ej/AAoqT+wY/wDn0P8A37/+tRS+sS7l8vmjjr/RUZtsiZGecDtXbQOPKgjhYRsoHI7AAc1PJp6upEirt7471zl213pUxSZHMJBAlHTmvgMVTlK1tj6jAVUlKDdm9jY1K6EkyKJMuP4+9SQTssEhkmdivqetYEMd1cyK9tuuG7FeRWpeO8duon8mOY9VUnj61zrRNnfbVJGlbXLFVMgwegFXGuFbMiHCBTiucinjBAeQ7j3X1otrsjyYt52+YGOfTmpvct6u510TbUQOMtjOfrT41G4HHFZIvgzEAjHQVaW8O0YxgdcVoooylfoXzEknEiIw9xmqsljbFiPs8Y9MCmx3e4ks4AA7mnQz+c4yevrT5F0CNyNbGFSTHEuD3AqV7CGQANGp9eK0liiXJL8jgn3pFkjIHzE9hWkaOmopVOxSh0+NCcIuw9MipfsEXmDEanPBOO/tV3eu0blxirFviQ7m4GentWipGbmZf9loxO0bO/FVLjSnliZPOcL6etdT5fyt5YyegBpjxgDYOW7itPZmXPY5+GSazgCNFvjCgfIOada36suHJ8zJwhPQVr3MKCPfIQO3/wCqsa508ysGuOE/hT/Gr5pR8xaSL1jI07Pc5wC21FHVa1vNJt+SQwIGRXJJcT2cgijVpLcDJUdB/wDXrRh1QGNIg+JwOM/xVvTmnp1Mpxa1RvJOEDI7bnyDn0qaGXzGlyfL46nuaxIrooYzIMODjn3rVXyy+2Vgyr8ysT901sjJodZgQgzM27D4m9Sa2QitDHMjcHtngH1rBuJ97BEdR5g3kj19KvQskcaJN8yOuOeg960g7MiSvuasbuWAACsvUjpionlWa6dFjKyYyoPtSwyRRRpskVc9Oeopt2fP8t+FCHhu65/pVyRnoZ91bJPAwmVVcn5WAxg1TglaKae3nXz7eU456/X6Vp3c0cal5J7dZU67mPzD1rJvb7Ti4Auos4zgnoPbiocOpaa2ZJp0m23ZAGkRCQ2eoHtVecCG6GCGjfGxu2O+fepJNSsWZZ7a9heZRgqp5P14qldarZSwN8rEEk7B/C3rR7KT0sJzine5ozRDzkIxvxhZB/WpJYm5OC2OoPWs2x12Oe0MEttPMw4J28L6GqV3fzwH97qBVV4CqeWraGGnPWxnKvCHW5JqF/a2UwYyh2xh4wpyf0rLvrpbxXBs/KtmGS8wzj6YrWstcv5o2S2UZIwCVHA9+KWOwikmF5qbK0vU/wB0Y/rXXTwUVvqctTFS6aHJx+G7e9dbie1VIU6TSjlh7c0t5p95NOINMnWwsMDc4BEjn611JL30hM0ixwrwiHjdU6aYrECOPLN/GnOK64Uow+FHNKbesmc1bae1iqo00s0nd2OSfrVwoGOwoFOckGttbe3ikZN3msBgl+1ZF5bp9pb7OxGTlgPT2q2mTe45FEUmUZV4+ZT/ADpz3FskoaORcY+YetVIIbmVtgJUcneOvHrV/TPD7XUge5MpAOdoA5HahA7Iz7jUI34gVndT8p702a41CWNjPCFhA5PGTVb4kNJYWUFrpkObhmOfKHzKMcfrXOeD7LX7/VY5dZ+1R6dF8wScABuvvW3srR5m7C5jsrfS726AWa8kWIjOHPatq00i2t9rK8gI4ypxV6CMiLd8vHUDoPapo3ZwAqgjPCjtWaQm2QfZ4/8Anvd/99Cir32eWinoI40ohLDYDjrzSNBFKrJIFI/2gD/OnqrBwwztI4G2hgTkkHHXpXx6R6pgaholscSRxmJhwTG5H04Fc9f6E24tHcSA+/P8671NsgI4H1qlPbjbtztbuMVPsovoaxr1I7SZ51c2F7ASEn3c9apTtf8AmxyvJgIMHac5969Au7QO+BgMRnpxWPc2WxSMAj09aaox3NVjKttzlotbuLeX55yB2zW3ZeJI3I3P854O3mqF7paOCSg56AjNc9eaU6SboyUI6FRVLC0p9bFxx9SO6uej2+oLcqQrkqfXirdtdbSQpOQflPPFeXWmrXNjJtulygPEijHH0rqbPU47mJZYZOfTPQ1hUw06Wr1R30cVCronqdzDcTyxkK+Vz365p8cjK3JJboTmuYg1ZYVAlOMDqDxWnDqMUiqquuTzn1qovTUuUdTcjuiG2s/HYmrkN58y7T1HTPNY0KqwU/eYnr2FXNwRgVGCo4OKu/Qho6CG4CBPMLZPoOhprXkavuz0OT71iRSk7WdyT3HQ1WmuA7zbQdqqevc1qkZON2dVFILkl2wX/wCWa9hVO+lhiY+a5abOAB/D9fSsiz1AwwGTcGYJwBzjiq1pfmSMyzRZDDJfPJNZNXKUWaVw4KkLGBj0OazJ08pw+wlhzgelWkl3nlSqkZAB6VTu7oGTZADIehPT8KzaKsPa8khgXfkKT8obt+NRnX3V1jDhozwVz1Pc5qlf+bMh3KTjoN1UrPTvMVmJ8s9STyD7Cj2lS+jF7ONrs6T/AISiEXMC3QbylPIVe1ajeKrOWHy4IJZGAx0OCK46O2txMRCGcg4y/rWtFaeRGi71MjnHyjvXdhVVquz26nFipU6ST6m5ceJ7hlSOxhWMr1kPb8DVB7i9v3C3NxLISeFQYz+RqLYiJhcjjkY5PrV2Ngls8MA+eQDdJnBUdgK9WNJI8qVWT6kEsMEcTK26W4bp85wo9j3PtVWO3BYFjknoMfyq0IQB97keoxUkAG0vwxIwg6YrWNNGbk2U0tzG2ISFY8bsDg1bsbJ7qY73BiXhnUD5qnt0VshUPPAz/Okl3XANnBm3UfekU8fh71rGCRDY29vY7Y+RYqN44GO1UrTTzdXRlklLN1wwFaMdgLcNGrfIgB3FfmP41ZsAZSr7AMsSBjHGPWtFG+5LlbYfZqltBM0h2KT16YHoKdEsd1mWX57cDCRg8luxx6VkX2obby2iVdzu+ERhx9TXQwKVnUIUyo5IXAFa8uhFyrJbWzYVw7Pn6Y9qvRRLAoEBZT3JNPhimViSyHcxwSlaAVkk3MgJAwcjApxiJsyjaq7tJMMnsenNTQ6XCQHihTczYyW+8KuzqjnJUgDkCmMyrs4kBUfwg4FVyIXOxn2ONAo8tQ24AkGr0h2AsxXCcDHFU5Z1Xact+KmoLm9DyEICWI4GOv1pqKQtSC92yT7m8svnjKgmlYS7VRUXb3JOAaihQ7/PkHOOnpT5HVWTdIxY8hdp6VO4yfzHEQBRflOThutNtZBGzu4I3A8AUNdRSAbSRgY+5TgrFQ6kbfWlYZD5z/3noqxx/s/kKKLPuFznfn+XMjEZxjPSlbdwrMSOwzTlQM25SAp65/lSOpVzgMQe9fHWPVEMW452g1SuF3Bs43enpVncyvlS+eQB3qm7mPfkHPf3p2C5TlGx1ORnHQ9qpyqrDkcmrkxOPmwT0qs3GFU/LVJCehmzW+DnkrWXdWYIOMlT+ldBKqP07VA8JYcgFfQ1SQrs4i/07dwATnkVzNxef2XdPFDjIb5hjOa9SurMKueDwcD04rgIdM/4nH2uRFdUk3kEdqqdSMV72x2YKN5N+QsV5dXqB3tnRMd+M06KW4SXKPyPQdK3Z7aW5QEyARMfujvUQs7dSVRfmA7VzKrHsd8Yvoy1pviO6tyBcKuwdwP511VlrkbbW8xHZjwgrhZoyiBVUup6j096pzCa0PmxyMFHTB4zRG0ndMp6HsVvKtyuWVdxHUelVWjYSMsn3VOBj0NeeaJ4mnhKx3LMCRxz/Liu8sdTikty5ICnGSD1qtdmJLqiK7RbQtJbfxcMp6Y9qitjLJJGqjMSsX2jtRqLNcK0ikLAMDPrUFjMVjdk4Udc0ti09C++opKfItz+9x+lQNDcCWNxlkzjCnH4mqkkqJcNO+3zGHJ/u89Kn/tGG3tHLFd/Q7aLX3JvbYnaX99kxtuORjtUEpkDAPkg8CNabaX7NExDIigZLjrirNu3mWMs5UBWGFJ6sB3FNRuTexLpr+ZJ5giKrEOjHOTV2BiHdyM84OKoaVIktmTGphQyEL6sMdTXO+NtY1zw3Fb3FtJBLY3HUyZyrZwBwK97B0kqcfM8HFTcqr8juYsuSxOG7Zp+1gNmV55PFc94VuNVm0tLvWxEJZsNHGmflXHU59c10MN0n2gLPCWUqSMdiBXVyWOW5OsQZQHBKnqMilcIhRbZC2Bkbqfb3docN9lDDHO7tUkWyW5YxRqmPuKKpITYyd0jCgOTIeAwPAHeprSON41JLpbq2c55J7mqTQKbxlZgYYuN46PnnFS3Nz5xSCAbU9R3PYVZI+8led5RE2FOBz3FUdd1y30m2SFpf3rJhUUZLHFaktvFFNHG8mDtDMB0ye1YfiibTtMzqDxB5QvlqW7H1/WtaUVKWpM3ZaHN+GHvNQ8Qfa79Zoj96PngDnoO1em2UhRkGzfk49q4LwrcXUqLc3KshkO/DDjHPA/Su0gmQXBXovBUDvWlSzk7ERvbU2Y3kfhIySp4J6CrscpLlpMuRw2eR+FVrd1aIZBwSeKtRFPLYIuGY4x360khNjL8o0atskDngEMAM+lLazF7fbtlU/74p16EeaIFDhBn6VgXOpxW8M07SeXBCDls9T7UwRp6hIEjDbXLZwPm/nWc03yu7bQcDGKa85NhAWj/AHknzkt2U8j9DUMNmHLGSR9meFXoaltFFmJiQGkyVIzweTS+aWn3gAcZyab9njjAVGbnrUgiUXBJI2DsOppAW4gMkyIAGOABxmlvNhLRxcRqBn60saRqvmrHyn3QKg2J82wHdJyQfWmkBFsX+/RUnk3HtRSshGNI+5QCvA6Y7VGxDALgjnmnnJjBxx0/CmlVPMoKr6dz/hXxx6zKcxLOdgwgPWmFVJLAfN6VcJIOMAg+nalSNVTO3BB4oB6GNNEdzFun61UdCQc4we3cVvXVuZAWBBf1FZcsZXIKnPfNUrCuZbqFBAHB7UxS20lTxVy4jYk5HH06VUliZQeOD71ewirJIwDfNzgnNYYgGyTHTOa3JoWCE5+QfrWfIiKnof5VhiVeKO3BStJorxkRqMg4NU5VUyF1GT6U9rkiTaQOKryOSwIHLenaso0zvVTuOkuC21Bt2kcn0ps8XnJGhYbAc8VHJwMgjj2qKZ3EaqGww4yK1VO+xXMQTWilXKr8i9CP51X+33tq0cZctBnopPy1pQyPlunAz071YewU/vAMtjOO1XdJ2YrdUWrfWxLGqOTuX7oPp71Ys75WYjf8rMTj2rl7yJorhmXo6j6g0y3uZIolXHzKfmxVqKYOfRnbJINjMG3lhgZ6D8aqSToupKg/iG3d1ArIh1FYmKmQhNuVOM1WMji7d5T8gYOp+nanybBfqdlcz/6OjNzEpKscY+lULnxEkcZjdvKK8I47fhVJ9RQxSC5JRMZx2NYMSE3YlmXzA2CgIxlf4Tiny6kdNTufDuoCa1dW3Bkk3rkc46ZrT1K0t9b0s2V2+5YphOoIHYYxXK6dN9mvgTjM/wC79gev5VtRagzyjaQD0Py17OEalTS7Hh4yPLVb7nUAxBYtrZUIFUAfdwMU1ZSLoBSXyCCCPasuxuJJo2VTGwXk5IUip4J2E/z7M44wwNdfKcZqRjaGYgMMce1P85Us7uVnT5YupOO9Uo7kbnAbBYcjGaZcvb6jo15ZM5HnxlOm3bz1zVpXEWbLV4dQsU+yyxNGASVhO4jHXOafBqFjE0bM0jqHB4AJ61m+D9Kg8JaJaf2e4Zmkw7uu/Oc8HNdVdzC+AlEcKg8ZWMDP4Ue7fYm76GXJr9o08jmObBY4ylcx4kjbV7yKWTItIn3Kn95unPtXVNDFHlCi54JwAazNVePeoJQDGM9BWsZxXwoVnsyvZZttkagvheCeK6G1lWTawUEsMHHasS1EzOxhKSoOQwPH51pWpkaVw42HaeAO9CEzrrQh0iAXdt6GtJI2WVZI0yRkj2rJ0y1usxjZJtwD93GfWtpNpkchioTjaaaJZzHijVhYWUs96XSPaQqKPvV5N/akviLXraCZcWqy7hCGONvPWva9esYL3TZLe5AkBU7cjoa8v8KaNLYeN7oXMaqqxNszjnrituZRi+41sd7b7c4dMJwMew6VpTzQtGMRHIGApGKIY2wSFUjOR3p8wym5uvP8NYxQmzMa4O8gHbz6daezgTKxY4x09arzvFG6s7qQe2etTxXYMsSqqHceO/FOSBGjKztFFEz53jPTGKjykUbENufOM0+ch2yeOQMg1HKkQ3fNwBgknHWpsUR+Y3980VB9li/56D/vqinYDOYbGG8HceQuen19qjZWZ9+d31qRDvPK8+oqRAGAzxz1NfGHqMhRDztAC9h3qf5Aqnkt+lCxbW6Dac81Ky5QKoxjmmIhKLgbTg9BVa6t9ykgMT6GrAB8wgcgnt296mJ39cEe9UgOfaFQfkOfUHtVaa2xgg5BroZrIsd67RnPy1CtiTGSUUe2KpAc1JbM2cL7DFYWs2zWt1mQYEi5x+PSvQ2tVA+Uc+n+FYOuact3btExUSjlG9DROm5xsjSjV9lNSZwNzHHL0+XPfNUZoJEHyPu7cVrXVhLbSbZlJ2kDPaoCIwdxJB9PSso80T1XKE1e5jCOQAA7uP51PErKuZRx04q2SjEnceOuaTKKkm457gVq3JER5VrchKYiLITlevv7Uq3EkRxu3HggY7d6ZPdI+DGNjDnHY1CJjlywBHGCO1JU5N6lOtFdS3cFJF3H7xxkevpiqs8IgkWQqSvRqkikZd2/5hwQT/KlkvBKCroQAMfjWsaTRLqpmbcxhgssZBVvvAD7tRCYlnhnkwCMg/yqZWCEgD5GOCP61UuUDMAQR6Z/nXRGm1uYSqpPQljuQU8qZg4UHr6VHdXTwLFMj5VflIJyQO1UJ43jBKknPTbUbOzRlChPsatU0zJ12tTc0298y4BlkGxRs3Dp/wDrrqLO8jlVpI2UkjDrj7prze3EioIVJ67hmrNlqstjcGTLZ6MueGFbUGoSMMRL2qt1PWbCWEOjLysn7t+emasvbiKUqjAsnT6HpXH6bepdQJPZS89WWTmtmDUWLLJJHyp+fPdf/wBVekeczoVGzbvOQR94elWIo4xH5mUIIxtx196zXu1UF4iTE3zIPRewp6P5hVhyCM8dqpIhs2rJVfTbq1UgtGd0Y98d61NMhaTTEu1/dqDsyehYcdK57TrpLW+dSw+ccH1rZmvk3R2i5EMQLLt6EtyTQ1oCY/cyuXBTfzkketc94ktGl/dsNm+LeRjmuhDRY3+SZ3GCufuj3NQ3UZvd8kuPMJ5I7Uot31KZxPgS8LaJJEjP5trJsdSep5Ndja3LyXWZPvMucjtgVhDTWsr+4+zQNGJX3uw6N2zW5o+nyXRBW4iilQ4KyAng/StW76mbOo0jWLx51/eNtAwMHsK3YDHgmQlizEn61xNu0tnftE8hZl5+XoQfSutsmMiD+7jNUiWRagfMuFQNjv8ASq9zbRy3AnxmTYVBx2qyFWWd2LcBsc9asmPaoZSAuOtFrhcdFbhUfZu4Awc98U22+ys5ivvNAI6o2BVmBgJHyvUL0+lU7tmWd9i8kcU7WEEsHh+LklmAPG45qtqM1lIiR6cihscsRyPpWPenYDtAznOarFpAYiXkw3GSelJxW5SZvAs5TgbgQMAcGoL2Ur5wVVbA5z0p1vbTJGJPNYB/u+lZtyrbzFuJLMBnPXNTcCj9qf0j/IUVrf8ACNt6j8qKj2jGf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The popliteal fossa is palpated to determine whether popliteal fullness or pressure pain is caused by the hydraulic pressure of a large effusion or a Baker's cyst. Two hands are used to palpate the medial side of the popliteal fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34864=[""].join("\n");
var outline_f34_3_34864=null;
var title_f34_3_34865="Abdominal port position";
var content_f34_3_34865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Position of abdominal ports for laparascopic lymphadenectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34865=[""].join("\n");
var outline_f34_3_34865=null;
var title_f34_3_34866="Lentigo maligna melanoma 3";
var content_f34_3_34866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lentigo maligna melanoma with a nodular component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34866=[""].join("\n");
var outline_f34_3_34866=null;
var title_f34_3_34867="Moderate hidradenitis suppurativa";
var content_f34_3_34867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderate hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEpAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC8MBSuB7N6GoZ4fLcuhOzoQOeauvCwXKrlB1QdvpTASckA9wRjFc1+5gU2XcA3H1qAgiX516/xDp+NXDthY9wTyB0+tDKJOVOT154qHqWiq68bWHI6ECnqSMqw4HIB6/nSMflw30pqONxRxh/4WNQ0WhVTLZXaSw5B9Kd5QG4qoGOdp5zUfIXeykMowwHT61PGxZNw4cd80ijO1SwiZMvEAh+8B29xXnfiHQ5LW6+22AKzkclW2iVfQkdD716sWUjdjfxl19R6isfVLGMg7M7G5w3Y+3tRdrVDVtmec2OsPcSCNLuUSk7GWbG4H0I/+vW7HrE0saQXkFskeApDJjeB3U9M1jeJ9FLSG7tFAmGNyHo4HY+h9DWdo+oQXFy32l9gQbCsi5A+tEveXMkaRVtGeiWTRWkyyafZLLbkss+VyoJUcqD3PPtXW6LFaWscM8ckUltKTy4z5bHsT2P/AOqvPNF+0RQR+XI1uVBVHUlkPXqMHg+3rWrHqGpWccF5aCJjKMzICJA3GCSp9PasrLdmqZ6MqXAlMKFJR9796udyemfXtz2qS2SVpjFC622RtMbJ83vg5ww5rl7LUtemtDFBDYyKBuwHZJFbsRuH6Vp2Wva3Knl3WkrLCCA7ZZgvH3iAp4+lNPW9wt0N21EkE0KzpHcQTjy3IO2RZAPlODxggfpReTxNFJFcRxifIUFoywbPZgOn16VXR3nt5CoAjYAARRMyA54IYjKkYq/YzrfiWNYwt7ABu3KVLAjgEHgg4OD0p35hW5RNP0y0Fp599bDbB8ixuQdo4wSQeSe1O1SwnL2sdliG9yZIZWY7OAOCO2elXtNitbyIN5j5kXbIh4B+g9KTSjHFf5mBceQggkYl+eQyN6EEfkaOUd7kLXsOsaLNDZ2srX2HVjEx3wyYwcn06j0IqtBPdr5EMcdw8ywndGjCKBkUDAc9QwGBwee/FXvDahrbU7mRAkz3sqB14P1HsM5+gqS3jl0vS3haMzJb3TSx3DnlopP7/ocHr7ChJsfwjNE0VLVGniitbQSBUuIgm8gsQTsbHXuQOCBXRXkbW9vOHubZo4wM4XBAPfjHbmoLG3E9pG8sheMyGRFzyxwMZI9MnH4VBd3llZ26211cSLucooVf3ki55VV65xkcdiD0qlCy0Jd2xUvmjZtlrIsO0sZ1GFCj+LB5/GoYphqF5DfTFrlfK8y3jYZIjb5RkdFL4zz0AA9aqrqAuLPUIyVVIlYNvOMgA4Bx6ccZ+tEMkk2pPPIUeLZuRmj8rYq575znByeKluyKUToGSC1f7RK8EUQIycgLGxPIz0ANIL3Tr1ZEtpEnjxjzU5EZHQgjuOtc5Bpd7qNusn2iOGFiTtRDIXHoS569DwK2dO8KxSRlJ7i9kU4ykz7UGO4VcAd6SbeyBxSWrKN5rEAkKzFnngBXzZHWLcxwRtGeeBz1FM0/UBdYnna2h8vkIrltrH+IleScYxir9x4d02xdGtLeGNRuyYIlJUE5J5XPv19aqX9lJG8pS4klbcGji+6gwvBYrgkcdOaLS6lJxehmzJHH4knMIZSIEtnlm+V97MWwF6nCnGOOvqak1GJLO4UwOsM4hSCS4kjBbyDubaPRVIwPQVnTQtpokSC7j81Nr3FwM7mby9+FJ4zz09hWP4ha7Ov3UE159qigWLbOq7HUuRlPl7/kMHJFTJ2WxXLdnQXk9yunSO0tuHkDeVFM7DPB4JPU4xnAxXH61rtw1sIpJrDEoIuNrmU4UYPy9AM4HHZatXMiJbNODbyW8rMnnOWaRiwIHGMtjaWxnA4rzLxnqFwmlmUQhYAiWsOwbCxGVycc8jkj0PvSTbI0MfV9Tjl11EmhF2sOEgh3Ar0yM4444zxzzWvoXhuSW5e6ukjBZvmKjCr7D2qt4M0SK2jW7uhi7YFyW7ntj+tei6TbC5QEBRCO4Hy59B6/WtVpoiJaas1dLtIo4wigLbgAAYwXPoPbmt/ebcfumPmuNyRqM7Qe+aoebHbIsdtB59y/ypH02+5re0jSWhAaVt0p+YsR/Kt4qyOaTu9R+l2ygbZiWugocjHAz0JP9K34LVOGlYnHAXHT86SGBQpafKqcYzxg+p/pV6G0ZyDEvDDJOMZ9q0SEMWJFUFRubHYd6nhifdjI3HscZ+pqdIs7toXaPu46/XP0qxFAuAufmYbsZAP5dcVaJbG20Oxt0ZBZurDt9avwqoH7sYJOS+MZqAsIyVds7RjGOBQHklyVBESDt1z34pkvUsCRVYBQcnpg9veoRMJAXCtGCSCx/KldEcjLhUVd5T+Jvc+1QzuHXggEnGPbHFMEiQtkbghMZ79M1Au3O6VQADgd/wAKGlCxBUJXnJz+lU5p2KsI+pHf+dK41EneZAGGOF/PiqEt8zSMVUtk88gVlandPGjeY4OByUPA9qwDqoXARDIuPvE9aSkWqbexzbkqAu3J7YqF9y7t3KHnHcVKHLxAnAI4x/WnfeUbgob271jcjlM27OcEJxjnFQgvExIXKn061pMqj5DheeCRVe4jAXAb9OlQ9GVbsVZAsmHwdp6gVQkRt2QwZC3y5HNakAwx4HPUdqqXCmJmwuYieQf4TSbKjEhWQ7gpwjgcE9HFBZVADLwep3d6c8bCMP8AeQHHvUDHaxcdDyeOtRYuL7lkTbCp6AdyP0qUyRSxhSp2NwMjofT6VQEquvls5GOg/oaljkIyoAPPT+9S1L5ehU1CwWRQy4JxivN/E2jy2ly2oaeuJ0GZIwOJF+nrXqokDxkEFJF5wedw9aydWgEsW/byvU+lJSs7oLNaM850fVLN0BR7gOw3AKnyk9xxXVaLexuFih3R30xK+S+Qsq44wexz7c5rjfElh/ZV6bm34sJ3BkHQRv8A3hjoDWlpM0Ey/Yb13EjOJ7abzMBSOThvetJxXxLYcX0Z6To89vdx4W6aKVRnD4XaPRl6ceo/KtOG8vrGc3EVyqwQjY6N92VMgk5HcZ68GuBtB/xMhuX7QkxySVCtI4/hz2bH4Gu28PXkElzNYQP8hUt5UqhSp6FTnp/Kuds3SOye3P2hbm0VBcNhnQtxOpGcjnBPofzqXzor4Ge2UtcxDaOMEDup9D39uvSuX0i2itZLaN55UWQGSJg2Fzj7hUnAII7Vp/PZsblHmuLNiGllhkyVPqw6gD2zj6Zpp9BNdieQBbm3ubeVYLkTeTcQqpAchSdpTs3RgR15rWttQ2292Y8R3sVw82Qvy7fuj6qQ361z8lxbtaW942f3cyRXIjwxKcsso9SpwfpkelOjeWbf9q+a1UpP9pg+bc/mAAAf3BuIIGcnFVsK1zodBskW2063SV181z9phbjYxBDkHsduMdju7Vt3Nwk2kXjROs5mie3fI2BSFHDA9MDJrndLvGvdXmngXbfPHj7M5KKyrlRJjsSWH+RS62jR3m+OZSyhjIzqDEXKouSo64UEZ681UfdQSTb1LUl7Po5v/wCygBpylP37/MsT427VXqwO0EHtkZNMhsEvpItZ1H7RPe+WHSQ4Vgp4Mar/AAg8gk/Sp5SZb2G7dJdrbbeESDCiXa2HK92zj1wMd+mdfaxNa6rqbRKsljbSJhFG9VuDktuB5bHYdATk8UPbXYErPTcffXb6tZ2lnawAW32hfNRRtjCckJnvjBJPA475NbM0cVw8VwzrJBE5YrGB5b8Y698H8657Q7SSeS5guZQbKJzIsYb5p2kGXlY9xnI/lwa6CJJZLubyVWKFFBWNh8rHkHA7Dj9ah9zRKxu2TySkN9yMDcQTxjPb8K0fOiGAhwzd/WuX0x7iOZoZi3lKSAoXIye3Y1ozXyZCxWzYJxueNgSfpirUtDKcbMuTXIilJK72PTaeDXM6lqEkkhhg8uFF3YmDZ8pT/fxx1+6Cc806+ubuWF87kiThio8tV56E5z+AxWVDCbiWO0ESiyhzO8fQOc8Ajv05J9BUyk+hUY2V2ZOsQ3Go2aw2zMbvH2iSbYNiJnJ57sc9OuMA1z/ie8js/tFzbSbhdxh8zrgR7GGDtHdlzkdKt293c3hs4Jt8FhIiyu3Vnh3khcDoC3Bz2U1V1vWNNhtI1KNdxPN5gtUwXbbkqzH0DN3PT2qGuZXQ3LlOOn1WOzMAs7iOVnQhY2PyRw4wrE9j/LHNYlnOmuXUNyPNeyt4mhhabG15CSXkUenQDPJx26Vh6zPd6pdtCPJgEu4zrb/6tUByB198AewrodMi+0eRa267baJVACjHA7f/AF6pLlViHeTub+kQSXhECEpbhQGeQ5yo6/Su3iUPHHFEOM7VQDk/7RP15/Ss7R9NEUSKo4Y9MHJ9B+Nd9oujzbcyqDK3BJGTjOcCrgjOb1H6BpP2ZWmlIaYklvX6fzrp7CBQvmOobbygzwKZsVYl2LnHJKkfMcfoK1dLi/cguDjjIB/SumKsYtaXJIrQudxyd/OzPWrDx5JSP7o5Yr1A7jNWIFAZ5AGHl4HTG72oiCsVyAvJJIPXnp/9atCSeIFBjaAuAFQcYGKq3jxRndsDzjgHqVHoPSop73zCRCpJwOQc8f0qqW2YWIhpXzlh0oEotl+GPzOWO4kcD0p8t2kZIGPkHrwKy57gKVUyggDJCnpVYXKyNiEEqTkM3APqaLmipXNGW7MpcH7uNvHce9VDIQEHzZA3Fuw96zrhyZOJMj9Kq3F1jam4rkHgHrScjVUS1favFbwMzPtGf4u5rKl1dX3eWzFmO3LcAfT2rE1zTLnU5olO5LVTuYg43HPWkvrqCwtZhvU+WdqsRjkD064FQpNs1dOKSS3KWs6oloH85gCvIUnH4knqa4i5m1C9uJJ4JrsxMflEXCgeg4rK8YeIZBKGkCy8gxRMMgn1NU7W71eaEG5vpVccbUlO1R6DHA78VolfdndQw11sd7DJuZRIfkPQjsavNgxhwvAAqrJGYi4ZAYz2z0PqKdaTO8BU5YKcZFcvN0Z47V1dFmWNZ4/u47VnzB1JWU5YD8cVbSQRkkOCCecnoabcqZcE8P69c0PUFpoUYjhyAwJ6/wD1qsGSLeC8e9GXawPcGs9hiRXzgE4J9ParsGHOH+96tSUuhTiVrq0+yyZXLREZx6j/AOtVSSMupIb8a2b9JLjZiMbF+8M/qPrWcy+SSoBKueefWiXkJXRkz2Uj5lhXc6fMUPRgOuPeqxn+WOVHyTyoHYVpRuA208KpII9Ky7qFWZo0B3csBjjmiKvuaqRcjut8hAx5vXb0z9KWQFWbAyrLn2xXMSag9rdKJGxu+63pXRWNyt4nyk7yMhT2qakXHU05dLmHrFhG0LpKPMtpBgjsM9RXnsls9jeHT5yXgU7o9pwzoe4zxuH+Fet3UR/eCQDyuQ3HQ9jXH+JNK+1WwMBxNE2+I+jen0PSnTnbToQ4lbTriOO3jkvCHVVB3RkgHt846qSOvbuM110F5BLLDcx3RaNE+S43gyKCfuSdmxj8RXG2F1Y3kHmukqSLw0Q+/HIOuD6d8GtjS4JLaE2NlNBLJdOAzceXOuQ3I/gPQZH41E42ZcZ6HZaJeR6hbshtyb5CSYozjeo5zHn+IZzjriuh8Pa9BJLuaYQ3jH5mUFQzqOGx6kda5K0mS+nFuyNZXtupNwj4V1x92RCOuOenqaJbiezuzcSzLFKJFbdj779N3TgEMc1Nmths1NSg+y65HCGmEUqtMPL+6y4JC4/h69fTPtV2zvo7WG50y5LR2BTAnXrZAggDj+HdtIPbH0rN1DUi80WpMrxeUuSyE4dgRlBjjkFh+NQRBVimYncn3PMYZMkb7WVT7LjOf9kii76DUeh2dnr1pJcXP29ne8srNI1+zJvZn3H7rD+E478c/Wk0E3H9oy3mtqp3OUgBTy4ycAkkk+vHPocVzVndGTVr+Exovm3UcrMrAY2kggDHtu49vU12sfl28kMzK8irEzL5v75iCck5PI9aOhVhPE2r3X9kXbZeRre8jhtAQDvK7HaRj3UDcMjNRpFapDbs8rHTbc/u0VNpuJyckn1yeOeMYrCkma91a1trjy08mRmlk6sMLgdeOeT06pW7YxGO0jlk3tEV3I0n/LJcAFjxkc/lSlJyY1FI0LdjpN7qU1/Mpmk8vAPCxHCgRr6KMnn61pwzKt99ok3Fmj2FOcIARjGe/JzXKXM4u9VsIJ3d4XusyseVwsQIHsCwAzWzrFzFDGJgWAVd3lk5LEnAXA9efyp3SiNLXU0INSkCAhV3yncAOgHYmp7i9hjj/fXGAoy4HT/69c3F+71pYnQEGJpxlumcAL+pA+lJqswlYW6PlAAz7M7mUf3fy6/WlGTtoKSVwur+fXbqS4+W3sbU+XaovBlJ43n05OBVfUdSSDUfIYhLKOJvOuCwwcY2xherEksSfb3qKW1urmBbLSxFbrI4idyu4L379CMVnywRW6tDE/2m5tsoDIexUZYt2IIHJHb3pttbku2yMDxJPc6Xvv44zMs1kYo9xIAPOTjt0U/j7mvO7vW/PLy3DyuHjIYhgxB9egxkjgduOtd/q+oztceVqemTTTiICOB3UIAcenbjOf5YrzDUbqW+mSAgCAS/KO3XGKuCuzJq7sO0OzkNkgcEAncAp4Zv8B+pr0jQNMNuIYYkWSdiMYHr6/TP6VieHdOIlDsCIIsFdy++Bx9RXrHhuxSztjeMhWeQlVA67fUU52b5UWvdV2X9A05bYb2kLSqeBjhfVjnr1wK6y2QrCI5HBBAd2Jydv93juTWdYxJMgMxAZApG3uc8f/qrahiDlAcnL5IwPy/rWkFbQ55a7jrWETyJIgaNV52joQK2pizQqqK2wgbRgcf/AKveqduw+faSABjGKlEjb5NqNiPuf/rVutiGTXEzErCrMVU/MT9P8moprrazFSEAG3jgA/4moWkKQnGNxJJA6+wrK1C/jiRVd+QDkD1ov3HGPM7I0GuEjjViM4O0FeMmsafVIbRiiyFpejBefzNYt7dyyuu8eWjfMVJxtUDvVC5uFNqssSBIlIxu6E5qHPsejSwy2Zsf2lJMSFQqB+X+eauDUtkXBwx6+g56Zrm7e4bHBV26gDjGa0rK2ZZj5oDvnIX0HX6VCkzadGETSjkldlfpnjZToI3L5fGAAo4wfr+FTqmFy4wSMkD0qteXK2tqxJ2gnG71PpmqZyN9EUtWu1hVkaUqxyCwHA4NefeKbiRvLjCFHlzsBPzBe5P611E5ZD5juDtAZlZs9efzwOa5Cd5Li9Ek4CSOGIDD+AjA/Oj1N6FK7OZ0jRodQu3kvy3mB/3cWOCPX29vWulhshbqYoI2kCkgkYAB9P5V0dhaSxLBG0aliQTtAyuR6dK3Le1SGIKjCJc528ZPueOtaOWlkdLqcpzE4yAyHqOcHnNRI3Bbbj8KWwdZF3cAN1B9akuU8sMRwMevQVzdbniR7DGaMgKVADcEiqiMQ/l7uh7elQTv8zBOh569KqC5Axl2BHGTQ7M2jS6ouX0JijEy5aNjhuM7TRE+9+TtboaktL4T20sUgXDAjis9D5cgUnODyw9PWolpsFr6G/aMrKRydowagubRBmRgMgbSPUU2ykJXHBJG0+9aATfDtOMdcVS1Rm1Y56aAqXZcnHBB7isnUUYbSvYdccEV0d5Cy7Tg5HHSsi6j327YGT3OelRexS1OP1qMzKAp3HPQ89O2ag8PXjQ3bRuxG0jac9K09btmg8p1VvKcZA6AGs2OLdKGZAHPO7Pat5axNoSVnFnZyziZTkg7hj65rIurVxCWaJiucZ7A1Y06RJ7eW3nBLFQFI7e9W42drJ4ZT8xwM46kHg1yrRiaPL9etjpuoi8icxwSkLNt7Hsx/kfatOznS6hWWKBhdW2A43FVc9TgjvjHIrb160jubVt6AEgrImMZ7GuU0SIiCazQSrdWZB8xP+WsTH5SfcdK6Y+/G3VGT913Onh1mPUrcRXYkS6jHmQS7SHU8c59DWkmoXDSC01QRypGDll+8E7k+q46elcdfTMJRc2UjRyKgU7myFI6nHOB7VoaZJ56faNTYh5UZUmHKgjJ2FR/Cfy71nKLRcZJmvY3dzbW+pRRMssUbu6IeRJESVZPYjIYY9aualqX2KwjhiaYyWsgiBYbkaL5XiJHYghlx35xXMxRiOVXhc+W77GTOMqcYI9O49eK0NeSaBlt5rmVArLDdqyHftb7re+0E/rWb1RolbY6nQPJntYwgceXdyF5DHgpEyKVY+3JNdRZau9zZWsyqVjjs2+YHbv2OoORjgbvx4rzGPXbeXSt6mWO8Fu1pKY2+TcvMbH1HJBHpius0aZbz+z2tBNHHG0cDRMeXZi3z/ix6eoz9FZ7rcrc6PT3iu/Fk0stupt5beJ22HDLgg9/Td16k5rV0m6ZoooLiaRXllKlD0C+Y20qPTAI+tcnaajHqniTVr+xaRY7m4jgg+XAK4OGKjGBuBPbqK37stqeiSRfZTbyRM1ycNlm+Y/KDjIGSAPfBPSknZ2Ha6uyjeSGz8S61bWzk+Sq3cDdC6blVlAPrlh9BWrDOTaRJvWWe5nTcR0SMtkAHsBgCuavr5Ejj1q6+e6mMwSOGPAaJVCYB9VIQlewPvU+pXU2maDFe2xQC3McJD8qkjjcW4OdqgjB5HOOtDuO+iNvUZlHiAiQr5EcLlSTwORhj6gHeB6nipwkn71XlC3khAmKEAqzEYQH2UHH4msaaaO00iyMkkcbkRQyFW80nc6sfm6Fsqfl9CfrVSXUIobsOWjSSaXP2YvxHtUgkLwSxxj04/N2sQ3c6O8S2Ro90exSWdAjkMzcKBnIzkkDJ9a5vXDaWaDbN5lyQWmWJwEibHy9OCR7+lZWsawYige02plRtKiXOSNoAHB57GsHXLlUMNvdhbWNJFkn/gWEHdywU5Zzg9ckDAFKwMz9b1WHZJHHNLLqcjFpWzkIuOFJyQW5/A1naDZkMZdm6QODuYcKo5yPcnP5UN5d7qj3Nvb+VA7DYh4woHU+56/jXW+HLPzpBn7g5YdjzWsZKC03FGPVnTeFNNYwrLNnax3AE8sT1P6V2ZmCSFh8oUbV54Az29+ay4QI7ZVgbG0BAeuWPp+GTWito0kp6bEG92HT/wCv2pRYpWkzY0078s+c/eIP8614bqRVdYVJLLxI2OevT8Ky9P3bFzlN4JZR1QdK1poop7u2B4EHUqcfh9cCt0RJJOzNGwYxQorfNIwI2nmkvJdtmI1XdI7YY4/wqMzRssjOQCeQM9B2FUL26xN5oKqFjI254q79DG12R6hctITFC4Dp0YHoTzisO+uRAS6hmZeQ3bPr+dOurwIM/dxliFXJcegrjfFF/dC3kVW2PIB0X5s+ntUSlY9HDUGznfG3jtbK8ksbFPtN4MSSH+GPtg+vNV/CGs3mpXROoKpKnJXJGfp6VzuhaKJfF1st6JntpZ0F3tID7Cfm2k9/TPU11+n6UunXdwkZDfvX256xrn5QT03Y6gZqHdx5j3YUqdKPJ1tudnp8jNcM7KAFJCYGBzXV2MIEqy43beAB647j+tc9oNulwwREJOQWPfI7V2cKeQuW27iRgrxVRPJxcknYdtVIWll3qB93vzWHcK0ssZYc8mMH06lj9K1Lx5AUCAMi8lifujH6nNY003lygqVMrnhD1A7U+upwR1dzD16ZUBWJGdmPC4wW781W06xkyk8gMt0y7ssfxwPQDgVr28HkXAMg8yVWJG7nitO0sndzJJhQ3BGOTn0q0dUKnKrEen2bhlIIZn5JYdz14rbFqqkgw+Z/tE1btLJtuHyEHIxwf88VqxW0ewBVzjgn196u1zlqVtTwWHdBcMjMMN0FaJmEkWCo5GD7Vn36Fkyh2ydQaFkHyvnbuHI6Vyy8jmSRFdRbM8HkVhXNz5fysobscnFbdxNhijH5T0PqKxtUjJTee42kDrxUo76GujKttemGdXJIAPfnittpY5Ys4XnHNcjNMsa+WzBs9CO1X9MuGMewtnbjaQehpO/U0r0rao6WykGe2Bxn39a3FmGxSrAMAOvc1yunXKmdxtwG6+1bNlKxBRx/qz3707uJxONy7dESKCM9ORWU8YQlgMjPOD2x3rROHYhiNuMfhVO4j2FsAlHGPxobJUTntShWWzKYZ1jbBH930INc1bRlJdjAseo9xXaSqu7cik5wHA9f8K5nUIHgnjZSQFNNSvoawVi7ZnymJ4K/z9q1GiEiDaxDEZIz29azLA7XWRSeo/Gt22hBlUHAYZKj8en5VjLcpmFqdu+3kbhnke/Q15/4ihktLlLu2yJ7c5wpI3oeq8fnXqF2IhcYwRE78Z7GuK8Y2n2RkfIaKQna2ensfzrenK0kZyjdGFpcltdTLMrYuHAPksxUONvBUjo2TVi5mns4ltknWS3YCTBGCjHoD6Hrn1xXOIBZXiI7AQ798asm4j+8P1yPxroLsq1kyyLICxwszSB0xnqOuM4FdEo/cY36GzmKTR5UugkQmlWSCVPnAyvzAlc8fKeD0INXDfo8VpKEhe+tJY1lXzD+/TD9jjtt/wD11yGl6n/ZcrNbzKyzYE0YG1wVyQcdj6MPX61v3Grw3TwWzbFdQP3rESKwXdyrLxjn8PpWLpNK6NFUWzLmoxRTqZ7OEQNLMwuIQflOGwrkHpgkD/gR9RV8yxroiX9vczFoLkwXFoGAwCC3DDng5waxbhlvJz+8C6msrb9x3CRCvXHUkY557ioNK1Jobl3mOZo4milt9v8ArtmRvHTBALEZ9CO9Q4N6lqS6HX+D5gNem3ZQGKGQqDtY5HLAf8B6+4rsL0F9K0po1Ine+KxlzgMFy54zxwqjmvLNMvRa+J7V4J3cT24UlVznKkMB+X4ba7S91a5Op6A9haK4t0aOzikHN3cynBmAPDIAvU4B6DvUciLctEaupRwwPbRJOyi1S6aEYzveU7GYgj/VlWVT3/dk+lULFzqd2LK8T/TbG3eB4t+A7IoUbu20Bmbd/tGohfpBNC/m3E88ViomnumyiqFbG0H+HIOP7xzx3rI1GYJObyZmjluEiiKON/mKccMO3c4HIAqpRWhEZGzp97HfwraSyJLcwJsmiZTi35xuXPG9sAj6/Wsua7imaDRldY0g8yV55WBGO3PZzz096xLlp4BfTTXH2aMyNuUbg7cAYAzwrL6+ho017Fbfzb8R29q0uY3kYKyhQQDsHbL9MH3zUWsaaGpqN1c4sJbe5EGmx8WqPD87nGN6rnnrwTx6VwRd9Z8QraicS2yHz5BnIYKeNx7k9fxp+oT3WryTDS2ZwrlZZlj2DPr09+v8q0PC9lb21ozwqDuHzMOrcdST7mtUlFXe5luzatYwMheM8+ufp+VdjoEbYihC4z6D8K4/SyzNkYAPQkcgetd94XiJYNngDjI5H+eaw3NtkdRFE0UscP3o4gGc9wx7/hW0sawlN+2QyLuYqfyH0/wrGs2MsF1LvLMWA2EcMP8A9VaUMsflsJGySOOMFRz6VtFpIjlJWkk+026wMi28QLFx0Ycn65q+kxkwQpViuBx19TXLtqH+lNscJC2dnzckD/Grmm3Zk3vIQdvCjPenew5U9LnRtNjeV2lYfmzjjOMmsTVL0vCI49itId0hweaS9nMNnGCWw/OMfeX/AAqjdLhpWdWMoyAB/Q1TkXRpa3ZWMwZ2znPO7PbH/wCo1jTwtJeBnh3ynp3C/wD1q14YYEkeZYA1wYwjMWwQucgehwef60tvEpv9rqQQBhxnIXv/APrqGr7npQajsYUWmW0P2iPyRKznLOf4cHoK25NFUrHJbPt3rhQ+Djgdu1athZRSXIOCIV+8AoXJ5IOO5reks0QjAy6LgALwTjpVct0KeJcdivoGnizjMmSWyOB0x61rtJsblf4fkVcjGf6U+GcJk43A8f7xrMuZzuIORnOfcCq2R5lSTqSYmpX0dtZ+ezcJkliOpxXNeG3a+mkuZvlGcKM5OPejxQ8t3Zpb27FASPZU5xzWv4UsHt7eMSgPIowzDoSPT8KFq7hZQpt9S/DpgkuC4JCgcNWvDaxRyohPzHp7Vdt7cxQBmAww3YB6mpomDucDBxknH3a1SscrqNqw0OWbam0joc96nicouAFxnvTIRiUjGADgEH07VbQxMuZcBzyQeMVSdzKVzwMorRkOcdQPY1hXQETOrN845FbbuuRk8j0rKvs5Ln5Q3f1FczsapWMua7LrGxwMHGBU7SefakL98deBWNqIaEuVBVHztz/eFXdDu1uIQTgv0P1rN+6d1P4VJGRqEI8xWJwhyOmNpqLTBIoHBzn16it2/SObcF/iOCKqwWhhPX6U3K+h2OSlAj8x4dSQpgIw4z6+ldRDP80LL90jByOprnr+HdCu0DerA5zitCJikcYUEK3zp6A9/wCVDfU86SOmBGCeu3jFQ5DIQTuQ/hVeC5LZb7w6dOtIrKcKsm05IP51LeliEirMVhuPKZfkfnIPQ1nX0JkG0gY9j3FXL/D7Dt+ZTkYPFRO6OQr4BP8AEBxUlJamesXzgoCM9j1rXgbzokcA70weOxqKzjLbwAd8RwSV6061Pl3biU7WlBB2ik9yrakGpxtuLZG1xvC+hrnvFMYltmBXETx7wP8Aa7V2FxGkkBR1AKE446iuY1OPzbaWORdzRqdtUpa3E1oeWakWvLQRMFWWBP3bDrgdM+46VPp901xbQbvNFqgzsXk7sY+gqa/hWOd5B9xXKk44welV9JSeK6vLKEPIAwnWEAMGXoTjg8V6Cd46HLNWd2aLvbTQoTOxkVuGEWGxjjcR17D15qmJIbdCkgkSGTAf0BHRhxx7+ver/wBgtL7LNeBCF3bxwRj64A+lQoIoLqdNRv4o9MQiKSVI9zurdWSLIJIwM8gZA5pRaIaY27eSw1WF0mhiaPbIJIXJRTnGSeoJK8jtnHFJ58HlXWD/AKcq+YH/ALjjqvuD/wDXzWXqM291igC7AzGJiCC47Fh0BIAzj1qhZ30s1/OxRUyv3QdqIAMfkP6Vr7NNEc7R2Phq3mv77TpIp4bXZdFfMd1jZAfmwSxAP8QHtXZ2F0ZNanvLeJZri8WUrKjGRYEfCZDYGcRqyjoOSRXneibkmiWNgkUUpfzVjLnkAAkeoBPcV12nSpPex2scN1Io+e9iXIPlqwGwnHyjoORxu9qwnFXNFNmvDPvvRHLNBCZjAJJnZpPssfzYjwevAI4B9B2zX1u9ghsRJelJ9TaQtPJIWMszH8OAoA56Z6ZqzepLaWcYtoooNsSGBgVLopABfbzy3B3t83QrjrWONLjuY0LC6n1FyZJSzARiLgJjvknOc+lZVLLQ0heWpg6hNdasVaXdiTBkllyG6kKpJ69M8ccilntYLLL3SGe424X7RuHX+JV45HbJxmt+6nuNGtlcwp9vMi7WBZ2Bx1Dfd59DyMVg3KXmoXYElrKjsM5jG8k8Yy3TAzmst9jX1Kkd7coGS3llilm+WRlxjB42nntx/kV0MMZt7ACVfLDIWAAySOxz9ay5rR4LyOyaBPNVyJJFkL4PHyjtgd/etbU90YVckvlUPfmqlskOOstDQ0I+bJE6ggDCqDxkivUPDqOsBBG0DALDknvXnHhe2Z723jlbCIS5PockgCvU7DMaQgpgDOcnqcd6xe+hpLYsW7RRWMXl8Eueh5I7is241OOKOdSdzsCh2DHze/r1FMvLkJEkQIXJY5A6Hn8jXDG5mvrmW4TabK2cRuVI3F2B24Gc9uT2pw95nRRo8yudKsyxpE8gDJkbQxwMZ5H410NrM22NWVQznJXPSuXUm6ZFDBiFypbGOP8A9VdJpwkiaKZQskinJVsc+31py00Qprvub7IouQiEDYo+8eBmqd+6PfgoT8o425wT1J/z6VTEctxcSHcxlYcrnguW7fT+lS2i+Zt6rv4XIxwOPy56/WqTuXCnyq5NFEH2sGTO0luD6Z61Ba5a4jeVgg24VW68ZJ/Lmpb5gtu8kflq6jhlB59c/XpSRvbSyQwpG5WNsGRhw3qR7DOM032NoNs2bMo0ixoxw45weQMdSK1mJNwIsnAH3gc5Pfj6Gs/RhLC7yoyuGJAJGTtzxWpIHMjDBIQAHA5zV9Djrzs7CiYyW6/KVG7OMcgetZGrM0ce9iAvQ5ODitWTO0oo25xkE9+tZ95BHcyRxsfkyO/Ujkj9DSk7rQ54vW5mW1mJJQJ5BsB5DH73QgfyrpNESdon3hAnmHAAz8oqrbwAO5AzJI3LYxx/hW02II0EPILBQen1NOOhFSd9C3HIjyAMwMaLyO5PYfnVtFZEkGz5nIwPSqOlqGdpJEJwQBn161oQu7Tn5Q23kn+VbI52tSytqIIE3AM65bntmoJMM25up56VYvZS20KCeenrVSV/mwjA4HPseuKenQNTwOZCFYAEk9RVO5RZoTuzjHUdq0bmNllLYyuePc1UnyocIOvABHFcrWptujlb6NJIHRt29TuB/wDrVX0W0a1lDA7VY9frWlPDsuuW6nnPp9KbjY21gSB8p/oaiex0UptKy6krW7edJJuBLfw+ppY4mmhCbckHBx3qSCRWBXO5u1XLRPLhMshO0dhzmpi9TVzaRQMO35GAxnFSWkO9Iwxyy88dKuyxqFLgnczniqOGE4GSoUnBzTZle7LUIMG4AgocEZNPLsQxGBnpk1TVZDZS+Yx8xidvfinW0hUhJFXds2HP86drk26jbtw29QQCvPB61Vt5g0KCQE4JU5OMZpLw+WVO456c85HtWV5/lSOhYsgxyOxpW10NFqdBAriZn+Yg9Vz1FMlge1nmmmupJ5Z2aRd6ABRnhAB2A4z361JCDHBb87v3YA44z2NGoB7lomIGxQdv+H6UrdxvcvKwe3diN3H6f0rJv7dSAwIwc8d/WrMc78I+cEKQD3qGcsiqCw+YE+uO1CViHueWa8rJc3SYIDLnHuKzbwtb6jYXMGVy3kkhtuQ3T5u1dD4tizNuI5Ylc/jWFq0e/TpkTIKAMo6/MuDXfRlojGorxsPhmaJXSSWXyyGYJOgcNknjcOce/eodRmth5Ri2CZRuUKh2t6HB/lz1qDzUuLKK5jiAZlO87ThTk9/f8as6hayw2ttPqMA/f5EbpJ5kZAIGGHUexBqrWZja6Oe1RvmAjSSNyoYKyYyO5HtWcrb3XcxJ7+pNbesTXN5NNPeXE95NMQGmnYvJkcZ3HJOOBWIwVZnL/IQ3KqOc+o9q6E9DBqx2GhTybEYQo0pZjG7sVDSYADemFzn/ADiussH2xM5nCQyZTykBJaRR94oPxGT3rlfD8MS6dDcGa5JLunzWwdVjXBYr8xzjPIx6c11F1ezW0kk8luirOyIiKfnK7SSB6ZzljjPOMiueqtdTSDL97esqskkUUUrOseGUDYBwA2OS3B4HfJNOuNailEWx4obaELFHDsAdQq4AGBxzk55681iLYGOH7VPEkIlZmjIcsUHIBC54Ge554461vWnh2yjnhknW4GYTIzXI2KjDPyk47/KRke1csmlozqjHqYkivdzY0+CadFk3tLISEyTkknpj+dMv9NaCFpbnVWjQN8xiJUEe5zn+Vbi2huLc+QYHnOf9WrlsfUkJ69RXNeIJ7eBVW682eZdqRLIy7FAPTC9PxpQ1eg27If4RQM8zRlhHJKsajHOB82CT7kH8K6WWxZmiRscuWIHJrnvBExFzC8xUoxeZh2JJxxXfW8bT3aOvzLtEYI7dT/jRV3HT7lnwrApTMmPmJHPbHrXcR5VwfVQcnjHHWuc8LWRjmlRgSPNdMZ6YIxXQXLlt7nJBzu9eBXM2bPVnI+KLpoYI1U4kYkhV9/Wue8OQFnndFPALLlurdN+OwAz+VaPiLdNJE6DcCef9movBsfkrLdSAyiNnh2kZDEgjd9BnP1qqbtY9GnJRps6PSYszKmQpVAc54/z0rpbGEqMswKYyQP0xWLpcDKioAVYYGT3A5/wrfskAdIQdrHlmYZJznAH1NU3zM4pu7J1hBRjJ8xjB43cKfXjv2qOMTIoZ8F3wAhPIz6/z/Gnud0d15eYyiqrMBnJPT+WakhkYq7yDaRjC56+9aW6FqVkOFoJreYbgCiHYCeuQOtQ2cey1cSMWZV+8DjPPp6e1aFqyMcbRwuc+1TQiERLkL8wPHpzR0EqjRPZuLZI8ozP5YHB5LHoB69OavJJtQhziQuWYj24rNlIe5WNApL/MSR0A4/wqeKRzduPMXywNygetFznn72pZkDSyZJ4j6c4yfcVVvJY7eBpnyQG5OOme9WFYqAAqfMwZt3JUe1VpTDcXpikIaPY2V9TjjjvzRuQlqa+nOHhjMQDRtnygV5Oec1oy+WLddxZgORg96z7IbIrdVRh5aDGD7Y/OrkjARgKG65z/AErRGMlqWrRdoCnHJOPUVoQhQzeWgZc9zWekkcCAzOERcHc3dquRsIhhWBHX6+1WtjNokuTiQbQSvtVF4pC7HBPPUECrcrHe7Rqdu3Ctngsc9aqSqVIBIJAGTtzk072QkeN3KEqM44P51nXEZRcsSADnI7Vty5YYXbnsazLpTtJI796xki4s5rU8JJvz8rDPrzVeWVGVZWwFdeSR3HepteQxhQo68/KKzoA8+mOoBDK2MVlJHRHVXK8OpL9tSNiQr4KsOmPWuutW8yKP5uEO8D1OK4eW2L3EL87h8rYOOldnYj/R1UqRhcFietZdTepZxVhZ2C/KxGMZ/GqkihFZlbPIIB7etS3soi2s2CBhTnjmo5T50alOwAzmrRnawjSLEJED5+Xg46mqm4CaNyxyOvFNuW2gqSev3T1HHWqPnuwDk8jC5FWthqNy7qCZ24fLZ6+1c1NPtlky2Ru6geldFcuptUYZZskY79K5a6V/tjfKdp54Haj1KidTp0reSilsjIPTtWi7CUSxqR8v3SDWdphDWiudrMy4BxjA6AVNmRUY8nHBz2qPMlvWxDFdny1Mucrwp74qV0Z0maNiVRQ2D6Zx/Wsi4lOMSDY25hwc5Hb8K0bOTzCylQwwB9KYehy3iGAyRqhXMhkG0546H+dc7ODJYCXBBbjnuen9a6vxKMIxGRsYkc+h4rFt0SG0uJ7klYYomlbjOeDt/WuihuZy01OV0G5ktomjWUouZItoAPJ9fw4rTdIEtLlY185YwMOSRuUk84Ixgf8A6s1kaREstrbPE5+1qXZw4ypBz09+auefPGVDSOPM+X5uT7hq65Ruzmi9CvqakWEcaph3Z9qkfMMD164OfpxXOyvumYuWZh93Prx1/WuhmMkcpVXYrGuN3Y5+9n1rnsyLA+QAhYMQe5H/AOutILQwnudZoBuWkWyti7zo8iBATwpwWwOvbJ9hXU2RtY9SlmtAJNgP74klSMct7jI4/kK5LwhKbfUDOgwzHYpJGcMORk+3euwvG0/TJ4ZJh8oX5oW5yB0B4GSSSfTvWNZe8a0loaelxGO1VLgRw2zwt5UkxBYKcBmb09OemenIp1zr8TswAmeMxrGqyy5aVtu0M2R06HbXNT3jz2k0m2NF43KPlMpPOc98EHj2B9KSye281Etj513ghgM+XGvTgdSxJ4A+prndM3UrnQ6vf+dDDDZyfY47f5JHj3LjI7+/68e9cB4qkjF06qWGwFFJJJYf3ua6q7kXTzbW0WJDGxk3E+Ydx9SDg9OcdMVxyQyapcyy4kkKh3G0dgdxP4Ac/SqpR15hVJaWOm0Q+VdafHboN6xYkGcZz90fpXp4RoNMtxb5aTy0kbp8snofbtXnfh5A1/FdbQu4jAx2ya9E04HzLiMEeWv3SeeKzqrXQ1hsdDpcqC9lljJ2THcPUZAP9KsXVyIreVlAYDLjsScfyrN0va8YbkeWQF+nNS6nKFjRtrMpXgj1ArmlexolqY99CDZbACMjcW9yKk8N2pt4PLPDBiWJGCenNWmjH2WAqA3GTjqc8fpU8KEx7CQrRjGRxWadtjo53y2NCyEhumZip4wQOw7EVqWUi+aFBJwu0k8dxz+lUNOjeEsWIUEAkjBI7f41Fa3UcMgZ2Adc9Bwx7H8q1gZON9jceSGKQxmT5iQSTzx0A/DnmqDXazXKhmZhkZIx8y5rIuNQaZmJX75C4PUAdKI5owxZc/KpKk9iOP5U5SNFTa3Og84vJmPCpvwTnH4Vos2JHIwVQjcvQHHv6Vg6U0ty5mILqMsVPGfer6sRaSsxBDsFGf5U07q5MlZ2LsM6/aC/l4TJOB0UH1qS3J8zBG5ZGOQScjB7flWZLc48tjtDNksV6AdKv6ehTBysZZs5wDgjv9Ka1E42RsvMkjyEnaSQvHC/5xUf2eOSZZwNzHI2kfdqC0YNIoYAlVIGR/KtAThbcSpG0iiPkY59/pTXmc7XK9DSYsrRTfL5Rjxs7tVW0nzKruTsOSBjrzip5kPkhQ2CoGGPvWfClxa2EjRkyspIUH03f0Jq2zLobV2PMVFcZUHeB9D0qwjYkhJzhz0HSq7+ZLIxbpt544H0qa1yJEJUHyvmwT19KpakvY0HG4EDCAE4XbgZzyf5n3pkgkRyByPU96p6RYHTrM2hurm8cSSP5106mU73LYOABgZwABwAKW6kxKdzsOPrWljJbnkrIUUb2BOcnB6Cq9wN2c9MVdl2gk8jHUelUZVzkgDPbPSsmkikznNcQ7F9MYrD0mWQ3EyyDaW5/Kum1WM7CxQjB4JHBrj5JBb6iNpBB4PPHWsZ3R003dWL7RBZpMZGcP7itqDLIF+bI68dc1juW8+PYOCpz7YNaaqrqmXbNZPe5abasUtShl2qByzN374qzlYrQKVIYfKAOKluPLd9u5lKgdVIz/n1qtdqfs7hRkAHDZ75q9y73sUJpBvwW3YPPvWZPKYiVBAGc4HSpb5wjKFIBx82eMGsC/vhLLmM7Vxtx/Wt4x0NacHJaHQQTrJtEmWGclV61WvDJFJDtABdCceoFUtFnMse0HJBP1Nbd04kiikYZbiJWHYHr+PNZtakNWFsz5Nso3ZjK7uuKuMS0QLHO5d3ucVC1sSI0Y9BxngYqWdBEuWX3zUkMw9ZmXzRg87Qqsgxz75q/pC5ilCk8nOBWTre5pWaMEgnhc5rW0WJo7f5gSX59/zq3sNbGTr7j7M6yYOCcA9c1x/iG9MHh0Wat8904AC9QF5J/I4rqPE8geUs3HmEtweB9PyFeba7dma+hiZyvkx/KR/C5+b+WBXTh4XdzmrTtEvy2qJZRvbMxkRRIrAcj0//AF/nVLzm+SYPKYWfhn6p6/yzV6yviY5oZcG3PRguGQnHIHQDJPFVZLf7NesECLG/zFS27b1x/h+Ndlr7nLfsW4L3fcFxFG8aMxVZkyEXOA2D1I/n61iyFZru6lkYNGo3kk8t0A/Ujj61bnuGltGlO8F0ZQRwD7fyqnAJpIYxbhjOcqWjDbwpHQgdVNVBIiRoQhN7FGwyEAAdvr9O1dJEYIluJrqCW6uGUra7fm3S8Y3ewrlrSF5JnkCsE4Ugc/KPvHj867DTisEEkqBnuF3eXtjyqhuA27pkZz9ayqbm1HaxkwjZbqbkgSTyDairyMcHPpgg/nV/TxFbGeWGRkK4WLy+cnPLHPQf41X1ofZncyTmS5feZWA/jLevfPLfjUEM6x2MMwxteYbgevBz+W3aPzqGror4WSaxfSxqIrY/PPE6M/8AFgtggen3cZHqRVqxdLfw84VSpnBQOR1IwWA9iTg/SshpVkvLeJhhVKliO/f/AD75rctbPGmSXU7fOQ0ak4wpbJOB2wOfxHrUuNkkLmNfwuDLpzBEO8y4DZ4HHH9a7XTJN5lzj5yH69sAEY+ozXLeBdFvNQSUibydMXCNIOWZskEID/OukvrQaFqEUQaR7eZS0Ushycjh1bA69PwIqKtCVuc0p1U58puWUyLY3KybTlgQ3pjPFS3zotjD3w5+TqMcdPxrHiu2NrID91WwexGRnp6e9OiuRIrgNkqu4bj0IwTXE4nXytmqsgMaME27SAAB06gYFSs/Clg21ixbPPt+PGaoly0jiNFG8hgM8D2pftDyARthTHgHcOnNZ2NEzWtQotljSR02oQVJ49s1zsk7B8gsY5WOCeoA/pW9G7ZVQm9WQDLHrnuK5nVk8u4ReQEJjyRwOaaVkb0Wrsia7dCz7u/B/wAKuWV55gWNSSuMc1yss7GTCkFA5GfetS0k4ffux/Car2btc6lC6O50qciM7sgeWCo7H61tErJChYlTv/Djr+Nc7pp2hYnIy3O0Lknjjj0ratBulkRA/A6Zz8w6tQjkmlcqapM1qqy5AhLhWcH+EnnitzQZlWFCP3gO7BxweeGFZl7E13bp53zRr0wCSpznH86u6A6CKCJEV1MW0Y4Ab0/nTUvesKVnTN6C4ZptoUuisee/PfP1rUtWZQOCqSRkHcOhHp+OfzrIEqwBfKVfKb5Tntn3/CtdCyQxOMnapQt1H+cGrXmcU/QlMiptd+w+YkcgfT8K0LZcQngbRkjPU1nByxjTCKejH3/p2q7A37lixBY4I5pxMGW0by7LKlQcHp+WaIdwOem79fansURDwMDHPXFRebmIFjjHXnvWq3M3sWhIHd2JAwc+n4VWmQSvnj05qQYSDJOSzdx0qNZlOdu3Ge4rVEXPK2Y5Yqc55qlKwAAYd8HNWJSQrFWw2MAE1RkLO3c4I69KykOKuUdWLGNPMUDccYU5A54rzXVpXTV4IlGRu5Fel6lhgAV9z2Ga4i5tVe/EgX5gfrWMzqo6M1UjZ0BUgEjbg89RVyzTy4grnoPvkVBbR7NhcHJHQ+1XGkG2MIo39/pWTXUpMWZ8gbhxVG7PylckEn7tTSTBGAK8nrWdeyZieXoxPamijndZld8sG5T0rm7iT72fvH0roLx2ZZQoU9+a53YzyMv8ROAOtdVPY7KTSib/AIUJ8v5Ry2Tk11NpArSKJPuockkd6y/D8CxIvG3gCuhQgqxfBIPUd6ylqzlnK7ZPbBJMk4GFz64IFUL8sbUdi/JOO3pVgShInAOCnHT1/nVfUnCI6/eKLgZ6D8KmxFznrgbp0ZQcyHt2FdBn7PAVjxtjAXd6nvWFEPMuZvMXOEAU9l5/wFbOpuken7gfnxlueAKbQXON8WTrc6m0cYOzYNoJ6DH/ANYmvM5omuXa4GVEshC7hxiu01y4aaOTywWnmPlDHGFxjj8M1zlxAv8AZiDIQx8qeoJHb6816GHjaJyV3rYq2FzHDehr0vLbgsrIjc5xwfcA4PPXFatokLgM6CVUj3S+XkbhnoPpXNbx5zMwwrHoK2tCkkW5REfBMTLnPC59f0rd7GMXqPmtiLJCrkM+VKcZXHqPQjv61nQTXFpteNpVAO04YgkHscGtq4IQSZHyOxYnPBHAAB+lZHzveP5BwVUtuPHAOO/WiITVtTqPDUUNtZNdyp5kUJMJKkf6x1IXIPbv/wAB7VPosuIEszIFSSRAxzyhXC8DuMDJ+lYmlXAMAjSYJEZcAbc47bq1kWF7yWIRKkSlpAQ+TjODj3BB/Cs5o0j0Zd1i3WfT9QZZY/3TbVU/K+MnDY+gyfwrlZZmG15kj4zGoUcZHf34IFa2qXiajfNdXK7IPKRSq8buVXHucZ+uKxpTCskoRmlhgMqpkDLj5sMcfVf8ilBaBUd2XLORJA80o83aQigDG8DsPfknPtXa66scOjySOpRs8IDn5yMsR7cADHbHpXEaQiJ9mMz4kMkaRgjK7GOWJ/DH612Wrs2pNbW0ZYGQNtRSN33gqk+h6UNakJ6HsvhfShZfD+wBiG/TyFmOMbo7iNZQ/wCEhP602+0+bU9AFvbRLJeXDma2VsDGOB14G7kZ9xXcaHbQTHTbWYgWms6Y1g5PA3ooaP8AHazflWDZwy2kFnDLu+2Rxvbtns8ZIbH48/jXXZNWOZOzueQSzOiyxSq6TwZR4pOGBBwRj1FMhuJBHayIjCORjh+vTGVx+XHvWz8SNEGnSx6xbviOZ0hukz92Yg4cf72MEeuD3rmIpRJHGkOVYHhT/ewM4+vavKq0eRtHtUK3tIJnX3F7EMmPPkZ3RlsAgf49KgS/+XzepZcnL859P61h374sZtjCQbeo4A9seoqnpdy4WBpJCzFTk9/pXPGO5pLa56ZZlJY7ZwrZUAtk8E9sVh+KZXE0pcfNknn6Ve0Z0MJ3Ng7cBvQgHA/OqHi5wyd8hCT9e4qZGuHtzHHQrvaZxcIpVgQn94n0rdSYGC1wzAtndlevP/6652CNXLFjtBGB71q2m5niK4IVa3lJclj1YtWO80mUm5TzR8q4Lf3gAO1dDpGZfMEYIyDnHGAe1c14ck3RSuzLuxhQTyxP/wCqui0+BkgaRGIYfLx9Oa5u1jz61k7FuOIMk7SEj5RtA6ls/wCFXLVUjiijdSpfO/HY9iPwrPZ0Ty9zPgPh8DhhnitWFV3P5sis4UlTng+1CMJyLMUQM5UAv/CDnjPXNbllkxsGU/MBweelZMcgCxhmKsxBLD/H/GtWGQC1KKRnfkHrz9fTiqW5zVLh/H90HPBHoRV2JxEFZQvXcc96z1nCsWf7u7dyKV33si5KjPU1aZi0as06iNn25A4J+v8A+uog+SOQw6/Ws57l5IjHE6pNkYd13gf8ByM8Z7irluwbYB9zGV/KtI6kSVkXxl1XcBg9u4zUyKuPmUA98VAnGAckA/5FWYwWUEgfnW6Ri2eObxvZmULGpwPeorfDTspUr3Gf51LJvWJiMdM8iqtszbyXBII5NZNWKRT1YfeQDtzzWGtuCVKjjv710N4C9y45B4HBqksZMjMOUHGKxqbm8HoUHXE8aDIOTwe3FJMCiL5ZwVH1p9zkSggfd+Y1V1B9wUAbQ2cHP86ixpFkE07B8qowy9+cVFeOvkt8oXjAHXNK8RVg0hzx8o6fjWfeq/mgZbg96C9zMnVVDlsZIC9Oait7VTJuAA5GDjFaLROWJPIbkY7U5Yh5QTIXDd6uMnaxpzNIuWG1E56le4xyKuSPgxK7gAru471nRyqHVQuXHy8VakkSSVAy9AFHvipWpkyzA/mI/ILO3IIz0qheSiVkiUkFz36Yq4ZFjhZjhXIAH49az5FAvVVFJ2AtjODVIH2JdPjI1KeN48oQC2ex9KoeJr1EspYFDs+Aqsp4BJ/wq/FMFhkfeS8hO7tjNcdrd7vMnlbSgzwOORxu9up/OrirsTskZQxJcxQjB8p9xI6k/wD1gKxb1WW1xIFEbKznHIBwSB+BrptKjInLuAcRlm49ev6Cuc1FVFogB+VkAJHbiu2Gjsck+5gHnZhM7QWPHWr2nK/nM6HHyH5iOACMf1qlbhjsVslc5A9z6flVyFm8sqBwzduM/wCf6VsYl9JSbf7PIPMGRhfoRj+VZ7yB1mbbiVWLZ/2SfTtjH603JBDZUdRu61YtRG11GjldspX5yOg5/Sq2G9dCxp0avCbZUcXCPwQMgqTzn9K3bW3Efkxb1c7vLJjyNy8kj8s/n71DoSBplBaRZXLxO3QbQmdv1NTSyi3ItxOxRf3oAzlnKNt69gSoPtmsZtyZtGPKrmbqj7obe2U5mVgqdACvJGfxH4fjWGG2s+znJz0z9BWxcyRRTWxZW3pEzv8Aw5LKQAPYY/Wsu5Q+VIgXD7txIOMdsEfrTjsZPe5o2mwXFuz7wiyfcAzuGecH6V6f4KRJ/F+lLNhQrxIqD5juaQbe2eTj8xXlNmnyWcbsTEXUHB65xyP1FelaFMY9XS7gJjk8xWheJsFWQAjH4gGhu2olq7H0IkuPDN49pzLot2s8OBztibDD/vjdU/je3W2v21GyO6JmF5x/zzkXDH6BlyfrWZ8ObtLqCF5SGg1C2/edAN7Ahh+ZIrU068jTQdAe5ZZXtWm0S7B5+cD5Q34qPzrq9DBq25z/AIi0a31HTtKs75Gl0253PM6ttbeVyrBuxHY+1eXeM/BNx4SjgvoL6W/01pNiytGEeBj91XxxzjhhwT6V7HDdvDB/ZFjF9odeFklHyQr6n1+laUmgWE9rLBqsX9oW80ZjnEx529yo6KQeRjkEVFSmpqzNKVVwd0fONxKfLkMbO6bcFsYyCOcj1qvpyE/umK8Occdieua6DxH4avfDWpyaReKZoyvmWl22ALhM43AjuOhXsfwzk20CxXi5DsoGGXGGJ7j868qcHB6nrpqpG6Ot0qTzA0Z2oxcAnI49PwxSeII/tnmbQBIi44PBx1x2rPs2WJVIcFeCCB1HPB/StsxOIYXK435ycZOMEcDuKykrm9O8HdHCRQMGU7CM9yK17K2LFPMAwcHAPQehrW+wLMzqsahkTlgMA8VfstOVRIy4jZWVSD6EdqhnY6ysaek2YW3iIJCkEkj2PStu2QeTIUbBLYwevuRWRZJJIskcjt5KgKOvNaN0/lQIIlwVU/Nnhsdz71KfVHHNtvVlpZFUHDg8gBs9DVyEmKU/KG8tugOD+VYtpMvmQho1XzBu9AeOvNaVpMWKuXJdzgnGeKCWjZEsaKMMCCc9OnYHNOWR48xNIWUsApB4PJAI/PNZqMDtCsMFs7W449RU8KjcEmGFDYIJxj1oZDRr2zNIMbuhI471Bq1wYLOSSQ8pGfmz0x0qWFtpA2kM3OD09vxqj4hhWfS7kfPvdSAw5yD61XQxjrJFHwtqb6lHIzsCVAHTnFdbZStvVCCdoOP0FeV/DB5F1C5gk3F8EEt2OeBXqVgdkhOQD06dO/X6mtKDukysbFQm0jVEp2cgFseucVbjx5anDcj1qgjjzQpPP9DWhEwKA5P/AAHpXWjzmeK3MhXcc/UnnHtTQdkROcsefeqTsxdlxznr2+tSysSoVD8p9KyZqtEMJEhDgdaSYYYR8AbRyTT3jxEgyAf5VAw7sCxwFOaykr6lpmcB5kr7sZAwMdahvwpDNtwVXIUdatH5XLAYPPFZ9/Kom2cgFR0rPY1RU8zcAHPzng8dBTb8fKuAOnrnBqtJMrSFQ4+/wPpTpn8wYZsDPQCgtxtqV1EbcbuQMnHI+lZ2fLuA0j5AH3atyFYgwjAwTgH/AOtWfdyhSVVgQejetVBX0GpF6ylDTMxJJc5A7ir6SmW6j2qdqDkA9TXNWVwXvJ8EHkpj+eK6O0hPlCXIDHOP/r05R5XYC3KVEaMWBIPQ9B6VQaRpJj5bGPanLZ59f8asXUi+SwYgou5gBz82OKyGcvDExJbfzwPz/SklcTYy/uPL0yRi2CASoHVmPTNczCvnXqcgxIuzp97jJ4+vFWtdu9w+zpkSHp7k9h/Ok0+Eo0Qj58s4HHU8dfxNdEFZXZlJ3diybdorSNgcCXch+bBxjk4/Sue8QwbtPlKL+7Q8Hp+FdYUNxP5jD9wHCuVHTqT/AFrM8RQiWzuEjxny2IDDG7j/AD+dXCTvqRNaHC6YZADscggEYXg4PBGfxq2bZp2eCAEuiFuPbkn8uarQ5gSC4CB1B5PTJ564rTsrw2+qTTR20I3WssRTLYPmRmM9TnPzZH0FdUm0YRRjRxlGZCOVyfXPNS2SNM7kAh1UEhQPXnH6VJfKou8qCiMgcL6c1HYSmOYEdTuIOf0NUpXJaL5nJjYKxDrJkqDlScYyB/I1HFLJ9qjlyWKNvIzyNuOh/WpzAlyWESBTtBzngexpbmB7V1BKNIVIwD0J4/TJzUXNGmM1CGTbDOfuMmNpIDfeIAx9P5GjTkV72N5x5tvJLhgpwzBlz1P07+lLcRDCSP8A6sSbGKknkc5z9D+tPiwIvmKncgUg8c4x/gf/ANdSpWRNrl3StNW602yVm3AYbpgAZOSfzGPWui8Mz4t4JEYo8XyLk55BwDj8O/Y1Yt7Saz8EW74IeCKOUKygFd0h6kckYGfbNRaLbiFnOCrrM8eTxtYY5x9etTe6ZUF7x7J8Nr6NHu9K/ityLqLPHyMfnH4P/wChCuo1jfLoviexi5uI5TfQ+xISUfruFeTWV/Jps9nqFuqmS3yHUD5mjPLj34Ofwr1WG9VfElvcKyvbX9ioDDkMUOAfxVq3oTvH0MsRT5ZX7lzS5kls7e5iKmK4USBgOckdf1rdjkLFWH0/z9a5Dwn/AKMl1pTnItpW8s/7BOVA+grqrXHljnkY3AVszFGb498Nf8JR4Ze1gXOo2L/arPaOXyPni5/vDGPcLXgtkWkkW5jjUyRMJCkgyG2nBUjv/wDWNfTFnK32kEEbm4X68V5F8WtEtdH1yHW7WGQafqbvFcpGdvlXWCyt7B+Tj1U+tYVqfMr9jrwtXllyvY5W227DiMEEkYJ24zyMfSti1kjlimE8rrMCrRKQTv8AVQew71h2OoLshE0IYCIK5B4dcnkjseccegrV01nYTzRr5ghjLYHRVJxk/TivOa1sevo0asJjnaZvk2uBt9UPce/SrHlb4EkQMrRNhiDnB5wOfYVkWMxiVh82GTIKrknpjj0rbgYy28ndioBGcbh6frWEmK1kWGmd7ZAFDDO1uOcmq94fLt8ZUPsKncc1ctETylJYqVIATuOOtUdUthcyQOrHzFGGIHyjnj9KgUbXsVrM3M0gVpPMIXYA3IVQO2fxrRvrmQhVtwMiLGc9ffH1/lXO2t1I8pQMdsbYDkcMc/pxV2eSNZGVA3Q8+g7cf0pGltTU0a7lYrFKXY8tydxAz29u9dLZXX7to8AljjLdCBz356V59ZXUqSzO5AfIdRjgDPT8ORXZ2DA2eWYALwpHbPofxoTFWjY6iFg0cZPzMMZwp64z/LvTrpQ9owUE/wCf/r0lpNgB9xxgAflUxRjENozkevA5rRanB1Oa0zTksNTmkVCscpJznofrXS2Eo2swU84XHXNMFsDMZud7KF68DBPGOmetOtkCS4J5DfNzWlJW0FVlzamhHmSdnCnC8D+takDMqYBwM+gNZcGEfCkkqOhP61pQMvlDPP4V1Q1OWR4KkxIOMsWNWUPzhmIqiCEcAkBVGasRuSjnj8B2rFm2iHTykMi7Tt68HtUNxOAdqLubrgnFRSSFpjwCO3PT2qCQEOzM3I/OokVFdxk8gWIscswxk9h9KxrmYSuVBw3Xird7IRG6n7xORj1rHSCaSYM+RvPWsmbRSJPs0SsH+85OOvWi5CPK4IwVbA9OKsTqMKnfOSTVOdTtO3t6mmtAbuUr6cMWUYRBkbs9awrmQsGVeQDxVq9kaaR1+Vcc4PpWXFc5mKkfLnB4rppR6oNi9o6FJ+gzu3NzySa6vz2jjihZUWQ9WzyB1rmNCyZZpdpIH8XbFbssipCzht5c4346DHSs6mshxehX1K43fu4SfmzlmPX3qqZAJtu9lSNdpZe471EGVjNKAcliqbuv+cVVv5fJwkIZm+6CwzniiK6EmUmbi6ecnG3KitjSowbhuu3b8p/2qghhWNMDJwvPH3vWrtqiSShRwD8xK849j/P8a0crrQmK11LZYJGrDjaQ20/r+IrE1aQBfJO/bIWXIPQD0+vFbUiM9w6JGy4xkjj5u5rntb3C6gjcNtTLjA5IIAx+GR+dXS1ZNRaXOY0SFJhNDJkAqdxPOAO9SzxHzfMhP7vGdzdTmrejmOTT9TVIJJCXIXHVG4Kk8dyDx7GopCDGoRMO2A5/2hwR9Oa0lJ3M4xuincgzzlmyy4CgnPzKBgY9gAKLuJ7WMsMDcQwbvjPH8q3haK9kzAcLlc4xx3P51h6iJDNbW7DO47mTHJA//VTpz5mE4cquaumsjiDZkmRW81AcAr35qXUlgt/N8otKqj93I8exiD1yOe2R+tQ6IoHzOuEVsHIzkVfuLYXElyWZWjEXygnljnoPpjFTKSTKUbxRjxn5WKyERA78t2DYGSPbC/pS3Nvu0xJyQPMbfjGdq8L/AEz+FIYgpdFYsihxnA5HHb8BVxHZ7BIJXPAKE9gvOD+f/oVQ5a6C5dDtkJn8OsGZSLiHZAFPDYOc/TDZqlpBG7yxJv37pfXkn+ZwDU/h28a48PaXEYiJIrVo3VSFLMGZQRxxlcA/Q+1MsFZNaW1jw2QQuT0w38sCtUly6Gafvo6VGd8FVMjhtxA6sCfy9R+Iro/D+oLBapp4JD2J8+1wc74DkFAf9nPT0ArmIGiJAVcMVyWXqTzzknjkCpEZ45HeBgJUTdCM42t3H8xj0IpU5ckjrq0lVgeo2W37al3GSwkwpH96unikAIc9GwAa4fwpdrcQAkYKABV9B/kH8q7C0+eLC/fGSMdK7jyXpoa9qdlwTnDAEg+hrG8Q6VHrOhahpM7lIbyPYJW+bypVwUk+oYKfzrRtXLxk9SvFPcpGnz5O4gBR1Y9hSA+YYVuLW5m07Ut1tfWkzWtzDjLRkdz6oeMHvkEV0GmOyQlzKqIq/L7+2P8AGvY/Ffg7R/FMATVoXivVIIv7TCTpgYC7sfOoHY5HpivK9T00+HtXl0a7mWaZY98FyePNRsgNj3xg+hB61yVqNveR6+GxSn7ktx+nMgDShhG+F/dHvnOcfStu2kR0PlMxQqSeQMHFc3G0cauJFMxDfKwJ445Bz2yetWoHia1kAVhOsqujZ+8mMEEHt0INcEkdWz1OjtNx/erMvmEA88hsdvqO1Ss9vllmLG4flSD27g1mWsv7tE8wPjGVx0I6H8ajuLm3uGdY2ckAK6MuGU9/wrG1g5W3crwwgCWCEcNmTDDnHHOamtI2MaI0QaXO5mHGB6H/AB9qWJWdS1ocsMhNoy2PQfrV7T0lSVZVViAoU7+Mg9ePr3qbdzSWiKSw7rgqir9/G0dh0roCTbRbsZhQduQMf/rqS3iikJkjRQSeRjO38fzqK4jRopRIThgQcnHPtUk35tDotEu1u7QKSCMBQ3vW3br5i/JkLjJ757Vy3h3bBAYjyc/u1K9Oe+Ovauo03d5vRBg44NbQ8ziqqzdiyhRHT5sg9vpUEkRaaV1UFN2fX6ipI3RJSTgryeBzU7oGRsDkr1z0962juc8tCvDJumI+XJA4Na6PhfkUkdeKxQDHdAuAG5Ge/Fa1uwaPIDn3DEV0R2MmeCI6+aCVwKLu4EMbvvAJGOvvUBdvLYnGc457VVkQXL/vCdgPQisr2NYpXLMbqylk55DZFLOxUgAZK4JxQMJEqxrg547ZpF5BOzDFs56k1lK5orGbqUgDou75slvpxUCyhsAEHGM84qa8jDSrlSxAxWeP3eXl4QHP1rPW5qrWI76ffd7RtaMYwB2xSXq/IQVG4gHr2qJpg04fGGOTx0pszh1XaMyn16U76iRiXmWZiVIYdMVmCB5jsUFT0JHety+hJG0Hc/TI61LbWyQ/IAzcck10QqKKBpsbYxLb2whB5HcdDUWp3LRloYzgkZ3fTqalmlVInAyUBxjHJrGnD7ru7lbkjyokHT/PSpUW3dhfoaCSqNOQfxAbixboO4+ppUhMvkSSK24scKf7uOv1/pUVvGXEW5SyKMNnpu/rxWlCd0YbgEDYD/hUSdnoUlfchYBJFb925B3FXGc/XFSafbGM5Yqrd1B657fh0pX8vzmG3aB79/rV2JTvBRuDyTjpQnoDHSQKGYhtpBGcZ+X/AD/WuW8UShAiKoyiuST1OccD8q6rzGELoASEJZmHHfj69a5jX1TMsgO+HKxsQeBkf/WNbUXdkVHaFjlLXdDdyeXuxJtBQZwTjI/rWjqNoFvIUSRz5ih5MAja+SP6CpdDiAe6uyyo8LRqsbdCNuOfzrZvrUJd2spVypl2ncMAfQ/jmnVqWkTTjdDHfzNHmtVXEsoA9lAxj/6/0rltTUedZjJDl2LuOcdh/Ku71m2BuJfsoSKLZ1GfmPQ4/wAa8/1QDETxl/kuNuD/AHc8H8c0UHqFVaG1AgtYjCG+aQrIxBwMdgf61rWs0L6FIECy300ixQHHQYJyPr/Ssi1ZJHklZZQwyhbd9AB9Bj9a6Lw9bxsEnQ5mhBRTu2rH6EH1xWU3ZlR1MnV7BFuk+zA+VBCI2ZhtJySGP/fRIH4VNHZgW8si489OW3dJEIOR+I/nXV6ZZwRXKSvFutpg8Tk87hjP881iwWwS0kjnOzzEOxn4IyRgg/QDg9jU87KcSno+Y4ba3aVWaMP5fmLkEcYB+vIP0FWIz/xMIJYVJRiGxjpkZwPzFZ5Bi1C2eWIBnYrIicKx3AHH5H862bxlkjyjCK4iKxMgGCqoQASPfiu6m+aJxTVpG0CUaNiECkBtykMSrDkcew6e1Tq++NlVVLK24N3/ADrMjcNb7nc79+QAOgx1HtnNaMLYQENt3KQ3HGe1Q1dnoUnoaXh6/Ok6xEytm1k+S4OcgHPDj88GvYLDeI/OjXeqcEDqR6ivDhB5srW7uFjYbFc8feA547V6h8M9aLW0VnqEmJo/3Zk7PtOO+OvBGfWuqjJ2szhxdLllzLqdxHHuhF1bK0kMoG7audrevt3qWCxcs0sjK0o9OiA+lSQxi2mlls3ASU7mjdeAe5FO/fx3BkXowAJUcce1anFch1e1msLQkgtHImY5B0PoPY1xvjjwx/wk2nJ9kkji1W2Bazd2wuTgmNj2BwOex9s16baSpqGmzW067lGEUH+LIPA9xjI/Kuckt2sb9oZSGjVfMjfpuX1pb6MqMnF3R4OzX0Ec9vqls9ncRSA3FtMuxoZG43Ad1IHUHB6ipFbMSIwVPLBAcdcdcfTivXPFXhe38W2SO0yWmqQqRbXR5BUnJikHVkPX1U8juD5He211pmqyaVqdu8Oo2+CSW+Vk28HI4YHsa8/EUeT3lsevQrqqrPcvKN7pFKGSQYdiGPHf+tSSyq26S48wSjCRvwSwHHJ/l9KhtpSZ4iM7QOD/AHD6VciYB0LbGccbXGQfeuBy1OpNos6bE2JJbZlDFt20E9++PwrdtGcFliXaWG1geSTWHZMn2hSHKxlgGCjO09zjr/8ArrVsZJJr5lSXdEowrjOM9RSu7EyvLUvqBFCquiAcjGOT65p80UUrlmBXGME8kDFKVfCshLggg7uRn6daUsqRrFIgVi4KupJx65/Gp3ITG6VHI18LZ33FUeUkHO7aQB/OurtSUA2DGAep4NcfbMbS5jkhwShOO4IPHNdTZSl0+c5YDGMg1tEzqK5oRBZC0rDaAefStCCIbcqeGB6HqKo25ycn5geq/wAxWjAwQHYuFHp6VtCxyTM26UrNvBO1WByeRipo5QEG4NU04EsO4gAdx6VnAyqoA2nHq2DW0WZyPAZJS21Yyck81fg+XIVQFPrVGzjGdzNgsOB6Vb3bANo5HfufesGarsSdWOM5Pf0psxJ2hGy+MU6Fi+WbAPQ4qF5BvyBwehqWVfoV7o5VuOowc96wL6chB0UnJz1xW5euNqkZBJ4AFc3dCOSXEYIXgE46VOxpF3IhKBKF6YUYxU6bgY88HGcdzVWGD9/vc9Tyf6VakYRkgAlgDtwcVO70NbJBBE8smQrluc5HaoHmMJk8zOAB07VIJnRMxjLNweaoc3E0js5wOAnqPWriu4mVsq0iNKw/eAkAfwjNRQsLi5MatuhiPAx95jUNx88m0AkjjHTAqzbwG3crHhuBkjt61q3ZXRNuhcUhJCA2VHG3tn/P8qsWjbQ2ccjPTuetQpnaPxzg4rQhTDJuYYxlvTJrBstqw3YhYsPunBYntir0DP5bKMYdhnPfnionjWV02rz1AZhjA/rxU8LqiLLJ8xzkZPWrIbIdQxhiwXcGw4A53Zrl9aUOGSIMVHJOOPlX5j9O9dRqc0lxlpO4HJGMdu3tiuX12TbBsQsdq4PP4n861ptXIqXsHhy3W+hXIA8xmcyYz1YAZ9QNtat8wlSG3dy8iSgyZ9TjIH/fK/mKh8NutlYW0KBdwiUsVXrnnPPfJrSNmqy28g2rJIS+/GSMODg9uBms56yZUdEhLuITW0VtyqxM2cnBbjIXPryf0rz3XQIraVecuokGexDHB/L+VelaiUPzoSckNGxBJyEwB9D/AE9q4LxLABbOyHhyVyecdCB/P86ui/esRU1iJpLPLDJsCbnjMzZOAeOBn1PavQ9Ca2s7GRbiPaIYvNhV49wL7RhiR69a8x8NbpBbgEYGdy9xj1/KvWPDwnWeGMyIXSYKCD8mMcZ/WlW0kOD90guFC23k2pJIYP5hJ2lVYHj3561a1CxtT5BKs0TKp24ySQSOPU45H0NE1pNLaGUMFRZDAiEEOoJUscg9f6CpodPjGVIJitwW54zuyAQT9cfhWbTRaaZyl7pAu2u4otqGCVGiZWwqsx6U24EcN+JCjIk8Qd0kOCHAAYfXP8q6XVLNMWojjJa5j8jAPO/dwT9MflXa+CfB1jJ4P1S7kdb3VbwzQbpY1KQCJy4EeRkF1Byc87gO1deFfPKxy4n3I3R5d5geOEq4kUAuCPT0rRt5WaTJXeJD91fXgf8A16vfELSIdP1aC7sbeC10/ULeO+ighXCxEgJLGB2AkUkY6Bqxrd98wjGBI5AAz1zgAfrWsotSsb4ed1dGoxZo1lz8pIAf8K3vA95HZ+KrW2vnYJfoIld2yNwwYwfTPIz7iuaCFJHQ/wDLMkOpPP50yeMSLJC4cDAwV6gjGMH1pKfK7nTVpe0hY+ibTzI3by3YDuGPT1FalreNuaO4HIbIcV518MPF/wDb8Nxpmoyq3iDT03SEcfa4eAJh/tDIDj1578d5CPNQgY3nlTn9P1rrTUtTxJwcHZm7LAsItGtzu8yQz7v7oAGP1qHxFAs1t50GSUzLHjkgf8tE/L5vwqa1YsvKgskYQZ6+ppbVmbzIVwJQRJH/AL69R+IyKCEY6x/IssfzR7QQB6Vm+KPDEHiqxWN8xarbRu1ldpwyNgnYT3jbGCp9cjBrXsMQymIqViceZCGPIU9vwwRWP8RtROkeFLqO2cpqGpK1pa4PzLuGHf8A4CpPPqRSk0ldlwTclbc8T8P3v2hCQCY3TLqRkAEdP/r1p3LfZoxiJhIMbWPOR3//AF1hWUMlhOFWMxhFCYUnkd/wxjit37RMkQUZMIIcJjPbGc9eQBxXgTtzaH0SWmozT7tXuJYdjiMkkE43Lzxmum0wFJPKib535YDk8fy6154jyR36HYVQsOMkd/WuwsJoppzIS0MUmWBB3BMdBnrz60hVIuOh0kly72/lIoQ/eO77vXn3z/WrRdGnEzOdvHQ+/f8AOskSg5YgFehY9MetWLaTdMu1i4I4C9MdKE+xko9SsXkN26x8RqRjPY5PT9PzrpNIuHcneMAjvx7VliyWaTeQV2sQCpxzjNWbNvKmRjyB1Y89e9aQ0IqNNHYgZjy3HA6GpbZwuUxngcn2rOg2NGwHJGMZP3quQKIY4lQYRQAAO3tXRE45ItuyspQgEYyMjt3FUJoyHOIlcepbGParm5QxKg9emM1FLy+WySeeRWiMrI+dS4VQqNweM/0pxZ8glQxY4AFVGlDSZA+bsMVLG2XI2k4Hc96yZrcuGYBCFDAHt0qorFc92AI9gKduR9u9mwOpA4zVe6mCJGGBGSWIHYe9SxxXUp6jOYVKgglRhR7kVThhQQlixaR1yTnp7VFPL9ruGlYbF52jPqetW32pATld4UYUelZSfQ3iurKbAxxg5ycdqYGL5D/XNNfgqpVhu+Y1G77h8v3SOvcULuXYRzuhICdMAkDGM96bGYtzDOGK857iiNmIAy2GPUmhlQtyDnoM1pFdyl7urKch827mcKGA2qMHrj0q9Am0suUDZznsTVZURbwhjliP++ausAWAGAvv6e1OWovMWFFbopPTaPerkMZzuLd8j2I/rVeJDsBPBHKnHXnrUqMNhyQQrc5HJJrOwMuPGrxvI4AViOD2FMt3UIq8MqnLZHTHalb5ZE3yH51Bzn5RThHuSJidoYZA6ZqzMr3DYiiI4Gcndx9RiuV1eT7SGtoY0L3DrCrYyVG7kj3Iz+FdFrUoWVtp3BUySBxnHNYlopl1S2dFyYUaQj2IK/nz+lbU9NSJ66Fm4u0XXSluSsaEoB0+Q4H+RW89x9ojs0PJLnj2wOv61gtYGa+WQsFYLvOO3p/L9a6ewty8bFygBDHA525OOtRUs7WNpWsiOfysbTnzdmVPUkdvpiuH1sboFhUKE3biScndtBP613tzD5UBkVeEXABPJ+vrXFa7EVQKq/vCdwOOv+f6UqejMJbGL4PRpJA6MqMJD8+OPpivSPDd6tvh3OxHQEg/wup/xz+deX+F8mYhWKjz8cDPavTdPWO4sZCP3MiqAM47EcfWqrfEKl8JvyoqwSEfMZJFZcjpyBnPbBx+dalzEqbJY2CNC2Xjbq+CMg8dmBrnpLVJrR4IRhUGSjHAJYHoT784rW0a4ju7mEwRxmVztfdhTyM4I9Sc/nWfQ1QsFjNcXDbo0Kyoot17hgp5+pI/WtbwbeC1u77S5WcwX8a3sIDGPa6H5wG6glQ3T+5jvmoLF2YF0IDK4GzHUbcrn3P9KkulkkjingK+ZbuZlb/pmwOSPxyCPQ06M/ZzUjOrHng4kPjuD7d4at5hnNhcMPmyP3FydwJHbEiMMdtwrzpVCRLjd5gPJz1Uf1r1Zo4tV0cQofkuoms5ElPK/wAKEf7syRkn/pp715YI+XUkgIwyOOvf+or1KqV1JHNhJ293saMMiiQbjhCNxLHg47/jxU65kR35Vx1BHD84P14rPg83chcjax2HAzjAx/Lmr8aq4+Qq/GCc9O+VrmkmtD3aaUlcorFPpWsW2q2u+C9g+eGZWA8vj9RjgjuCRXvPgDxNa+KtK+326CGaKTyru2B5gfqMd9rDlT9R1Brxa4jZVdYiFdMPhjgNj+Z5zj61D4S1e78M6omq6XIJZQPKms2BC3cROSpPYjGQeoOPerp1OXRnJi8I6uq3PqMgqA8W7ccng/z9OtOZyY2mXIkBBB7565rG0rxToV1olvq0WqWsNjMDxczLG6MPvIyk53D9eo4IrC1L4l6JGHj0OOXV7jHylFMUAPu7DJ79AeldPPFLc8aNGbdkjq9curaHS21W5kFtDCfNZj1DdHQepJwwHfJrzLVb+58QalJqtzmLeoit7QdbeLkYz3J5JPr7AVnahqF9rEzXes3IIVyYbeP5IYccZVM8ntuOTxU3nxWi2yDf/pZPlqSRlQ3UH6hh9a4cRW5lyx2PUw2EcNXuY2pWu26njaENEwVopQx3KeQR+gPHrUkM0khaR85UBXdB1ByPpXQPsmLmVfkY/KCCMHOCQfw61TtLNGlQ4IaPIORjJ9vb/GvOkrHZ6mXd6eCq8YJYsP7p/wA5q1pUEiKoO4sq72DcowBwCOcnNbC26yICVyGzkKOgxzg/l+tWI7QRokbSF4shEDc+X3AoTuLm0K1pIMlFXy8kAgn5f/rVatdPZHR1K70bcVBx0PQU+2tpxIzHALAluMkj1rZsISIoZIzgSHcWOO+f1oS1M3Ow6yBKMxX779AM4GOoqxNCd8cgCbCTGwHf0NWlhwu4fe24A7E4pJofPhdOQXAA28EH1FbRRzylcjspF3bGAIzjJ4xWvACu4Z+UcAnuKwQHSfMoCkEFiR0I7ite3kSXeS4f5gw2n5a2ijGRY8xMEYy4JB9TT2jduUnCD0K5qs27fmMDzE9uo+tNaebjy4vMGOTk1ojNo+cHlV5FwuI1GCSMZNSGXyzgNkgcgVSDKg4UYBwM/wA6PP2EK7knPYenesXuWkWppVRSofC7ck55FZd9e+cY7dfvsvzc9PTP+FRT3XnN+5G9ickk8Ae9LbwLGd+d0p5JAyTWcn2Noq+5Y8v9znjcOg6Cq8sucD7o6bvepmlLqdyZ9welQyFCo8wDC8ciotY0RG4UPljkNx1pk0QyfmwD6dDU8cA8rOSAO/tUdwdj7F5A745qkVsQbRCwAUtzzUDEsWHAAOOtT3cvlxswPJNZstwdu5gDg4Pua0jG4XLgAADRgZzy1WydwUIdxbls9qowl5ICeDk9M9Kv26gW7fMNx7gU5D0LAx0PzHFKiDeqnAOdoqaGL91llySO3T60Ku0g9Q3U4zioSuQ2PeIBRkYHQnFNdyxErkkk4AB7elOnkYw+SpDbTuODxUMx2wFl2kt0GOcVSViNzM1R1WF5WIJLhAhz065+lL4eg2288+0eZPNtPoFAzx+Jxj2qprMp8uJOrspYc+vb8s/nWzptq0emwq4O1fvt7k5xj65rR6RIWshhjPluyE8AuxJ6jsP0rWs5WEXlsCrbMls1RggDTvvDAkDCd8CrZWQL5KAgEkgt+H+BNYtGtyWaQ4WMDeCu3P1GOtcnrTM8SsoIZcDk565/liuomQKAU+VlYMBjGewrl9XhKxOquTuYqB3P+eacdzN6HIeHT5d1KvQCU9/wFekaU4iR5mUsSMAH6c15r4bJfULhcjYzErnvzXoult+5BIzj73Hfpz61rX3IpPQ3tyLGqpu+ZPm9Qc1U85oriKVXdXlUM6r0IB6fTpVy22BNpypXkY4NULwfY7qVJk3I+GjYD7hHX88VgjVanVQzGSWKcsrKu4lj6nnPuOlbUZiij3JD++ZcNGOA6kDdx7EZ/AVxFlctsjCuGY/Lg9Mf54robO6bfhlKSKD0/hzx/wDWpJjtc1NMDG/vbABRBer+7LEqoZio3A+xEbf8Argtdt/s2s3UjZhEjeeV24G9smRMez7q7GaJzKku8M8ADx9xkEjp/T3qn47s459Pi1K0FxIJF+1y7vmZA/BLH/fUjHuK9ShL2lPl6o4ZL2VW/RnGx/JKxDbVYZCnnGM4IPrU6ScZB6DGOnHp7d+KptPHIrOibZCQygHhRg5+vOPyNLazBdwPIOcHPOfpWU9dD2MO3E14/wB6cMp3tnJBxhfSqNnEFdpELeYjfIGHOPXNXLTGWWVQSOisOn9eeKjjRPPYvnyzkgx88+nvzWLWljuTuXLa0jlvDLNGsk7NknaMk57f4d617KIRSK8QclOMoeRnjoev3vxqjZDymRZEyoO7j+Y+lbcMZiOY5SI5EB6/eB9f89qy5mhTihojVikccKqYnJLdyxyeuMkYOD6Gq2p2M91DDHaytG9uxeMjOFBOSB+JJ68ZrTtYVVw3yFuoxkY5Ixz3q8scUzLFOr5Y7kkOAMY5P86zk7kqp7N6FSATwojA+dEvBfnr3z+ea28MTjCGQpv2no4//VVN40Xy43l3bvmbrhB60kEoUALGzKhDNx0Ge3qM1m7mU48/vI1IojGxdCArDAUnIA9fr71pLFEITuXDHAVmJAz34FZZkEsKKr4R1wFAwR34rTguI/KJk24P3sLgHpj+lNJHHK5dNoOOD8hJIPUH86nhQYxtwCc4A9qfAnlplVKJ0Iz2qw64kGxvlOQNvAq0jFu4RKqRgheOg7Dp6Uu1hs28gj8aU73LAqyKuCuT97jtR5Gw+Z0z1AJODitUiCC5iyHKjLcMCT91jxz+VR20wKbMEYGMdcexq1IpKbzvbP3Qf61lzobaUSgko/DAdvT8PetEJo1BIuwoAxx0PTP+NI7uxyMoMdAazobgP8ieYXGeo6fSpFuVGfkVjnrIcmrM2j5g+2HkEqXPRVGcVGn2iaQiZtqHAKL1P1PpSqY1QFNq5HankF1zGwV+MDFc77G0EWYPujIAQDI9KkYkAgHDYOf8KrE7XwXGMfrVhtqoCMEsM4qOU0bSHwgu6uF4AwRjrU0UShWR8gg59/aqdvJKqllUBSRznmrCyOQcZGODn/PNHKJS1JJQoU/Juz3z0rIv5FVflYnJwcdsVfdMrjzfY561Qfq4JXjIBqkrGiZgajdtIwC5XcOlOtLea5xtOEA5PetBLRJGLkAnpyat20bRRhQRtz+FbOStoO/YlsIFVdmPnPc1qWsAWF0IBwdwA60yxiUkNLgEHqBU8EnlRzLuw3GM/wCFYS1IEcOAq7yW4J9AMVHEQJSMkrnOO2PWldtke5cMxPJHIqvcOqJGCwZwCXx68YA/WqigJZSFLh8ZPU46VDJJG6oc8jO4nv7CqMt4QzIclTk4xUCTny2YH7hJBNaJXCUeVXZUMYvNZtoUfILhnOOgHJ/QV111LtRRlVQNkA9vr9K5/wAMwPJd3t6Bt2AxKSOBn7xH8qfql387QRHcc43Z46U5q7sjKCNiJo1aMSSbfmJLd8dwa0bRg3zOBvxkgnp71iadE3lIWBO4YroINkRAbGQC5z6DvWbRbK16yh1O4s208njr3rk/EJEcTMhwNvHbBxXQalcKC7qScDg45Ncrr8xeNAy4DIDj2pxjqQ+5zGiDbPNLyWSQgj24z/WvQdPdksy0TAxgjJ7jPP8AWuC8Jyq95d7sYc5FdvpbCIFCAUyBg9cYrWqrsyhI3YJw7+VhkJPcY6Djn61ckia5h34BwNjgnnr1FVY42dcKCCOcnp/k1fjjcREglecetcyizoTRmALbSKDkN19QB6VdgnErIIWxKFIPvx0/SnyxpOY/M27ieB684rIntLq3uQUJZATgHuD7+tFjWmzs0viVgkj2yuAocMMeufrz3rZ8P3Ecb3Om3cZksG3MY+u6J1AkUfT5WHutc1po+eGVi6kdR3PHYelaEgmjkSSIhJImDj0Y54x69wRWtGp7OdzKvRVSPKcBfaTP4e1+70a+fzoYMG0uQOJYG+ZHBPqMfiCKtm3WGRSXyQcByuAQfWu81jTIvGOlpb2ThNXtziyRyACGzutmPZSeVY8A8cAmuB06bz1KXIeKWAlHWQfMp6EEeoPUV2VYL4o7MvC1+ePLLRrc0IbaWMbCrJJJl4Tv3bsZzn05B4pLFUaZygAXbuweMmtG1tkW2QlFZ8sFO71I5P64/wD1VAGQ3UqMT5g/vdT+XeuaXZHoU5+7Yt2UOQGkjKsBkoxwVXHQ89Rx0zWxZjZCYiBInABbtz0z/nrWbbxFgvknB4cYG7n/AA74rSs/lO7bgbuDnv6gVjItyLEbSRwksFZgDjByPxq1aOTyVyjEct2UH/I9OaYqRtA4MjJyQevXHWiKOQCQKg6AYXoPoPzrKzJeqNdYI54kkfBYcqQMZGe9PtLLZMCcLtOQGPPP86pWhOVPllkKjpkA8dQa6G2O6LBxjG0H0PTNNI55SlHRED24VgUUqVyVwMYHtSxSKMADCxjOGHJP+NaMQMyb3HLgqewApZbWOEZyXIwxwfl/KmkYN9yW3EhjVEAUYznsOen9asx7WG3cMgdR1yKqqpikBDAkjnPQD14qeKPfkSPvVgRtA6itEkYMlZh/Bg+uO3vSNclnwzFSBjIGM/400uDGrYIweQPSmIx3BCQU2g7sjrVcoi3cPuZV++R0J45qAp5iSRFspgEjsPXPrUqgSR/OVDqOec5qvyCW+6mc7c9M/wCelacpnexkPvtZkUPvTHy/7APUE+3GDT1usABshhw21CRmtNhGPl2luw3Cq2xY2ZVklQZzhRkVoiXqfKsbqRkkbh61ctpxIzCNQGxjJrIX75+tW4P9YKwaNFoaCoFc8MzHjeO1T2cTIQjEt1x7VFaf8e7fU1at/vL/AL1S9EJO+jEaEwuOPqo71ZBWE5Q4DDJJ5/Cmj/j4l/3RSXv+qT/eP8hS31Lj2KDzf6QzgbkP3R6e9RlTLIcrzyADRL91/pVsf6qH8P5UzdDI7XcpdRge9WbeANwucYzyKnT/AI9/xP8AOpYf9cv0rNyJGwx+WCdoBPof1psuwtIrEOxIJ9fxqQf6pv8APeqk/wDx8t9RVRWtg6XI7mVFi2lCowep5FY8lxkhT6ZyR09qva394/WsWf7sf0FbqCsXTsTTSs+0xggjjOOvtUcsgCKgyx9MdTTY+q/7xp9n/wAhO2/67L/WrUUiKkmzobK1ey0oW+SZGJdyO5PJrMFgftZ4JHGSeK6S5/5afUVUh/1K/jWXUmOhpWEMa2yleQegFNkcNJIVUhpPlwPT0/Sp7L/j3H1plz/rU/3F/rQkRKWpiXypOSIgdikoRzwQe/41yPimdY1ENsWMvAVQPvE8Cuzf/U3P++39K422/wCRxsf+u39DXRQpqdSMO5hWqOFNy7DZvCV7oR0O4tfOv/7TRF2RQtlJyf8AVAdWPI6da6FJFnheRGG9eDxgqRwQR+FdtpH/ACM/hL/sNWH/AKElcXrP/I1+Jf8AsJ3v/o5678xw0KWsTzsBiJ1VaX9bf5m9odwk6IoYK546enWt+1+VgM/JjO4VxWg/8fDfUf1rs1+4v+6teO0eq0NvbMXEHmQjEqjjK9ee1M09VuG5XbMowQePxrUs/vn/AHjVRP8AkKP/AL5/nUSRtTehftrSWO4jkI+QZz6YPBrVWNThJVHGMMOv+e9NXov+6f5VZP3l/wC2X8qm3Ud7iTacHbzoiBIAclOMj8Ko69oA8RTCZDBaeIYxt3vhYr8fwqx6K4HAY9e/rW1a/df/AHT/ADNLf/6s/U11UKrT5XszmrK3vrRo8wgmuLG8ktbm3e3ljJzBJxtIODj16duKPOLXBDMyrktx0U9x79q734qf8hjw5/2Dx/OvOrn/AJZf9c1/ma2qwUXobYevKSudBYvuhUo4J9Bz+RrWsTgj5gyHjaR+lYel/wCpi/3xW1F/rT/vf1FcbWtj04y0NCLmRgdroQWz3yPWnSfuQVXKqwB4PBIP+H86Zaf8fjfQ/wAhTpf+PWT/AHx/I1LRN3exbg3iQhXBUjJH93/OK1LK6wuDsPc+mayo/wDj5P8Au/4VPD/qD/vH+dPlM5am/A8gY4IZm+VQoI4+lXY2wuQpBXGfc+1UU/1cX+8v9auW3+oX6H+tNRuYS1QlxCC3mSAKOxHbPqKSIYOxySMcZPOPqKfJ9z8f61HB/rf+A/4VSjZkdBZZsLI0nQc7R1I9gPfirMeDtyADgFhkdO1ZM/8Ax8v/ALp/pVi37fT+pq0iJLqX5HXYNq5GMgKf0xUbEhhxwMl+fSok6D/db/0Gkbqn+6K0RlJFjKAnzNvznIPvjtSBAvGQPqTUkvU/UVetf9WfrVGTZ//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34867=[""].join("\n");
var outline_f34_3_34867=null;
var title_f34_3_34868="Megaureter natural course";
var content_f34_3_34868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Megaureter: Natural course",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Series of imaging studies that demonstrate spontaneous resolution of a left megaureter without surgical intervention: The imaging studies are intravenous pyelograms (IVPs) as a neonate (panel A) and at 10-year follow-up (F/U, panel C), and a diuretic renogram at two years F/U (panel B). The second image of the renogram shows a delay in washout. The diuretic renogram image is taken from back to front of the patient reserving the position of the left and right kidney and ureter from the IVPs images, which are taken from front to back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34868=[""].join("\n");
var outline_f34_3_34868=null;
var title_f34_3_34869="Honey bee 2";
var content_f34_3_34869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Honey bee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34869=[""].join("\n");
var outline_f34_3_34869=null;
var title_f34_3_34870="Paracocci imaging";
var content_f34_3_34870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Imaging of paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 594px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images of paracoccidioidomycosis. A. Chest radiograph demonstrating a \"butterfly wing\" pattern. B. Chest radiograph with a diffuse nodular and micronodular pattern. C. Chest computed tomography (CT) scan demonstrating multiple cavities. D. Abdominal CT scan demonstrating enlarged adrenal glands bilaterally. E and F. Head CT demonstrating hypodense ring-enhancing lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shikanai-Yasuda, MA, Queiroz Telles Filho, F, Mendes, RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright &copy;2006 Sociedade Brasileira de Medicina Tropical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34870=[""].join("\n");
var outline_f34_3_34870=null;
var title_f34_3_34871="Halothane hepatitis";
var content_f34_3_34871=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Halothane hepatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34871/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34871/contributors\">",
"     Anne M Larson, MD, FACP, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34871/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34871/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34871/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34871/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/3/34871/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled anesthetics were first used in the mid-1800s with the discovery of diethyl ether [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The halogenated anesthetic, halothane, was first introduced into use in 1956, and replaced ether as the surgical anesthetic of choice. Soon, isolated case reports of severe hepatitis were being reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In 1969, the National Institutes of Health (NIH) organized one of the largest epidemiological studies ever performed in the United States to evaluate halothane toxicity. A review of 250,000 cases of halothane use revealed an incidence of fatal hepatic necrosis of about 1 in 35,000 exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/8\">",
"     8",
"    </a>",
"    ]. A similar large-scale review in the United Kingdom showed nearly identical results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/9\">",
"     9",
"    </a>",
"    ]. Less and less toxic alternatives have been serially introduced:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/47/34548?source=see_link\">",
"     enflurane",
"    </a>",
"    (1972),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    (1981),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    (1992) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    (1995), although reports of hepatoxicity with these medications also exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/10-23\">",
"     10-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern about hepatotoxicity has virtually eliminated the use of halothane in adults in the United States. Initially, toxicity to halothane was not reported in children. However, subsequent reports demonstrated that the incidence of halothane-associated hepatitis in children is between 1 in 82,000 and 1 in 200,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. Halothane use in children has been largely replaced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/30\">",
"     30",
"    </a>",
"    ]. The reason for the lower incidence of halothane-associated hepatitis observed in children is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Furthermore, halothane is possibly the most commonly used inhalational anesthetic in all patients worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/33\">",
"     33",
"    </a>",
"    ] and reports of hepatotoxicity continue to be published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Halothane is associated with two clinical patterns of liver injury: hepatotoxicity and hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/36,38-43\">",
"     36,38-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Halothane hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity can occur with or without prior halothane exposure. Postoperative elevation in serum aminotransferases has been observed in up to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/8,9,38,44,45\">",
"     8,9,38,44,45",
"    </a>",
"    ]. Most patients are asymptomatic, although a subset develops symptoms of mild clinical hepatitis characterized by nausea, lethargy, and fever. The aminotransferases remain elevated for one to two weeks following exposure, and resolve without treatment. This reaction is generally considered a non-immune phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/46\">",
"     46",
"    </a>",
"    ]. Recovery is the rule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Halothane hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more unpredictable and rare occurrence is an acute severe hepatitis, \"halothane hepatitis,\" with potential development of hepatic necrosis and acute liver failure, which is often fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/40,47,48\">",
"     40,47,48",
"    </a>",
"    ]. The incidence is 1 in 6000 to 1 in 35,000 following a single exposure to the anesthetic and increases to about 1 in 3000 following multiple exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/9,48-50\">",
"     9,48-50",
"    </a>",
"    ]. Other risk factors for severe hepatotoxicity may include short intervals between exposures, female gender (2:1), age greater than 50, obesity, and a genetic predisposition to hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/8-10,51-54\">",
"     8-10,51-54",
"    </a>",
"    ]. These risk factors have also been demonstrated in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms generally develop about two days to three weeks after exposure. About 75 percent of patients present with a fever and may complain of anorexia, nausea, myalgias, arthralgias, and rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/56\">",
"     56",
"    </a>",
"    ]. Eosinophilia occurs in approximately 40 percent of cases, suggesting that toxicity is immunoallergic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Tender hepatomegaly and jaundice are common. Some patients present with acute liver failure, markedly elevated serum aminotransferases and prothrombin time and possibly hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that are toxic to the liver result in a variety of histopathologic patterns of injury, including those characterized predominantly by damage to hepatocytes, bile ducts, or a combination of the two. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .) Halothane leads predominantly to hepatocellular damage.",
"   </p>",
"   <p>",
"    Halothane is metabolized by the cytochrome P450 system. While the exact mechanism of hepatotoxicity is unknown, it is believed that toxicity results from halothane's metabolism to reactive intermediates. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,49,59-64\">",
"     41,49,59-64",
"    </a>",
"    ]. Of the commonly used volatile anesthetics, halothane is the most extensively metabolized, which may explain its propensity to hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/49,65,66\">",
"     49,65,66",
"    </a>",
"    ]. Both oxidation and reduction occur concurrently, depending upon the relative hypoxia within a particular region of the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41\">",
"     41",
"    </a>",
"    ]. Conditions of low oxygen tension (hypoxia) favor reductive metabolism (via CYP2A6 and CYP3A4), while conditions of normal oxygen tension (normoxia) favor oxidative metabolism (via CYP2E1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,59,60,67-69\">",
"     41,59,60,67-69",
"    </a>",
"    ]. The oxidative pathway predominates under physiologic conditions; less than 1percent is metabolized via the reductive pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/59,68,70\">",
"     59,68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Halothane hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic injury leading to halothane hepatotoxicity is believed to be secondary to intrahepatic anaerobic halothane reduction (1 to 3 percent of the total dose) via the reductive pathway. Halothane decreases both portal venous and hepatic arterial blood flow in proportion to the degree of anesthesia, leading to hepatic hypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. The risk may be increased in patients with chronic liver disease. Although hypoxia alone does not explain halothane hepatotoxicity, it may predispose the liver to halothane-induced damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reductive pathways produce the free radical intermediate 2-chloro-1,1,1-trifluroethyl (CF(3)CHCl). This free radical may form stable metabolites (chlorotrifluoroethane or chlorodifluoroethene) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41\">",
"     41",
"    </a>",
"    ]. However, it can also covalently bind with cellular proteins and lipids, which may lead to lipid peroxidation, inactivation of CYP450, and serum aminotransferase elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/69,75-79\">",
"     69,75-79",
"    </a>",
"    ]. The reductive pathway leads to destruction of P450 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,61,75,76,80\">",
"     41,61,75,76,80",
"    </a>",
"    ]. This is likely the mechanism responsible for the milder form of hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/78,81\">",
"     78,81",
"    </a>",
"    ]. However, it is generally accepted that a significant free radical-mediated toxic mechanism is unlikely to take place under the usual physiologic conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/82\">",
"     82",
"    </a>",
"    ]. Biotransformation appears necessary for halothane hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Halothane hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Halothane hepatitis is widely believed to result from an immunologically-based hypersensitivity reaction initiated by oxidative metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,83,84\">",
"     41,83,84",
"    </a>",
"    ]. Halothane hepatitis is often associated with clinical features of an immunologic disorder, including rash, arthralgias, eosinophilia, and increased levels of circulating immune complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/58,67,85\">",
"     58,67,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The halothane oxidative pathway is catalyzed predominantly by CYP2E1 and to a lesser extent by CYP 2A6 (at high halothane concentrations). This pathway accounts for the majority (approximately 50 percent of the dose) of the drug's metabolism. Oxidation leads to a reactive acyl chloride (CF(3)COCl) that reacts with lysine to produce a highly reactive metabolite, trifluoroacetyl chloride (TFA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,59,60,68,86-89\">",
"     41,59,60,68,86-89",
"    </a>",
"    ]. Hydrolysis of TFA yields trifluoroacetic acid, which is nontoxic and is excreted in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/49,68\">",
"     49,68",
"    </a>",
"    ]. However, in certain cases, TFA may also bind covalently to hepatocyte macromolecules and phospholipids, producing trifluoroacetylated-protein adducts (TFA-protein adducts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,87,88,90-92\">",
"     41,87,88,90-92",
"    </a>",
"    ]. Covalent binding to liver proteins may be the preliminary step in acute halothane hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/81,93\">",
"     81,93",
"    </a>",
"    ]. The TFA-protein adducts are subsequently viewed as foreign to the adaptive immune system and act as sensitizing neoantigens, evoking an immune-mediated response and the development of antibodies. With subsequent exposures, these antibodies can mediate the immune response and lead to acute hepatic necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41,49,67,86\">",
"     41,49,67,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies against hepatocytes and TFA-protein adducts can be detected in the serum and liver of patients with halothane hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/57,87,94-103\">",
"     57,87,94-103",
"    </a>",
"    ]. The antibodies recognize either TFA-adducts or native proteins that mimic TFA-adducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. TFA-adducts may also be located in the Kupffer cells, which may function as TFA-protein antigen-presenting cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/65,106,107\">",
"     65,106,107",
"    </a>",
"    ]. Neoantigens, including CYP2E1, may be expressed on the hepatocyte surface, and are also recognized by these antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/67,99,103,108\">",
"     67,99,103,108",
"    </a>",
"    ]. TFA-products have also been identified in the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/109\">",
"     109",
"    </a>",
"    ], heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/110\">",
"     110",
"    </a>",
"    ], testes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/108\">",
"     108",
"    </a>",
"    ], and lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/111\">",
"     111",
"    </a>",
"    ], although in smaller amounts than seen in liver and they are of unknown clinical significance.",
"   </p>",
"   <p>",
"    As noted above, the severe hepatitis induced by halothane results predominantly from an immune-mediated response directed against the hepatocytes. However, while all exposures to halothane produce a variety of TFA-protein adducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/49,90\">",
"     49,90",
"    </a>",
"    ], halothane hepatitis remains rare. In addition, not all cases support a purely adaptive immune mechanism. This suggests that an additional predisposition to hepatocellular damage must be present. A genetic susceptibility has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/100,112,113\">",
"     100,112,113",
"    </a>",
"    ]. Patients who experience halothane hepatitis have an increased frequency of HLA-DR2, and halothane hepatitis can be seen among closely related family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/101,114\">",
"     101,114",
"    </a>",
"    ]. However, identification of genetic susceptibility factors remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Halothane hepatitis must be considered whenever postoperative jaundice occurs following its use. However, the differential diagnosis of postoperative jaundice remains broad. Conditions that must also be considered are surgical complications (particularly in bile-duct surgery), perioperative hypotension, sepsis, infections, other drug hepatotoxicity, and viral hepatitis.",
"   </p>",
"   <p>",
"    Liver biopsy is usually not necessary for diagnosis. When obtained, the histologic appearance is often indistinguishable from viral hepatitis. Patients with severe disease develop centrilobular hepatic necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/115\">",
"     115",
"    </a>",
"    ]. Fatty degeneration and vacuolation may be seen. Occasionally, an increase in eosinophils may be seen in the inflammatory infiltrate, and rarely, granulomata may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of both halothane hepatotoxicity and halothane hepatitis is supportive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/40\">",
"     40",
"    </a>",
"    ]. Corticosteroids are of no proven value and there are little to no data in the literature to support their use. An exception is a single case report in which resolution was observed after initiation of corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/116\">",
"     116",
"    </a>",
"    ]. Another case report described resolution of jaundice after treatment with methionine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/117\">",
"     117",
"    </a>",
"    ]. In acute liver failure, the case fatality rate is about 50 percent, but can be as high as 80 percent in those who develop hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/40,118\">",
"     40,118",
"    </a>",
"    ]. Severe, progressive cases may require emergent orthotopic liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective preventive tool is to avoid the use of halothane in adults. This is particularly true in patients with prior exposure to the drug since the overall incidence of hepatic necrosis rises to as high as 1:1,400 after multiple exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/50\">",
"     50",
"    </a>",
"    ]. Guidelines have been proposed to minimize toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34871/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Halothane is associated with two patterns of clinical hepatotoxicity. Halothane hepatotoxicity is associated with an increase in serum aminotransferase either without symptoms or with mild, self-limited symptoms, while halothane hepatitis is associated with severe hepatitis or acute liver failure.",
"     </li>",
"     <li>",
"      Halothane hepatitis must be considered whenever postoperative jaundice occurs following its use. However, the differential diagnosis of postoperative jaundice remains broad. Among the conditions that must also be considered are surgical complications (particularly in bile-duct surgery), perioperative hypotension, sepsis, infections, other drug toxicity, and viral hepatitis.",
"     </li>",
"     <li>",
"      In patients who have developed halothane hepatitis, we suggest supportive treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The most effective preventive tool is to avoid the use of halothane in adults, particularly in patients with prior exposure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/1\">",
"      Eger EI 2nd. Current and future perspectives on inhaled anesthetics. Pharmacotherapy 1998; 18:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/2\">",
"      Eger EI 2nd. Characteristics of anesthetic agents used for induction and maintenance of general anesthesia. Am J Health Syst Pharm 2004; 61 Suppl 4:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/3\">",
"      Virtue RW, Payne KW. Postoperative death after Fluothane. Anesthesiology 1958; 19:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/4\">",
"      LINDENBAUM J, LEIFER E. Hepatic necrosis associated with halothane anesthesia. N Engl J Med 1963; 268:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/5\">",
"      BRODY GL, SWEET RB. Halothane anesthesia as a possible cause of massive hepatic necrosis. Anesthesiology 1963; 24:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/6\">",
"      HEIDENBERG WJ, TORIO I. Additional case of halothane hepatitis. N Engl J Med 1963; 268:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/7\">",
"      KERBEL NC, HILLIARD IM. HALOTHANE HEPATOTOXICITY. Can Med Assoc J 1963; 89:944.",
"     </a>",
"    </li>",
"    <li>",
"     Bunker JP, Forrest WH, Mosteller F, et al (Eds).. National Halothane Study. A study of the possible association between halothane anesthesia and postoperative hepatic necrosis. U.S. Government Printing Office, Washington, DC 1969.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/9\">",
"      Walton B, Simpson BR, Strunin L, et al. Unexplained hepatitis following halothane. Br Med J 1976; 1:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/10\">",
"      Stachnik J. Inhaled anesthetic agents. Am J Health Syst Pharm 2006; 63:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/11\">",
"      Ihtiyar E, Algin C, Haciolu A, Isiksoy S. Fatal isoflurane hepatotoxicity without re-exposure. Indian J Gastroenterol 2006; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/12\">",
"      White LB, DeTarnowsky GO, Mir JA, Layden TJ. Hepatotoxicity following enflurane anesthesia. Dig Dis Sci 1981; 26:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/13\">",
"      Paull JD, Fortune DW. Hepatotoxicity and death following two enflurane anaesthetics. Anaesthesia 1987; 42:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/14\">",
"      Weitz J, Kienle P, B&ouml;hrer H, et al. Fatal hepatic necrosis after isoflurane anaesthesia. Anaesthesia 1997; 52:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/15\">",
"      Martin JL, Plevak DJ, Flannery KD, et al. Hepatotoxicity after desflurane anesthesia. Anesthesiology 1995; 83:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/16\">",
"      Tung D, Yoshida EM, Wang CS, Steinbrecher UP. Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth 2005; 52:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/17\">",
"      Singhal S, Gray T, Guzman G, et al. Sevoflurane hepatotoxicity: a case report of sevoflurane hepatic necrosis and review of the literature. Am J Ther 2010; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/18\">",
"      Turillazzi E, D'Errico S, Neri M, et al. A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia. Toxicol Pathol 2007; 35:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/19\">",
"      Christ DD, Kenna JG, Kammerer W, et al. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/20\">",
"      Carrigan TW, Straughen WJ. A report of hepatic necrosis and death following isoflurane anesthesia. Anesthesiology 1987; 67:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/21\">",
"      Chase RE, Holaday DA, Fiserova-Bergerova V, et al. The biotransformation of ethrane in man. Anesthesiology 1971; 35:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/22\">",
"      Eger EI 2nd, Smuckler EA, Ferrell LD, et al. Is enflurane hepatotoxic? Anesth Analg 1986; 65:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/23\">",
"      Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983; 98:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/24\">",
"      Carney FM, Van Dyke RA. Halothane hepatitis: a critical review. Anesth Analg 1972; 51:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/25\">",
"      Warner LO, Beach TP, Garvin JP, Warner EJ. Halothane and children: the first quarter century. Anesth Analg 1984; 63:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/26\">",
"      Munro HM, Snider SJ, Magee JC. Halothane-associated hepatitis in a 6-year-old boy: evidence for native liver regeneration following failed treatment with auxiliary liver transplantation. Anesthesiology 1998; 89:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/27\">",
"      Lewis RB, Blair M. Halothane hepatitis in a young child. Br J Anaesth 1982; 54:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/28\">",
"      Kenna JG, Neuberger J, Mieli-Vergani G, et al. Halothane hepatitis in children. Br Med J (Clin Res Ed) 1987; 294:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/29\">",
"      Vorrakitpokatorn P, Limsakul A. Drug-induced hyperthermia and rhabdomyolysis during the perioperative period: report of three patients. J Med Assoc Thai 2002; 85 Suppl 3:S884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/30\">",
"      Goa KL, Noble S, Spencer CM. Sevoflurane in paediatric anaesthesia: a review. Paediatr Drugs 1999; 1:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/31\">",
"      Wark H, Earl J, Chau DD, Overton J. Halothane metabolism in children. Br J Anaesth 1990; 64:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/32\">",
"      Gallagher TM, Black GW. Uptake of volatile anaesthetics in children. Anaesthesia 1985; 40:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/33\">",
"      Wiklund RA, Rosenbaum SH. Anesthesiology. First of two parts. N Engl J Med 1997; 337:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/34\">",
"      Qureshi MA, Saeed F, Hussain T. Halothane induced fulminant hepatic failure. J Coll Physicians Surg Pak 2007; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/35\">",
"      Kumar GP, Bhat VJ, Sowdi V. Fulminant hepatic failure following halothane anaesthesia. J Clin Forensic Med 2005; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/36\">",
"      Otedo AE. Halothane induced hepatitis: case report. East Afr Med J 2004; 81:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/37\">",
"      Eghtesadi-Araghi P, Sohrabpour A, Vahedi H, Saberi-Firoozi M. Halothane hepatitis in Iran: a review of 59 cases. World J Gastroenterol 2008; 14:5322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/38\">",
"      Brown BR Jr, Gandolfi AJ. Adverse effects of volatile anaesthetics. Br J Anaesth 1987; 59:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/39\">",
"      Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/40\">",
"      Lo SK, Wendon J, Mieli-Vergani G, Williams R. Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. Eur J Gastroenterol Hepatol 1998; 10:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/41\">",
"      Kharasch ED. Adverse drug reactions with halogenated anesthetics. Clin Pharmacol Ther 2008; 84:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/42\">",
"      Bond GR. Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. J Toxicol Clin Toxicol 1996; 34:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/43\">",
"      Kenna JG. The molecular basis of halothane-induced hepatitis. Biochem Soc Trans 1991; 19:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/44\">",
"      Trowell J, Peto R, Smith AC. Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Lancet 1975; 1:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/45\">",
"      Wright R, Eade OE, Chisholm M, et al. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975; 1:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/46\">",
"      Fee JP, Thompson GH. Comparative tolerability profiles of the inhaled anaesthetics. Drug Saf 1997; 16:157.",
"     </a>",
"    </li>",
"    <li>",
"     Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver, Appleton-Century-Crofts, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/48\">",
"      Mushin WW, Rosen M, Jones EV. Post-halothane jaundice in relation to previous administration of halothane. Br Med J 1971; 3:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/49\">",
"      Gut J. Molecular basis of halothane hepatitis. Arch Toxicol Suppl 1998; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/50\">",
"      Summary of the national Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis. JAMA 1966; 197:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/51\">",
"      Voigt MD, Workman B, Lombard C, Kirsch RE. Halothane hepatitis in a South African population--frequency and the influence of gender and ethnicity. S Afr Med J 1997; 87:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/52\">",
"      Cousins MJ, Plummer JL, Hall PD. Risk factors for halothane hepatitis. Aust N Z J Surg 1989; 59:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/53\">",
"      Inman WH, Mushin WW. Jaundice after repeated exposure to halothane: an analysis of Reports to the Committee on Safety of Medicines. Br Med J 1974; 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/54\">",
"      Inman WH, Mushin WW. Jaundice after repeated exposure to halothane: a further analysis of reports to the Committee on Safety of Medicines. Br Med J 1978; 2:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/55\">",
"      Dugan CM, MacDonald AE, Roth RA, Ganey PE. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 2010; 333:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/56\">",
"      Holt C, Csete M, Martin P. Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroenterol Clin North Am 1995; 24:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/57\">",
"      Beaune P, Pessayre D, Dansette P, et al. Autoantibodies against cytochromes P450: role in human diseases. Adv Pharmacol 1994; 30:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/58\">",
"      Kenna JG, Neuberger JM. Immunopathogenesis and treatment of halothane hepatitis. Clin Immunother 1995; 3:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/59\">",
"      Spracklin DK, Thummel KE, Kharasch ED. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos 1996; 24:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/60\">",
"      Sipes IG, Gandolfi AJ, Pohl LR, et al. Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J Pharmacol Exp Ther 1980; 214:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/61\">",
"      Kharasch ED, Hankins DC, Fenstamaker K, Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000; 55:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/62\">",
"      Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997; 84:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/63\">",
"      Masubuchi Y, Horie T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit Rev Toxicol 2007; 37:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/64\">",
"      Minoda Y, Kharasch ED. Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology 2001; 95:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/65\">",
"      Carpenter RL, Eger EI 2nd, Johnson BH, et al. The extent of metabolism of inhaled anesthetics in humans. Anesthesiology 1986; 65:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/66\">",
"      Rehder K, Forbes J, Alter H, et al. Halothane biotransformation in man: a quantitative study. Anesthesiology 1967; 28:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/67\">",
"      Kenna JG, Jones RM. The organ toxicity of inhaled anesthetics. Anesth Analg 1995; 81:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/68\">",
"      Spracklin DK, Hankins DC, Fisher JM, et al. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther 1997; 281:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/69\">",
"      de Groot H, Noll T. Halothane hepatotoxicity: relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology 1983; 3:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/70\">",
"      Reichle FM, Conzen PF. Halogenated inhalational anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/71\">",
"      Gelman S, Dillard E, Bradley EL Jr. Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl. Anesth Analg 1987; 66:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/72\">",
"      Gelman S. General anesthesia and hepatic circulation. Can J Physiol Pharmacol 1987; 65:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/73\">",
"      Cousins MJ, Sharp JH, Gourlay GK, et al. Hepatotoxicity and halothane metabolism in an animal model with application for human toxicity. Anaesth Intensive Care 1979; 7:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/74\">",
"      Cowan RE, Jackson BT, Grainger SL, Thompson RP. Effects of anesthetic agents and abdominal surgery on liver blood flow. Hepatology 1991; 14:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/75\">",
"      Manno M, Ferrara R, Cazzaro S, et al. Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro. Pharmacol Toxicol 1992; 70:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/76\">",
"      Baker MT, Vasquez MT, Chiang CK. Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes. Biochem Pharmacol 1991; 41:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/77\">",
"      Awad JA, Horn JL, Roberts LJ 2nd, Franks JJ. Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes. Anesthesiology 1996; 84:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/78\">",
"      Plummer JL, Beckwith AL, Bastin FN, et al. Free radical formation in vivo and hepatotoxicity due to anesthesia with halothane. Anesthesiology 1982; 57:160.",
"     </a>",
"    </li>",
"    <li>",
"     Zimmerman HJ. Drug-induced liver disease. In: Schiff's diseases of the liver, Schiff E, Sorrell M, Maddrey WC (Eds), Lippincott-Raven, Philadelphia 1999. p.973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/80\">",
"      Krieter PA, van Dyke RA. Cytochrome P-450 and halothane metabolism. Decrease in rat liver microsomal P-450 in vitro. Chem Biol Interact 1983; 44:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/81\">",
"      Bourdi M, Amouzadeh HR, Rushmore TH, et al. Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility. Chem Res Toxicol 2001; 14:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/82\">",
"      Royston D. Free radicals. Formation, function and potential relevance in anaesthesia. Anaesthesia 1988; 43:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/83\">",
"      Pohl LR, Satoh H, Christ DD, Kenna JG. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 1988; 28:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/84\">",
"      Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol 1988; 2:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/85\">",
"      Neuberger J, Williams R. Halothane anaesthesia and liver damage. Br Med J (Clin Res Ed) 1984; 289:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/86\">",
"      Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 347:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/87\">",
"      Satoh H, Fukuda Y, Anderson DK, et al. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther 1985; 233:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/88\">",
"      Kenna JG, Martin JL, Satoh H, Pohl LR. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab Dispos 1990; 18:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/89\">",
"      Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/90\">",
"      Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/91\">",
"      Trudell JR, Ardies CM, Anderson WR. Antibodies raised against trifluoroacetyl-protein adducts bind to N-trifluoroacetyl-phosphatidylethanolamine in hexagonal phase phospholipid micelles. J Pharmacol Exp Ther 1991; 257:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/92\">",
"      Beaune PH, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol 1997; 26 Suppl 2:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/93\">",
"      Dansette PM, Bonierbale E, Minoletti C, et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998; 23:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/94\">",
"      Vergani D, Mieli-Vergani G, Alberti A, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/95\">",
"      Mieli-Vergani G, Vergani D, Tredger JM, et al. Lymphocyte cytotoxicity to halothane altered hepatocytes in patients with severe hepatic necrosis following halothane anaesthesia. J Clin Lab Immunol 1980; 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/96\">",
"      Kenna JG, Scatchard K, Van Pelt FN, et al. Antibodies to halothane-induced liver antigens in sera from patients with halothane hepatitis: Evidence for a conformation-dependent antigen. Br J Clin Pharmacol 1992; 34:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/97\">",
"      Chen M, Gandolfi J. Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs. Drug Metab Rev 1997; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/98\">",
"      Pohl LR, Kenna JG, Satoh H, et al. Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989; 20:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/99\">",
"      Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/100\">",
"      Satoh H, Gillette JR, Davies HW, et al. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol Pharmacol 1985; 28:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/101\">",
"      Hoft RH, Bunker JP, Goodman HI, Gregory PB. Halothane hepatitis in three pairs of closely related women. N Engl J Med 1981; 304:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/102\">",
"      Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/103\">",
"      Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996; 9:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/104\">",
"      Gut J, Christen U, Huwyler J, et al. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur J Biochem 1992; 210:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/105\">",
"      Christen U, Jen&ouml; P, Gut J. Halothane metabolism: the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts. Biochemistry 1993; 32:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/106\">",
"      Heijink E, De Matteis F, Gibbs AH, et al. Metabolic activation of halothane to neoantigens in C57Bl/10 mice: immunochemical studies. Eur J Pharmacol 1993; 248:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/107\">",
"      Christen U, B&uuml;rgin M, Gut J. Halothane metabolism: Kupffer cells carry and partially process trifluoroacetylated protein adducts. Biochem Biophys Res Commun 1991; 175:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/108\">",
"      Huwyler J, Gut J. Exposure to the chlorofluorocarbon substitute 2,2-dichloro-1,1,1- trifluoroethane and the anesthetic agent halothane is associated with transient protein adduct formation in the heart. Biochem Biophys Res Commun 1992; 184:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/109\">",
"      Hastings KL, Thomas C, Hubbard AK, Gandolfi AJ. Screening for antibodies associated with halothane hepatitis. Br J Anaesth 1991; 67:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/110\">",
"      Huwyler J, Aeschlimann D, Christen U, Gut J. The kidney as a novel target tissue for protein adduct formation associated with metabolism of halothane and the candidate chlorofluorocarbon replacement 2,2-dichloro-1,1,1-trifluoroethane. Eur J Biochem 1992; 207:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/111\">",
"      Kenna JG, Martin JL, Pohl LR. The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem Pharmacol 1992; 44:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/112\">",
"      Farrell G, Prendergast D, Murray M. Halothane hepatitis. Detection of a constitutional susceptibility factor. N Engl J Med 1985; 313:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/113\">",
"      You Q, Cheng L, Reilly TP, et al. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006; 44:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/114\">",
"      Otsuka S, Yamamoto M, Kasuya S, et al. HLA antigens in patients with unexplained hepatitis following halothane anesthesia. Acta Anaesthesiol Scand 1985; 29:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/115\">",
"      BLACKBURN WR, NGAI SH, LINDENBAUM J. MORPHOLOGIC CHANGES IN HEPATIC NECROSIS FOLLOWING HALOTHANE ANESTHESIA IN MAN. Anesthesiology 1964; 25:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/116\">",
"      Moore DH, Benson GD. Prolonged halothane hepatitis. Prompt resolution of severe lesion with corticosteroid therapy. Dig Dis Sci 1986; 31:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/117\">",
"      Windsor JA, Wynne-Jones G. Halothane hepatitis and prompt resolution with methionine therapy: case report. N Z Med J 1988; 101:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/118\">",
"      Elliott RH, Strunin L. Hepatotoxicity of volatile anaesthetics. Br J Anaesth 1993; 70:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34871/abstract/119\">",
"      Neuberger JM. Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines. Drug Saf 1990; 5:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3633 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34871=[""].join("\n");
var outline_f34_3_34871=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Halothane hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Halothane hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Halothane hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Halothane hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_3_34872="Dermoscopic asymmetry";
var content_f34_3_34872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    The concept of asymmetry in dermoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asymmetry refers to the distribution of colors and structures within the lesion in one or two perpendicular axes. The lesion on the left is asymmetrical; the lesion on the right is symmetrical, in spite of its irregular contour.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34872=[""].join("\n");
var outline_f34_3_34872=null;
var title_f34_3_34873="Trigeminal neuralgia";
var content_f34_3_34873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trigeminal neuralgia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Charles C Ho, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Sajid A Khan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34873/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/3/34873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigeminal neuralgia (TN) is one of the most common causes of facial pain. TN is defined as paroxysmal, stereotyped attacks of usually intense, sharp, superficial or stabbing pain in the distribution of one or more branches of the fifth cranial (trigeminal) nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of TN is presented here. Other causes of facial pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link\">",
"     \"Overview of craniofacial pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal nerve (",
"    <a class=\"graphic graphic_figure graphicRef63085 \" href=\"mobipreview.htm?25/48/26378\">",
"     figure 1",
"    </a>",
"    ) is the sensory supply to the face and the sensory and motor supply to the muscles of mastication. It has three major divisions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ophthalmic (V1)",
"     </li>",
"     <li>",
"      Maxillary (V2)",
"     </li>",
"     <li>",
"      Mandibular (V3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nerve starts at the midlateral surface of the pons, and its sensory ganglion (gasserian ganglion) resides in Meckel's cave in the floor of the middle cranial fossa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of TN is 4 to 13 per 100,000 people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Approximately 15,000 new cases occur in the United States each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/4\">",
"     4",
"    </a>",
"    ]. TN is one of the most frequently seen neuralgias in the elderly. The incidence increases gradually with age; most idiopathic cases begin after age 50, although onset may occur in the second and third decades or, rarely, in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The male to female ratio of TN is about 1:1.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/4\">",
"     4",
"    </a>",
"    ]. This slight female predominance may be related to the increased longevity of women compared with men. Rare familial cases have been reported, but the vast majority of patients have sporadic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are not entirely consistent, hypertension may be a risk factor for the development of trigeminal neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of TN are caused by compression of the trigeminal nerve root, usually within a few millimeters of entry into the pons (the root entry zone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/11\">",
"     11",
"    </a>",
"    ]. Compression by an aberrant loop of an artery or vein is thought to account for 80 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Idiopathic TN or TN caused by a vascular compression is considered classic TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other causes of TN via nerve compression include vestibular schwannoma (acoustic neuroma), meningioma, epidermoid or other cyst, or rarely a saccular aneurysm or arteriovenous malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. TN caused by structural lesions other than vascular compression is classified as secondary TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanism by which compression of the nerve leads to symptoms appears to be related to demyelination in a circumscribed area around the compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Precisely how demyelination results in the symptoms of TN is not entirely clear. Demyelinated lesions may set up ectopic impulse generation, possibly causing ephaptic transmission. Ephaptic cross-talk between fibers mediating light touch and those involved in pain generation could account for the precipitation of painful attacks by light tactile stimulation of facial trigger zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, alteration of afferent input may disinhibit pain pathways in the spinal trigeminal nucleus.",
"   </p>",
"   <p>",
"    Evidence for a role of central pain mechanisms includes the presence of refractory periods after a triggered episode, trains of painful sensations after a single stimulus, and latency from the time of stimulation to the onset of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, electrophysiologic evidence of central sensitization of trigeminal nociceptive processing has been observed in patients with atypical TN who have concomitant chronic facial pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demyelination of one or more of the trigeminal nerve nuclei may also be caused by multiple sclerosis or other structural lesions of the brainstem. In multiple sclerosis, a plaque of demyelination typically occurs in the root entry zone of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/25\">",
"     25",
"    </a>",
"    ] although vascular compression also has been noted in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;TN is divided by presumed etiology into classic and secondary categories by the International Headache Society (IHS) criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic TN encompasses both idiopathic TN cases and those related to vascular compression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"       1",
"      </a>",
"      ]. The rationale is as follows. The IHS acknowledges that TN found to be related to compression of the trigeminal nerve by a vascular loop at surgery should strictly be regarded as secondary. However, most patients do not have surgery, and it is often uncertain as to whether they have primary or secondary TN. For this reason, the IHS uses the term \"classic\" instead of \"primary\" for patients with a typical history of TN who have a vascular source of compression as the presumed cause [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Secondary (or symptomatic) TN is reserved for patients with TN caused by structural lesions other than vascular compression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;TN is defined clinically by paroxysmal, stereotyped attacks of usually intense, sharp, superficial or stabbing pain in the distribution of one or more branches of the fifth cranial (trigeminal) nerve (",
"    <a class=\"graphic graphic_figure graphicRef70877 \" href=\"mobipreview.htm?12/32/12802\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain of TN tends to occur in paroxysms and is maximal at or near onset. Facial muscle spasms can be seen with severe pain. This finding gave rise to the older term for this disorder, tic douloureux. The pain is often described as electric, shock-like or stabbing. It usually lasts from one to several seconds, but may occur repetitively. A refractory period of several minutes during which a paroxysm cannot be provoked is common. Some patients with longstanding TN may have continuous dull pain that is present between paroxysms of pain. Unlike some other facial pain syndromes, TN typically does not awaken patients at night.",
"   </p>",
"   <p>",
"    TN is typically unilateral. Occasionally the pain is bilateral, but not on both sides simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/4\">",
"     4",
"    </a>",
"    ]. The distribution of pain most often involves the V2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    V3 subdivisions of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ]. The V1 subdivision is involved in &lt;5 percent of patients. Of note, V1 is most commonly affected by postherpetic neuralgia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trigger zones in the distribution of the affected nerve may be present and are often located near the midline. Lightly touching these zones often triggers an attack, leading patients to protect these areas. Trigger zones can sometimes be demonstrated on physical examination.",
"   </p>",
"   <p>",
"    Other triggers of TN paroxysms include chewing, talking, brushing teeth, cold air, smiling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    grimacing.",
"   </p>",
"   <p>",
"    Some patients have a history of \"pretrigeminal neuralgia,\" which is said to be dull, continuous, aching pain in the jaw evolving eventually into TN. This brief, milder pain is sometimes suspected to have a dental origin and unnecessary dental procedures have been performed in many cases. On the other hand, TN can be precipitated by dental procedures (eg, dental extraction), resulting in increased confusion about the precise etiology of this problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of TN is variable. Episodes may last weeks or months, followed by pain-free intervals. Recurrence is common, and some patients have continuous pain. Most often, the condition tends to wax and wane in severity and frequency of pain exacerbations. However, there are no pure natural history studies of TN, most likely because the severity of the pain leads to intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of TN is based upon the characteristic clinical features described above, primarily paroxysms of pain in the distribution of the trigeminal nerve.",
"   </p>",
"   <p>",
"    Once the diagnosis of TN is suspected or confirmed on clinical grounds, a search for secondary causes should be undertaken. Patients with trigeminal sensory loss or bilateral involvement are probably at higher risk of secondary TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. Younger age is also probably associated with a higher risk of secondary TN. However, age is not a clinically useful predictor for distinguishing classic from secondary TN because there is considerable age overlap. In addition, absence of any of these clinical features (sensory loss, bilateral involvement, younger age) does not rule out secondary TN.",
"   </p>",
"   <p>",
"    Neuroimaging and trigeminal reflex testing are considered useful for distinguishing patients with classic TN (ie, idiopathic or caused by vascular compression) from those with secondary TN (ie, caused by structural brain lesion other than vascular compression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Headache Society (IHS) diagnostic criteria for classic TN are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal attacks of pain lasting from a fraction of a second to two minutes, affecting one or more divisions of the trigeminal nerve",
"     </li>",
"     <li>",
"      Pain has at least one of the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intense, sharp, superficial, or stabbing",
"     </li>",
"     <li>",
"      Precipitated from trigger areas or by trigger factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks are stereotyped in the individual patient",
"     </li>",
"     <li>",
"      There is no clinically evident neurologic deficit",
"     </li>",
"     <li>",
"      Not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary (symptomatic) TN is characterized by pain indistinguishable from classic TN, but is caused by a demonstrable structural lesion other than vascular compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ]. Unlike classic TN, there is no refractory period after a paroxysm of pain. Secondary TN may exhibit sensory impairment in the distribution of the appropriate trigeminal nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging with head CT or MRI is useful for identifying the small proportion of patients who have a structural lesion (eg, tumor in the cerebellopontine angle, demyelinating lesions including multiple sclerosis) as the cause of secondary TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, high resolution MRI and magnetic resonance angiography (MRA) may be useful for identifying vascular compression as the etiology of classic TN, but the utility of these studies has not been established.",
"   </p>",
"   <p>",
"    While specific evidence-based recommendations regarding the indications for neuroimaging in patients with TN cannot be made, we suggest obtaining brain MRI for patients in the following groups to rule out a causative structural brain lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with trigeminal sensory loss",
"     </li>",
"     <li>",
"      Patients with bilateral symptoms",
"     </li>",
"     <li>",
"      Young patients (under the age of 40)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians obtain an imaging study in all patients who present with TN.",
"   </p>",
"   <p>",
"    An evidence-based systematic review and practice parameter published in 2008 from the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) identified four studies that evaluated consecutive patients with TN and normal neurologic examinations with head CT or MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. In the pooled data, routine brain imaging identified a secondary cause of TN (other than vascular compression) in 15 percent of patients (95% CI 11-20 percent).",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    practice parameter identified seven studies that performed high-resolution brain MRI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance angiography (MRA) to identify neurovascular compression in patients with TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was wide variation among the included studies for both sensitivity (range 52 to 100 percent) and specificity (29 to 93 percent)",
"     </li>",
"     <li>",
"      In three of the five highest quality MRI studies (cohort surveys with prospective data collection), the difference in rate of neurovascular trigeminal nerve compression on the symptomatic side compared with asymptomatic side was statistically nonsignificant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these inconsistent results, the",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    concluded that there is insufficient evidence to support or refute the utility of MRI to identify neurovascular compression in classic TN, or to indicate the most reliable MRI technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrophysiologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic trigeminal reflex testing is probably useful for distinguishing classic TN from secondary TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, testing with trigeminal evoked potentials is not useful for making this distinction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trigeminal reflex tests include the blink reflex (obtained by recording from the orbicularis oculi muscles after electrical stimulation of the supraorbital nerve [V1]) and the masseter inhibitory reflex (obtained after electrical stimulation of the infraorbital [V2] and mental [V3] nerves). The responses are recorded by surface electrodes using standard electromyography equipment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/31\">",
"       31",
"      </a>",
"      ]. These tests are usually normal in patients with classic TN.",
"      <br/>",
"      <br/>",
"      The 2008",
"      <span class=\"nowrap\">",
"       AAN/EFNS",
"      </span>",
"      practice parameter identified five studies that addressed the accuracy of trigeminal reflex testing in the evaluation of TN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"       29",
"      </a>",
"      ]. One was a prospective report of 120 consecutive patients with TN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/32\">",
"       32",
"      </a>",
"      ], while the remaining four studies were retrospective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]. The pooled sensitivity and specificity of trigeminal reflex testing for distinguishing secondary and classic TN was 94 percent (95% CI 91-97) and 87 percent (95% CI 77-93). Based on high sensitivity and specificity, the",
"      <span class=\"nowrap\">",
"       AAN/EFNS",
"      </span>",
"      concluded that abnormal trigeminal reflexes are associated with an increased risk of secondary TN.",
"     </li>",
"     <li>",
"      The 2008",
"      <span class=\"nowrap\">",
"       AAN/EFNS",
"      </span>",
"      practice parameter identified four studies that used trigeminal evoked potentials to distinguish secondary from classic TN and found that the pooled sensitivity and specificity was 84 percent (95% CI 73-92) and 64 percent (95% CI 56-71) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"       29",
"      </a>",
"      ]. However, many patients with classic TN had abnormal evoked potentials and many with secondary TN had normal evoked potentials. Thus, trigeminal evoked potentials were not considered clinically useful for distinguishing classic from secondary TN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of TN includes short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), cluster-tic syndrome, jabs and jolts syndrome, and other neuralgias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy is the initial treatment of most patients with classic TN (ie, TN that is idiopathic or caused by neurovascular compression). Surgery is reserved for patients who are refractory to medical therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    is the best studied treatment for classic TN and is established as effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/28,29,37\">",
"     28,29,37",
"    </a>",
"    ]. Side effects can be a problem but are generally manageable, particular if low doses are prescribed initially with gradual titration.",
"   </p>",
"   <p>",
"    A systematic review and practice parameter published in 2008 from the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    is effective for controlling pain in patients with classic TN,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    is probably effective, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    are possibly effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. There is limited data and uncertain effectiveness regarding other drugs that have been used for TN, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , tocainide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Periodic attempts to gradually withdraw these drugs are warranted in patients achieving relief of pain with oral medications.",
"   </p>",
"   <p>",
"    No placebo-controlled trials have evaluated the treatment of secondary TN (ie, TN caused by a structural lesion other than vascular compression) and no medications have been established as effective for secondary TN. Treatment of the underlying condition (eg, multiple sclerosis) is recommended, if feasible. In addition, it is reasonable to treat the pain associated with secondary TN using the same medications that are employed in classic TN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four randomized, controlled trials with a total of 147 patients have established the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    (200 to 2400 mg daily) for TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and practice parameter published in 2008 from the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) noted that the treatment response in these trials was robust, with complete or near complete pain control attained in 58 to 100 percent of patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , compared with 0 to 40 percent of patients on placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. For the outcome of important pain relief, the number needed to treat was &lt;2. However, carbamazepine was sometimes poorly tolerated, with numbers needed to harm for minor and severe adverse events of 3 and 24 respectively.",
"   </p>",
"   <p>",
"    The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    is 100 to 200 mg twice daily. The dose can be increased gradually in increments of 200 mg daily as tolerated until sufficient pain relief is attained. The typical total maintenance dose is 600 to 800 mg daily, given in two divided doses for tablets and extended release capsules, or four divided doses when for oral suspension. The maximum suggested total dose is 1200 mg daily.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    include drowsiness, dizziness, nausea and vomiting; slow titration may minimize these effects. Carbamazepine-induced leukopenia is not uncommon, but it is usually benign; aplastic anemia is a rare side effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The HLA-B*1502 allele is a genetic susceptibility marker in Asians that is associated with an increased risk of developing Stevens-Johnson syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    toxic epidermal necrolysis. For most patients of Asian ancestry, genetic testing for the presence of this marker is recommended by the manufacturer prior to initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oxcarbazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     Oxcarbazepine",
"    </a>",
"    , an analogue of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , was developed to retain the antineuralgic effect of carbamazepine while reducing side effects.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    practice parameter identified several randomized controlled trials that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    (600 to 1800 mg daily) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    in 178 patients with classic TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. In the pooled analysis, both medications were equally effective, with a &gt;50 percent reduction of attacks achieved by 88 percent or more of patients in both treatment groups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     Oxcarbazepine",
"    </a>",
"    can be started at a total dose of 600 mg daily, given in two divided doses. The dose can be increased as tolerated in 300 mg increments every third day to a total dose of 1200 to 1800 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence from a small double-blind crossover trial suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    is beneficial for TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/42\">",
"     42",
"    </a>",
"    ]. Treatment with baclofen 40 to 80 mg daily resulted in a reduction in paroxysms in seven of 10 patients with typical TN, compared with one of 10 who received placebo. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    is 15 mg daily given in three divided doses, with gradual titration to a maintenance dose of 50 to 60 mg per day. Sedation, dizziness, and dyspepsia can occur with treatment, and the drug should be discontinued slowly since seizures and hallucinations have been reported with upon withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a double-blind, placebo-controlled crossover study of 14 patients with TN that was refractory to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , adjunct therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    (400 mg daily) was beneficial for improvement on a composite outcome index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients continued taking either carbamazepine or phenytoin for the duration of the trial.",
"   </p>",
"   <p>",
"    Similarly, an open-label study found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    was beneficial 11 of 15 patients with TN once the 400 mg dose was reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the clinical utility of lamotrigine for severe pain is limited by the need to titrate the dose over many weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who are not taking other anticonvulsants,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is typically started at 25 mg daily for the first two weeks, and then increased to 50 mg daily for weeks three and four. The dose is then titrated to effect, increasing by 50 mg daily every one to two weeks. The suggested total dose of 400 mg daily is given in two divided doses.",
"   </p>",
"   <p>",
"    For patients taking an anticonvulsant drug that induces hepatic enzymes (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ), the initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is 50 mg once daily, titrating upward as needed to 100 mg once daily at week three, 200 mg once daily at week five, 300 mg once daily at week six, and 400 mg once daily at week seven.",
"   </p>",
"   <p>",
"    For patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , the initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is 12.5 to 25 mg every other day, with increases of 25 mg every two weeks as needed to a maximum of 400 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pimozide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6472?source=see_link\">",
"     Pimozide",
"    </a>",
"    , a dopamine receptor antagonist, was more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    in a randomized, double-blind crossover trial of 48 patients with refractory TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/45\">",
"     45",
"    </a>",
"    ]. There were no drop-outs among patients taking pimozide. However, pimozide is seldom used because it has many potentially serious side effects, including sedation, arrhythmias, anticholinergic effects, acute extrapyramidal symptoms and parkinsonism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     Tizanidine",
"    </a>",
"    appeared to be more effective than placebo in a small one-week trial, but patients who continued the drug in follow-up developed recurrent attacks of TN within one to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tocainide was as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    at two weeks in a small cross-over trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small open label studies have suggested benefit with a number of medications used for TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/50\">",
"       50",
"      </a>",
"      ] and intravenous phenytoin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/51/14138?source=see_link\">",
"       Fosphenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Valproic acid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      , in patients with TN and multiple sclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these agents have not been studied in controlled trials, and their effectiveness in TN is not established.",
"   </p>",
"   <p>",
"    Although there are no controlled data regarding the efficacy of opioids in TN specifically, we have used opiates in patients with acute exacerbations of pain lasting for days to weeks. Opiates may help make the pain bearable while other, more effective and long-term, treatments take effect. Our experience with opiates suggests partial analgesia with central side effects (particularly sedation) when these drugs are used alone, as high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    are usually required. In combination with other neuropathic analgesics, opiates seem to be more effective at lower doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Refractory pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to support treatment alternatives for patients who are refractory to first-line medical therapy. However, some patients who fail",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    monotherapy may benefit from combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    . Intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    may provide analgesia while oral medications are titrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/51,62\">",
"     51,62",
"    </a>",
"    ]. Phenytoin and fosphenytoin are dosed at 250 to 1000 mg intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/51\">",
"     51",
"    </a>",
"    ] at no more than 50",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    and lidocaine is given at 100 to 300 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/62\">",
"     62",
"    </a>",
"    ] over one-half hour while monitoring pulse and blood pressure.",
"   </p>",
"   <p>",
"    Nevertheless, there are no randomized controlled trials comparing monotherapy with combination therapy for TN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with TN who are refractory to medical therapy are candidates for surgery. A variety of surgical methods have been employed to relieve the symptoms of TN. The major types of procedures are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microvascular decompression",
"     </li>",
"     <li>",
"      Ablative procedures, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rhizotomy with either radiofrequency thermocoagulation, mechanical balloon compression, or chemical (glycerol) injection",
"     </li>",
"     <li>",
"      Radiosurgery",
"     </li>",
"     <li>",
"      Peripheral neurectomy and nerve block",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, few have been studied in controlled trials, and most of the evidence comes from observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and practice parameter published in 2008 from the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) concluded that microvascular decompression, percutaneous procedures on the Gasserian ganglion (rhizotomy), and gamma knife radiosurgery are possibly effective in the treatment of TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. Evidence for peripheral neurectomy was considered negative or inconclusive.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    noted that definitive conclusions regarding the relative effectiveness of surgical techniques for TN are precluded by the lack of studies directly comparing them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. Indirect comparisons of the findings from different surgical studies suggest that microvascular decompression has a longer duration of pain control than other surgical interventions for TN.",
"   </p>",
"   <p>",
"    Microvascular decompression is invasive, although the overall mortality and complication rates are low. Ablative procedures are less invasive, but recurrence may be more common. The incidence of facial numbness is higher with rhizotomy procedures than with microvascular decompression or gamma knife radiosurgery.",
"   </p>",
"   <p>",
"    Although surgical therapy for TN is generally well-tolerated, a feared complication is anesthesia dolorosa, a condition characterized by persistent, painful anesthesia or hypesthesia in the denervated region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"     1",
"    </a>",
"    ]. It can be more intolerable than the pain from TN itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/64\">",
"     64",
"    </a>",
"    ]. This risk warrants careful decision making when considering surgical treatment for TN.",
"   </p>",
"   <p>",
"    Anesthesia dolorosa most frequently occurs as a complication of rhizotomy or thermocoagulation for TN, but is rarely if ever a complication of gamma knife surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Microvascular decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microvascular decompression is a major neurosurgical procedure that involves craniotomy and the removal or separation of various vascular structures, often an ectatic superior cerebellar artery, away from the trigeminal nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    practice parameter identified five studies of microvascular decompression for TN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/66-70\">",
"     66-70",
"    </a>",
"    ] that used independent outcome assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. The practice parameter concluded that initial pain relief is attained in 90 percent of patients, but that pain-free rates decline by one, three, and five years to 80, 75, and 73 percent.",
"   </p>",
"   <p>",
"    The average mortality is approximately 0.2 percent. However, major adverse events, such as cerebrospinal fluid leaks, infarction or hematoma, occur in up to 4 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common complication is aseptic meningitis in 11 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. Long term hearing loss occurs in up to 10 percent of patients, and sensory loss is found in 7 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Rhizotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhizotomy encompasses a number of percutaneous surgical techniques that are performed by passing a cannula through the foramen ovale, followed by lesion of the trigeminal ganglion or root using one of several options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiofrequency thermocoagulation rhizotomy, which creates a lesion by application of heat",
"     </li>",
"     <li>",
"      Mechanical balloon compression, which uses a Fogarty catheter to compress the gasserian ganglion",
"     </li>",
"     <li>",
"      Chemical (glycerol) rhizolysis, which involves the injection of 0.1 to 0.4 mL of glycerol into the trigeminal cistern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    practice parameter identified four uncontrolled case series that used independent outcome assessment of these procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ], including two reports of radiofrequency thermocoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], one report of glycerol rhizolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/74\">",
"     74",
"    </a>",
"    ], and one of balloon compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/75\">",
"     75",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    found that initial pain relief is achieved in 90 percent of patients, but that pain-free rates decline by one year to 68 to 85 percent, by three years to 54 to 64 percent, and by five years to approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major perioperative complication after rhizotomy procedures is meningitis, mainly aseptic, seen in 0.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. Mortality is rare. Postoperative dysesthesia, described as a burning, heavy, aching, or tired feeling, occurs in 12 percent. Longer-term sequelae include trigeminal distribution sensory loss in nearly one-half of patients, anesthesia dolorosa in approximately 4 percent, and corneal numbness with risk of keratitis in 4 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma knife radiosurgery produces lesions with focused gamma radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link&amp;anchor=H16#H16\">",
"     \"Stereotactic cranial radiosurgery\", section on 'Gamma Knife'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The therapy is aimed at the proximal trigeminal root since targeting the gasserian ganglion produced poor results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/77\">",
"     77",
"    </a>",
"    ]. The aiming of the beams is carried out with a stereotactic frame and MRI. The doses used are 70 to 90 Gy. The beams cause axonal degeneration and necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/77\">",
"     77",
"    </a>",
"    ]. Pain relief with gamma knife surgery occurs after a lag time of about one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    practice parameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ] identified one randomized controlled trial of gamma knife surgery for TN that compared two different treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/79\">",
"     79",
"    </a>",
"    ] and found no important differences. In addition, the",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ] identified three case series with independent outcome assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Complete pain relief at one year was found in up to 69 percent of patients, and at three years in 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. An earlier systematic review found that approximately 75 percent of patients report complete relief within three months, but the proportion decreases to 50 percent by three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New or worsened facial sensory impairment occurred in 9 to 37 percent, with more bothersome sensory loss or paresthesia found in 6 to 13 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ]. However, anesthesia dolorosa is rarely, if ever, a complication of gamma knife surgery.",
"   </p>",
"   <p>",
"    Linear accelerator radiosurgery has been evaluated for the treatment of TN in retrospective case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], but no prospective studies or controlled trials are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link&amp;anchor=H17#H17\">",
"     \"Stereotactic cranial radiosurgery\", section on 'Linac'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Peripheral neurectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neurectomy can be performed on the branches of the trigeminal nerve, which are the supraorbital, infraorbital, alveolar, and lingual nerves. Neurectomy is accomplished by incision, alcohol injection, radiofrequency lesioning, or cryotherapy. Cryotherapy involves freezing of the nerve using special probes, in theory to selectively destroy the pain fibers.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAN/EFNS",
"    </span>",
"    practice parameter noted that the evidence regarding peripheral techniques for the treatment of TN is either negative or inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/24/1409?source=see_link\">",
"       \"Patient information: Trigeminal neuralgia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trigeminal neuralgia (TN) is divided by presumed etiology into classic and secondary categories. Classic TN encompasses both idiopathic TN cases and those related to vascular compression. Secondary (or symptomatic) TN is reserved for patients with TN caused by structural lesions other than vascular compression. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TN is defined clinically by sudden, usually unilateral, severe, brief, stabbing or lancinating, recurrent episodes of pain in the distribution of one or more branches of the fifth cranial (trigeminal) nerve. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TN is based upon the characteristic clinical features. Sensory loss, bilateral involvement, and younger age are associated with a higher risk of secondary TN, but their absence does not rule out secondary TN. Neuroimaging and trigeminal reflex testing are considered useful for distinguishing classic from secondary TN. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest obtaining brain MRI to rule out a causative structural brain lesion for all patients with suspected TN who have trigeminal sensory loss, bilateral symptoms, or age &lt;40 years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic therapy is used for initial treatment of most patients with classic TN. No medications have been established as effective for secondary TN. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with classic TN who require pain control, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      as initial therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Carbamazepine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with classic TN who require pain control who do not respond to or tolerate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Oxcarbazepine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are refractory to or intolerant of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      , we suggest switching to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatively,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      can be used as add-on therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Baclofen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Lamotrigine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with TN who are refractory to the first and second-line agents listed above, a number of other medications with limited evidence of benefit may be considered. The choice among these agents is driven by patient preference, side effect profile, cost, and physician familiarity. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other medications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Refractory pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with TN refractory to medical therapy, it is reasonable to discuss options for surgical therapy using microvascular decompression, various types of rhizotomy, or gamma knife radiosurgery. The decision to have surgery and the choice among surgical options will be influenced by individual circumstances including patient preference, adverse effect profile of the available techniques, and expertise of the local center. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/2\">",
"      Katusic S, Williams DB, Beard CM, et al. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991; 10:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/3\">",
"      MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123 ( Pt 4):665.",
"     </a>",
"    </li>",
"    <li>",
"     Rozen, TD, Capobianco, DJ, Dalessio, DJ. Cranial neuralgias and atypical facial pain. In: Wolff's Headache and Other Head Pain, Silberstein, SD, Lipton, RB, Dalessio, DJ (Eds), Oxford University Press, New York 2001. p.509.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/5\">",
"      Childs AM, Meaney JF, Ferrie CD, Holland PC. Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports. Arch Dis Child 2000; 82:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/6\">",
"      Fleetwood IG, Innes AM, Hansen SR, Steinberg GK. Familial trigeminal neuralgia. Case report and review of the literature. J Neurosurg 2001; 95:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/7\">",
"      Pan SL, Yen MF, Chiu YH, et al. Increased risk of trigeminal neuralgia after hypertension: a population-based study. Neurology 2011; 77:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/8\">",
"      Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990; 27:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/9\">",
"      Siqueira SR, Teixeira MJ, Siqueira JT. Clinical characteristics of patients with trigeminal neuralgia referred to neurosurgery. Eur J Dent 2009; 3:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/10\">",
"      Teruel A, Ram S, Kumar SK, et al. Prevalence of hypertension in patients with trigeminal neuralgia. J Headache Pain 2009; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/11\">",
"      Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain 2001; 124:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/12\">",
"      Bowsher D. Trigeminal neuralgia: an anatomically oriented review. Clin Anat 1997; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/13\">",
"      Hamlyn PJ. Neurovascular relationships in the posterior cranial fossa, with special reference to trigeminal neuralgia. 2. Neurovascular compression of the trigeminal nerve in cadaveric controls and patients with trigeminal neuralgia: quantification and influence of method. Clin Anat 1997; 10:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/14\">",
"      Cheng TM, Cascino TL, Onofrio BM. Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors. Neurology 1993; 43:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/15\">",
"      Linskey ME, Jho HD, Jannetta PJ. Microvascular decompression for trigeminal neuralgia caused by vertebrobasilar compression. J Neurosurg 1994; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/16\">",
"      Ildan F, G&ouml;&ccedil;er AI, Ba��dato��lu H, et al. Isolated trigeminal neuralgia secondary to distal anterior inferior cerebellar artery aneurysm. Neurosurg Rev 1996; 19:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/17\">",
"      Figueiredo PC, Brock M, Prill A. Arteriovenous malformation in the cerebellopontine angle presenting as trigeminal neuralgia. Arq Neuropsiquiatr 1989; 47:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/18\">",
"      Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 1997; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/19\">",
"      Haddad FS, Taha JM. An unusual cause for trigeminal neuralgia: contralateral meningioma of the posterior fossa. Neurosurgery 1990; 26:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/20\">",
"      Mohanty A, Venkatrama SK, Rao BR, et al. Experience with cerebellopontine angle epidermoids. Neurosurgery 1997; 40:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/21\">",
"      Love S, Hilton DA, Coakham HB. Central demyelination of the Vth nerve root in trigeminal neuralgia associated with vascular compression. Brain Pathol 1998; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/22\">",
"      Hilton DA, Love S, Gradidge T, Coakham HB. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery 1994; 35:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/23\">",
"      Fromm GH, Terrence CF, Maroon JC. Trigeminal neuralgia. Current concepts regarding etiology and pathogenesis. Arch Neurol 1984; 41:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/24\">",
"      Obermann M, Yoon MS, Ese D, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology 2007; 69:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/25\">",
"      Gass A, Kitchen N, MacManus DG, et al. Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging. Neurology 1997; 49:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/26\">",
"      Meaney JF, Watt JW, Eldridge PR, et al. Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging. J Neurol Neurosurg Psychiatry 1995; 59:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/27\">",
"      Fromm GH, Graff-Radford SB, Terrence CF, Sweet WH. Pre-trigeminal neuralgia. Neurology 1990; 40:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/28\">",
"      Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. BMJ 2007; 334:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/29\">",
"      Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/30\">",
"      Goh BT, Poon CY, Peck RH. The importance of routine magnetic resonance imaging in trigeminal neuralgia diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/31\">",
"      Cruccu G, Deuschl G. The clinical use of brainstem reflexes and hand-muscle reflexes. Clin Neurophysiol 2000; 111:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/32\">",
"      Cruccu G, Biasiotta A, Galeotti F, et al. Diagnostic accuracy of trigeminal reflex testing in trigeminal neuralgia. Neurology 2006; 66:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/33\">",
"      Kimura J, Rodnitzky RL, Van Allen MW. Electrodiagnostic study of trigeminal nerve. Orbicularis oculi reflex and masseter reflex in trigeminal neuralgia, paratrigeminal syndrome, and other lesions of the trigeminal nerve. Neurology 1970; 20:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/34\">",
"      Ongerboer de Visser BW, Goor C. Electromyographic and reflex study in idiopathic and symptomatic trigeminal neuralgias: latency of the jaw and blink reflexes. J Neurol Neurosurg Psychiatry 1974; 37:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/35\">",
"      Kimura J. Clinical uses of the electrically elicited blink reflex. Adv Neurol 1983; 39:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/36\">",
"      Cruccu G, Leandri M, Feliciani M, Manfredi M. Idiopathic and symptomatic trigeminal pain. J Neurol Neurosurg Psychiatry 1990; 53:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/37\">",
"      Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev 2011; :CD005451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/38\">",
"      Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966; 29:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/39\">",
"      Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/40\">",
"      Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol 1968; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/41\">",
"      Nicol CF. A four year double-blind study of tegretol in facial pain. Headache 1969; 9:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/42\">",
"      Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984; 15:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/43\">",
"      Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/44\">",
"      Lunardi G, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997; 48:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/45\">",
"      Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/46\">",
"      Fromm GH, Aumentado D, Terrence CF. A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia. Pain 1993; 53:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/47\">",
"      Lindstr&ouml;m P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987; 28:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/48\">",
"      Yang M, Zhou M, He L, et al. Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev 2011; :CD004029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/49\">",
"      Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/50\">",
"      Braham J, Saia A. Phenytoin in the treatment of trigeminal and other neuralgias. Lancet 1960; 2:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/51\">",
"      McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg 1999; 89:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/52\">",
"      Cheshire WP. Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis. J Pain Symptom Manage 2001; 21:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/53\">",
"      Peiris JB, Perera GL, Devendra SV, Lionel ND. Sodium valproate in trigeminal neuralgia. Med J Aust 1980; 2:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/54\">",
"      Karlov VA, Savitskaia ON. [Comparative effectiveness of antiepileptic preparations in the treatment of patients with trigeminal neuralgia]. Zh Nevropatol Psikhiatr Im S S Korsakova 1980; 80:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/55\">",
"      Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/56\">",
"      Obermann M, Yoon MS, Sensen K, et al. Efficacy of pregabalin in the treatment of trigeminal neuralgia. Cephalalgia 2008; 28:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/57\">",
"      P&eacute;rez C, Navarro A, Salda&ntilde;a MT, et al. Patient-reported outcomes in subjects with painful trigeminal neuralgia receiving pregabalin: evidence from medical practice in primary care settings. Cephalalgia 2009; 29:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/58\">",
"      Caccia MR. Clonazepam in facial neuralgia and cluster headache. Clinical and electrophysiological study. Eur Neurol 1975; 13:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/59\">",
"      Court JE, Kase CS. Treatment of tic douloureux with a new anticonvulsant (clonazepam). J Neurol Neurosurg Psychiatry 1976; 39:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/60\">",
"      Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/61\">",
"      Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology 1995; 45:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/62\">",
"      Scrivani SJ, Chaudry A, Maciewicz RJ, Keith DA. Chronic neurogenic facial pain: lack of response to intravenous phentolamine. J Orofac Pain 1999; 13:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/63\">",
"      Zakrzewska JM, Akram H. Neurosurgical interventions for the treatment of classical trigeminal neuralgia. Cochrane Database Syst Rev 2011; :CD007312.",
"     </a>",
"    </li>",
"    <li>",
"     Heros, RC, Heros, DA, Schumacher, JM, et al. Principles of neurosurgery. In: Neurology in clinical practice, Bradley, WG, Daroff, RB, Fenichel, GM (Eds), Butterworth Heinemann, Philadelphia 2004. p.963.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/65\">",
"      Jannetta PJ. Microsurgical management of trigeminal neuralgia. Arch Neurol 1985; 42:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/66\">",
"      Barker FG 2nd, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med 1996; 334:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/67\">",
"      Zakrzewska JM, Lopez BC, Kim SE, Coakham HB. Patient reports of satisfaction after microvascular decompression and partial sensory rhizotomy for trigeminal neuralgia. Neurosurgery 2005; 56:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/68\">",
"      Broggi G, Ferroli P, Franzini A, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/69\">",
"      Piatt JH Jr, Wilkins RH. Microvascular decompression for tic douloureux. Neurosurgery 1984; 15:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/70\">",
"      Barker FG 2nd, Jannetta PJ, Bissonette DJ, Jho HD. Trigeminal numbness and tic relief after microvascular decompression for typical trigeminal neuralgia. Neurosurgery 1997; 40:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/71\">",
"      Lopez BC, Hamlyn PJ, Zakrzewska JM. Systematic review of ablative neurosurgical techniques for the treatment of trigeminal neuralgia. Neurosurgery 2004; 54:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/72\">",
"      Mittal B, Thomas DG. Controlled thermocoagulation in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1986; 49:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/73\">",
"      Zakrzewska JM, Jassim S, Bulman JS. A prospective, longitudinal study on patients with trigeminal neuralgia who underwent radiofrequency thermocoagulation of the Gasserian ganglion. Pain 1999; 79:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/74\">",
"      North RB, Kidd DH, Piantadosi S, Carson BS. Percutaneous retrogasserian glycerol rhizotomy. Predictors of success and failure in treatment of trigeminal neuralgia. J Neurosurg 1990; 72:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/75\">",
"      de Siqueira SR, da N&oacute;brega JC, de Siqueira JT, Teixeira MJ. Frequency of postoperative complications after balloon compression for idiopathic trigeminal neuralgia: prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/76\">",
"      Young RF, Vermeulen SS, Grimm P, et al. Gamma Knife radiosurgery for treatment of trigeminal neuralgia: idiopathic and tumor related. Neurology 1997; 48:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/77\">",
"      Nurmikko TJ, Eldridge PR. Trigeminal neuralgia--pathophysiology, diagnosis and current treatment. Br J Anaesth 2001; 87:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/78\">",
"      Sheehan J, Pan HC, Stroila M, Steiner L. Gamma knife surgery for trigeminal neuralgia: outcomes and prognostic factors. J Neurosurg 2005; 102:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/79\">",
"      Flickinger JC, Pollock BE, Kondziolka D, et al. Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery? A prospective double-blind, randomized study. Int J Radiat Oncol Biol Phys 2001; 51:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/80\">",
"      Maesawa S, Salame C, Flickinger JC, et al. Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 2001; 94:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/81\">",
"      Petit JH, Herman JM, Nagda S, et al. Radiosurgical treatment of trigeminal neuralgia: evaluating quality of life and treatment outcomes. Int J Radiat Oncol Biol Phys 2003; 56:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/82\">",
"      R&eacute;gis J, Metellus P, Hayashi M, et al. Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia. J Neurosurg 2006; 104:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/83\">",
"      Lopez BC, Hamlyn PJ, Zakrzewska JM. Stereotactic radiosurgery for primary trigeminal neuralgia: state of the evidence and recommendations for future reports. J Neurol Neurosurg Psychiatry 2004; 75:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/84\">",
"      Smith ZA, Gorgulho AA, Bezrukiy N, et al. Dedicated linear accelerator radiosurgery for trigeminal neuralgia: a single-center experience in 179 patients with varied dose prescriptions and treatment plans. Int J Radiat Oncol Biol Phys 2011; 81:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34873/abstract/85\">",
"      Chen JC, Girvigian M, Greathouse H, et al. Treatment of trigeminal neuralgia with linear accelerator radiosurgery: initial results. J Neurosurg 2004; 101 Suppl 3:346.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5283 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34873=[""].join("\n");
var outline_f34_3_34873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrophysiologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oxcarbazepine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pimozide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Refractory pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Microvascular decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Rhizotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Peripheral neurectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5283|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/48/26378\" title=\"figure 1\">",
"      Trigeminal nerve distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/32/12802\" title=\"figure 2\">",
"      Cutaneous fields head neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/24/1409?source=related_link\">",
"      Patient information: Trigeminal neuralgia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_3_34874="Clinical utility of cardiovascular magnetic resonance imaging";
var content_f34_3_34874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical utility of cardiovascular magnetic resonance imaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Anthon R Fuisz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Gerald M Pohost, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/3/34874/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/3/34874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has been used to image the brain and other stationary organs within the body and has become widely available as a diagnostic technique for cardiovascular imaging. This has been possible because of sophisticated ECG gating and respiratory motion suppression methods that facilitate high-quality cross sectional images of the heart. It is now customary to use the term cardiovascular magnetic resonance (CMR) when referring to MRI of the heart and blood vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the many techniques employed on MRI systems, three are the mainstays of clinical CMR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spin echo imaging &mdash; Spin echo imaging depicts the tissue structures of the heart as bright and the blood pool as dark (black blood approach). The spin echo method is predominantly used for anatomical imaging, and for identifying the fatty infiltration of the right ventricular free wall frequently seen in arrhythmogenic right ventricular cardiomyopathy (ARVC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gradient echo imaging &mdash; Gradient echo imaging generates images in which the blood pool appears bright and myocardium dark (bright blood approach). This technique is used to evaluate left and right ventricular cavity sizes and function, ventricular mass, intracardiac shunts, valvular functions, and to detect intracardiac masses. Steady state free precession (SSFP), a related approach, can generate high temporal (less than 30 msec) and spatial (2mm in-plane) resolution cine images in an 8 to 12 second breathhold.",
"     </li>",
"     <li>",
"      Flow velocity encoding &mdash; Flow velocity encoding (also known as phase contrast) is a technique that is used to directly measure blood flow and is useful for quantifying the severity of valvular regurgitation and stenosis, intracardiac shunt size, and the severity of arterial vascular stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other &mdash; Precise assessment of myocardial dynamics can be performed using radiofrequency (RF) tagging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/4\">",
"       4",
"      </a>",
"      ]. There is a general trend to develop new methods to perform CMR without the use of contrast agents. Magnetic resonance spectroscopy has been studied as a means of evaluating myocardial metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GATING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although real time CMR methods (acquisition of an entire image in less than 100 msec) are available and sometimes used, this approach suffers from lower temporal and spatial resolution. Thus, cardiac gating is generally used for CMR since data are typically acquired during many cardiac cycles to optimize spatial resolution. Robust ECG gating generally enables good spin-echo and cine image quality during sinus rhythm and even during atrial fibrillation or in the presence of occasional atrial or ventricular premature beats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/5\">",
"     5",
"    </a>",
"    ]. Although flow velocity encoding imaging can be performed in the presence of atrial fibrillation, image quality may be degraded.",
"   </p>",
"   <p>",
"    Although most CMR imaging can be performed during breath holds, longer image acquisitions (eg, for high resolution coronary artery imaging) require respiratory gating in addition to cardiac gating. Respiratory gating can be accomplished using either a navigator approach (to track the motion of the diaphragm) or respiratory bellows (using an elastic band wrapped around the thorax) to monitor respiratory motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR has no ionizing effects on patients or caregivers. However, CMR is potentially problematic in patients with ferromagnetic metallic implants. Thorough screening of all patients prior to CMR imaging or spectroscopy is mandatory. Devices such as prosthetic heart valves, prosthetic joints, sternal wires, and intravascular stents do",
"    <strong>",
"     not",
"    </strong>",
"    preclude study with CMRI at field strengths of 1.5 and 3.0 Tesla. Issues related to the safety of MRI, including specific recommendations regarding cardiovascular devices (eg, pacemakers), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=see_link&amp;anchor=H19#H19\">",
"     \"Principles of magnetic resonance imaging\", section on 'Precautions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gadolinium contrast agents administered to patients with moderate to severe kidney disease (estimated glomerular filtration rate (eGFR) less than 30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    has been rarely associated with the syndrome of nephrogenic systemic fibrosis. It is recommended that gadolinium-based imaging be avoided in such patients. This issue, including the definition of patients at risk, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR uses high intensity magnetic fields and radiofrequency to generate",
"    <span class=\"nowrap\">",
"     3D/tomographic",
"    </span>",
"    images with high spatial resolution and excellent contrast. In 2002, an AHA scientific statement made recommendations for standardized myocardial segmentation and nomenclature used with tomographic imaging of the heart (",
"    <a class=\"graphic graphic_figure graphicRef55080 graphicRef64968 graphicRef65139 \" href=\"mobipreview.htm?34/36/35402\">",
"     figure 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/6\">",
"     6",
"    </a>",
"    ]. CMR has been used for a growing list of applications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The advantages and disadvantages of CMR are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef79652 \" href=\"mobipreview.htm?18/22/18795\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AORTIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and assessment of diseases of the aorta is an area in which CMR excels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/9\">",
"     9",
"    </a>",
"    ]. Spin-echo and cine steady state free precession (SSFP) CMR can precisely define the dimensions and extent of complex aortic aneurysms, false aneurysms, dissection flaps, periaortic abscesses (eg, with endocarditis), aortic arch abnormalities, and coarctation. It can also be used to monitor patients with thoracic and abdominal aortic aneurysms and patients at risk for developing aortic aneurysms or dissection. In patients with homozygous familial hypercholesterolemia, CMR can detect atherosclerotic plaque and supravalvular aortic stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMR has a major role in the diagnosis, characterization, and determination of the extent of aortic dissection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69616 \" href=\"mobipreview.htm?15/49/16144\">",
"     image 1",
"    </a>",
"    ). It can provide information about the differential flow velocity in the true and false lumens, and can identify involvement of branch arteries anywhere from coronaries to the femoral arteries. Because of the inherent 3D nature of the technique, the images of the aorta and its pathology can be readily reconstructed into 3D display of the aorta and its branches, thereby facilitating planning for surgical repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamic instability limits the utility of CMR in some patients with aortic dissection. Time of acquisition (in older systems), difficulty with access to the patient, while in the magnet bore, and distortion of the electrocardiogram by the magnetic field make monitoring more difficult. CMR systems optimized for cardiac and vascular imaging can acquire 3D images of the entire thoracic aorta within 25 seconds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PERICARDIAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR permits direct visualization of the normal pericardium, which is composed of fibrous tissue and has a low CMR signal intensity on spin echo imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/11\">",
"     11",
"    </a>",
"    ]. The normal pericardium measures less than 3 mm in thickness. Although pericardial fluid also has a low signal intensity, it can be distinguished from pericardium with cine SSFP CMR images on which transudative pericardial fluid has a very bright signal that contrasts with the dark line of the pericardium.",
"   </p>",
"   <p>",
"    CMR is the diagnostic procedure of choice for the detection of certain pericardial diseases, such as noncalcified constrictive pericarditis, tumor invasion of the pericardium, and congenital absence of the pericardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. Myocardial tagging techniques can demonstrate tethering of pericardium to the heart during the cardiac cycle. Furthermore, real-time cine imaging allows direct visualization of the effects of respiration on ventricular filling and septal configuration to assist in the diagnosis of pericardial constriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, the presence of pericardial effusion can be established and the distinction made between a hemorrhagic and nonhemorrhagic effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]; however, echocardiography is generally used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial enhancement seen after administration of intravenous gadolinium contrast agent suggests an inflammatory process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, tissue characterization can give important diagnostic information in patients with primary and metastatic cardiac tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36991928\">",
"    <span class=\"h1\">",
"     MYOCARDIAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR enables characterization of the range of myocardial diseases from ischemic to inflammatory and various types of cardiomyopathy. It enables visualization and quantification of the size, mass, and global and regional function of the left and right ventricular cavities. Myocardial scar and fibrosis can be identified by gadolinium contrast enhancement techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36991943\">",
"    <span class=\"h2\">",
"     Gadolinium contrast techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36992798\">",
"    <span class=\"h3\">",
"     Late gadolinium enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late gadolinium enhancement (LGE) is thought to reflect fibrosis and irreversibly damaged myocardium including acute and chronic myocardial infarction (MI).",
"   </p>",
"   <p>",
"    The possible role of LGE as a risk predictor for subsequent cardiac events was evaluated in a group of 195 patients without known prior MI, but with known or suspected coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/23\">",
"     23",
"    </a>",
"    ]. During an average follow-up of 16 months, patients with LGE on the baseline study had a higher incidence of major adverse cardiovascular endpoints (MACE) compared to those without this finding. In addition, LGE was the strongest predictor of MACE taking into account traditional clinical, angiographic, and functional variables.",
"   </p>",
"   <p>",
"    The proper role of this diagnostic tool in the evaluation of patients with suspected or known coronary artery disease remains to be determined.",
"   </p>",
"   <p>",
"    If LGE CMR is being considered as a diagnostic option, renal function should be assessed. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Kidney disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36992805\">",
"    <span class=\"h4\">",
"     Infarct detection and sizing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic MI can be demonstrated with LGE. This technique may be used to identify the location and extent of infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Infarct sizing is precise and highly reproducible, with minimal interobserver and intraobserver variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/26\">",
"     26",
"    </a>",
"    ]. Imaging is typically performed 10 to 20 minutes after intravenous injection of 0.1 to",
"    <span class=\"nowrap\">",
"     0.2mmol/kg",
"    </span>",
"    of gadolinium chelate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter, double-blinded, randomized trial evaluated the efficacy of infarct detection by LGE in 282 patients with acute MI (up to 16 days post MI) and 284 patients with chronic MI (17 days to 6 months post MI) using varying doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"     gadoversetamide",
"    </a>",
"    (from 0.05 to 0.3",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/27\">",
"     27",
"    </a>",
"    ]. Comparing the doses of 0.1, 0.2, and 0.3",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    at 10 minutes after contrast administration, the sensitivity of CMR for detecting MI increased with a dose of gadoversetamide from 84 to 95 to 99 percent for acute MI and from 83 to 87 to 94 percent for chronic MI, respectively. The accuracy for identifying MI location (compared to infarct-related artery perfusion territory) also increased with a dose of contrast agent from 78 to 93 to 99 percent for acute MI and from 80 to 89 to 91 percent for chronic MI for doses of 0.1, 0.2, and 0.3",
"    <span class=\"nowrap\">",
"     mmol/kg,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    In a study in both animals and humans, LGE imaging was superior to single photon emission computed tomography (SPECT) for infarct detection in patients with known or suspected CAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/24\">",
"     24",
"    </a>",
"    ]. CMR identified 181 segments with subendocardial MI in 91 patients with known or suspected coronary disease compared to only 96 segments detected by SPECT. SPECT was more comparable to CMR in detecting transmural MI. The superiority of CMR for subendocardial MI detection is likely due to the greater spatial resolution of CMR.",
"   </p>",
"   <p>",
"    In a direct comparison of CMR and SPECT in the setting of acute MI, 78 patients who underwent urgent percutaneous coronary intervention were evaluated by both techniques seven days after the infarct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/28\">",
"     28",
"    </a>",
"    ]. CMR was significantly more sensitive than SPECT for all infarcts (97 versus 87 percent), small infarcts (92 versus 69 percent), and nonanterior infarcts (98 versus 84 percent) and there was a nonsignificant trend toward increased sensitivity for non-Q wave infarction (85 versus 46 percent).",
"   </p>",
"   <p>",
"    CMR may also detect the presence of microvascular obstruction; defined as a central dark area on inversion recovery, CMR images performed one to two minutes (early) after contrast injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. The extent of microvascular obstruction and infarct size increases substantially over the first 48 hours after an MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of CMR-defined microvascular obstruction after an MI has been assessed in small clinical studies. In a report of 44 patients, those with CMR-defined microvascular obstruction had a significantly higher rate of cardiovascular events during a 16-month follow-up (45 versus 9 percent for those without this abnormality) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, LGE in the infarct zone within 24 hours after primary PCI is an independent predictor of impaired left ventricular systolic thickening and remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of inferior wall MI, LGE has been compared to physical examination, electrocardiography, and echocardiography for the detection of right ventricular infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/34\">",
"     34",
"    </a>",
"    ]. In an initial report, LGE CMR was significantly more sensitive than any of the other methods. The clinical and prognostic relevance of this finding remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link&amp;anchor=H5#H5\">",
"     \"Right ventricular myocardial infarction\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36992887\">",
"    <span class=\"h4\">",
"     Myocardial viability",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGE can also be used to assess myocardial viability. Studies in laboratory animals have found that, independent of wall motion or infarct age, regions exhibiting enhancement at least 10 minutes after the injection of gadolinium-based contrast agents coincide with regions of myocardial necrosis and irreversible myocardial injury; regions that fail to enhance are viable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies have confirmed that a normal LGE pattern occurs in dysfunctional myocardium that is viable and displays improved contractile function in response to low dose (5 to 10",
"    <span class=\"nowrap\">",
"     &micro;g/kg/min)",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion, while central regions with enhancement where the infarct is transmural display no contractile activity in response to the dobutamine infusion. Territories that have nontransmural necrosis display a diminished contractile response to dobutamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/37\">",
"     37",
"    </a>",
"    ]. LGE as a marker of scar closely agrees with the finding of matching defects on PET viability scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=see_link&amp;anchor=H14#H14\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\", section on 'Positron emission tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further support for these findings comes from a clinical study of 32 patients with a proven MI who underwent coronary angiography; LGE, performed 3 or 14 months after the MI, accurately established the presence, location, and transmural extent of healed Q wave and non-Q wave MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/39\">",
"     39",
"    </a>",
"    ]. Large infarcts were predominantly transmural, while small infarcts were nontransmural (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79527 \" href=\"mobipreview.htm?23/40/24199\">",
"     image 2",
"    </a>",
"    ). The transmural extent of infarction predicts improvement in left ventricular function. In one study of 24 patients, the extent of dysfunctional myocardium that was not infarcted or had necrosis comprising &lt;25 percent of left ventricular wall thickness, as established by LGE performed within one week of the MI, was the best predictor of global improvement in contractility at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduction in the extent of LGE early after an MI is associated with early restoration of blood flow and improvement in contractile function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/41\">",
"     41",
"    </a>",
"    ]. This is in contrast to what has been seen with microvascular obstruction and early hypoenhancement immediately after an infarction, as discussed above; this myocardium has no contractile response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LGE CMR can also be used to establish the presence of hibernating myocardium. In one series of 24 patients with stable coronary artery disease and left ventricular dysfunction, LGE (three to 15 minutes after contrast administration) was associated with nonviability as established with rest-distribution thallium imaging and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography; the absence of enhancement correlated with radionuclide and echocardiographic viability, regardless of the status of resting contractile function (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63447 \" href=\"mobipreview.htm?40/55/41842\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of enhancement with LGE can predict recovery of left ventricular systolic function after revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. As an example, one study of 50 patients with coronary artery disease who had left ventricular dysfunction prior to surgical or percutaneous revascularization found that 33 percent of myocardial segments in 80 percent of patients had evidence of LGE; 38 percent of segments had abnormal contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/43\">",
"     43",
"    </a>",
"    ]. After revascularization, more dysfunctional segments without LGE improved (78 versus 17 percent with enhancement of more than 75 percent of the tissue). The likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of LGE increased. The percentage of the left ventricle that was dysfunctional and not enhanced was significantly related to the degree of improvement in left ventricular ejection fraction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the size of LGE enhancement may decrease with time, there may be predictive value in assessing nonhyperenhanced regions of the ventricle. One study demonstrated the value of measuring the nonenhancing wall thickness to predict improvement in systolic wall thickening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMR myocardial tagging is another noninvasive method that quantifies local myocardial segment shortening throughout the left ventricular myocardium at sites across the left ventricular wall thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/46\">",
"     46",
"    </a>",
"    ]. Quantitative analysis of regional intramural function can be performed independent of accurate border detection when this technique is used in conjunction with two-dimensional strain analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"strain\" refers to an object's fractional or percent change from its original, unstressed, dimension (ie, a change in length corrected for the original length) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/48\">",
"     48",
"    </a>",
"    ]. It reflects deformation of a structure, and when applied to the myocardium, strain directly describes the",
"    <span class=\"nowrap\">",
"     contraction/relaxation",
"    </span>",
"    pattern. Strain rate is the rate of this deformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When combined with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , CMR myocardial tagging can quantify the amount of myocardial viability after an acute MI and provide prognostic information. In one study of 20 patients with a first reperfused MI, a normal increase in shortening within the midwall and subepicardium, but not the subendocardium, during a low-dose dobutamine infusion predicted greater functional recovery eight weeks after the MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/49\">",
"     49",
"    </a>",
"    ]. A second report compared dobutamine CMR with thallium and tetrofosmin SPECT in 30 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/50\">",
"     50",
"    </a>",
"    ]. The sensitivity and specificity of dobutamine CMR was 50 and 81 percent, respectively; SPECT imaging with thallium or tetrofosmin had higher sensitivity (76 and 66 percent, respectively), but lower specificity (44 and 49 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36992969\">",
"    <span class=\"h4\">",
"     Prediction of post-MI mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR has been used to evaluate the size of the peri-infarct border zone size in relation to the core infarct as a predictor of post-MI mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/51\">",
"     51",
"    </a>",
"    ]. The peri-infarct border zone is postulated to represent a mix of viable and scarred myocardium, a heterogeneous region that may represent substrate for ventricular arrhythmias. Thus, the size of the peri-infarct border zone may predict future arrhythmic risk.",
"   </p>",
"   <p>",
"    The survival of 144 patients with documented coronary artery disease and LGE consistent with infarction was assessed at a median follow-up of 2.4 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with a peri-infarct zone to total infarct (core and peri-infarct zone) ratio above the median were at higher risk of death (28 versus 13 percent in those below the median). This emerging methodology requires validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36992976\">",
"    <span class=\"h4\">",
"     Chest pain without significant coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In various clinical trials and the CRUSADE registry, 9 to 14 percent of patients with a non-ST elevation acute coronary syndrome (ACS) have, on coronary angiography, either minimal disease or no vessel with at least 50 to 60 percent stenosis. In addition, as many as 7.5 percent of patients with an ST-elevation myocardial infarction do not have a critical coronary artery lesion and approximately 3 percent have normal epicardial coronary arteries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28505?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Absence of significant coronary disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\", section on 'MI with normal coronary arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible role of LGE in the diagnostic evaluation of troponin positive chest pain patients without coronary obstruction was investigated in 60 such patients, 40 percent of whom had ST elevation on the initial ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/52\">",
"     52",
"    </a>",
"    ]. CMR was performed within three months (median interval of 15 days) of initial presentation. Based on the LGE pattern, a cause for the troponin elevation was identified in 65 percent of the patients, with myocarditis in 50 percent, MI in 12 percent, and cardiomyopathy in 3 percent.",
"   </p>",
"   <p>",
"    CMR has also been used demonstrate abnormal subendocardial perfusion in patients with cardiac syndrome X with chest pain and normal epicardial coronary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36993816\">",
"    <span class=\"h3\">",
"     Detection of diffuse myocardial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGE is useful for detection of focal but not diffuse fibrosis. An equilibrium contrast CMR (EQ-CMR) technique has been proposed as a means to identify diffuse myocardial fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/54\">",
"     54",
"    </a>",
"    ]. However, there are not enough data to make any definitive comment on this approach. The technique was clinically tested in a small population of patients by demonstration of a good correlation between EQ-CMR and histologic fibrosis (r",
"    <sup>",
"     2",
"    </sup>",
"    = 0.80) in 18 patients with aortic stenosis and eight patients with hypertrophic cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36993685\">",
"    <span class=\"h2\">",
"     CMR characterization of myocardial diseases",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR can be useful in assessing patients with possible or definite ischemic heart disease. Since CMR provides a dimensionally accurate, 3D perspective of the heart, it has been considered by many to be the gold standard for measurements of left and right ventricular ejection fraction, volumes, and myocardial mass. It can detect regional wall motion abnormalities and high-energy phosphate abnormalities in ischemic tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of CMR in the setting of acute coronary syndrome (ACS) is under investigation and has not yet been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A preliminary report evaluated the use of CMR in 161 patients presenting to an emergency department with chest pain suggestive of an ACS and a nondiagnostic ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/56\">",
"       56",
"      </a>",
"      ]. CMR was obtained within 12 hours and included assessment for regional wall motion abnormalities, myocardial perfusion defects, and myocardial infarction using LGE. Sensitivity and specificity of CMR for diagnosing ACS were 84 and 85 percent, respectively. Further analysis showed that CMR was the strongest predictor of ACS and provided incremental diagnostic information over clinical parameters such as ischemic ECG changes, peak troponin-I, and TIMI risk score.",
"     </li>",
"     <li>",
"      An augmented CMR protocol (including T2-weighted imaging and assessment of left ventricular wall thickness) was compared to a standard CMR protocol (function, perfusion, and LGE) in 62 patients presenting to the emergency department with acute chest pain with negative cardiac biomarkers and no acute ischemic ECG changes. (See",
"      <a class=\"local\" href=\"#H36992976\">",
"       'Chest pain without significant coronary artery disease'",
"      </a>",
"      above.) As compared to the standard protocol, specificity, positive predictive value, and overall accuracy increased from 84% to 96%, 55% to 85%, and 84% to 93% respectively when using the novel protocol. In addition, this augmented CMR protocol demonstrated value over that of the initial clinical risk assessment and traditional risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Pharmacologic stress CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR has been evaluated using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , vasodilator (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , adenosine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    ), and both agents to produce or simulate stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h5\">",
"     Dobutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    has been used to induce stress with CMR imaging before and during infusion, allowing visualization of segments that become ischemic (ie, demonstrate reduced motion) during stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. This technique provides an accurate alternative for the diagnosis of coronary artery disease and for quantification of \"myocardium at risk;\" it may be particularly useful for patients in whom adequate echocardiograms cannot be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography with dobutamine stress CMR in 208 patients with suspected coronary disease who underwent x-ray coronary angiography. Compared to dobutamine stress echocardiography, dobutamine CMR had greater sensitivity (86 versus 74 percent) and specificity (86 versus 70 percent); the results were similar in men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    CMR may also be useful in predicting left ventricular functional recovery after coronary revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In a series of 43 patients with a prior MI who subsequently underwent coronary artery revascularization, dobutamine-induced systolic wall thickening predicted functional recovery of the affected wall with a sensitivity and specificity of 89 and 94 percent, respectively (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56784 graphicRef68495 \" href=\"mobipreview.htm?17/13/17623\">",
"     image 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMR myocardial tagging is a noninvasive method that quantifies local myocardial segment shortening throughout the left ventricular myocardium at sites across the left ventricular wall thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/4\">",
"     4",
"    </a>",
"    ]. Myocardial tagging improves the sensitivity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress CMR. (See",
"    <a class=\"local\" href=\"#H36992887\">",
"     'Myocardial viability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential prognostic value of CMR myocardial tagging in this setting was evaluated in 194 patients with suspected myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/63\">",
"     63",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress CMR with tagging detected more new regional wall motion abnormalities with stress than dobutamine stress CMR without tagging (68 versus 58 patients). Cardiac catheterization demonstrated coronary artery disease in 65 of the 68 patients with a positive tagged scan; 62 of these required revascularization. In contrast, among the patients with a negative tagged scan, the event-free survival rate was 98.2 percent at 17 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h5\">",
"     Dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic territories can be identified by using intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    and gadolinium for a first-pass perfusion study and estimation of a myocardial perfusion reserve index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. As an example, one study of 48 patients and 18 healthy subjects found that a coronary flow reserve less than 1.65 had a sensitivity and specificity of 91 and 94 percent, respectively, for the detection of coronary artery disease as defined by positron emission tomography (PET) scanning; sensitivity and specificity were 87 and 85 percent, respectively, when compared to quantitative coronary x-ray angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/65\">",
"     65",
"    </a>",
"    ]. This technique was accurate even when perfusion abnormalities were confined to the subendocardium.",
"   </p>",
"   <p>",
"    The myocardial perfusion reserve index obtained from CMR is also useful for assessing the results of a percutaneous coronary intervention; one study found that this index improved, but did not normalize, after angioplasty, while it completely normalized after angioplasty with stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h5\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine stress CMR has been used to detect myocardial ischemia by inducing wall motion abnormalities and by creating relative perfusion differences seen in first pass perfusion imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. In a report comparing CMR adenosine-induced wall motion abnormalities and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -induced wall motion abnormalities, the sensitivity of adenosine testing for significant stenosis as determined by quantitative angiography was much lower with adenosine wall motion stress (40 versus 89 percent), while the specificity was higher (96 versus 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic accuracy of adenosine stress CMR varies significantly according to the CMR parameter evaluated. Direct assessment of myocardial perfusion after adenosine stress is sensitive, while adenosine-induced wall motion abnormalities have a high specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/68\">",
"     68",
"    </a>",
"    ]. The performance of adenosine stress CMR may be improved by the combination of stress perfusion imaging and LGE infarction imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/70\">",
"     70",
"    </a>",
"    ]. In the CE-MARC trial, comprehensive CMR including adenosine perfusion was compared to standard SPECT for the detection of significant stenosis with x-ray angiography as the gold standard in 752 patients. The sensitivity of CMR was found to be superior to that of SPECT with similar specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h5\">",
"     Adenosine plus dobutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report assessing the prognostic value of CMR using combined, single session adenosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress, 513 patients with known or suspected coronary disease were evaluated during a mean follow-up of 2.3 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/72\">",
"     72",
"    </a>",
"    ]. The three year event-free (cardiac death and nonfatal myocardial infarction) survival was 99 percent with normal and 84 percent with abnormal combined stress images.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     CMR after myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular ejection fraction and end-systolic volume index are important prognostic indicators after acute myocardial infarction (MI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquisition of 3D stacks of CMR images permits calculation of left and right ventricular volumes without geometric assumptions which may lead to inaccuracies (especially in focally deformed ventricles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/73\">",
"     73",
"    </a>",
"    ]. In addition, CMR can detect and quantify the many potential complications of MI. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral regurgitation and ventricular septal defect (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=see_link\">",
"       \"Mechanical complications of acute myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Left ventricular thrombus (see",
"      <a class=\"local\" href=\"#H36993959\">",
"       'Intracavitary thrombus'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link\">",
"       \"Left ventricular thrombus after acute myocardial infarction\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Left ventricular aneurysm and pseudoaneurysm (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=see_link\">",
"       \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pericardial effusion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=see_link\">",
"       \"Pericardial complications of myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, acute and chronic myocardial infarction can be identified with LGE CMR. (See",
"    <a class=\"local\" href=\"#H36992805\">",
"     'Infarct detection and sizing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36995756\">",
"    <span class=\"h4\">",
"     Coronary MR angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production of diagnostic quality angiograms of the coronary arteries with CMR is another area of rapid development. The utility of coronary MRI in patients with native vessel or bypass graft disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronary MRA may be particularly useful for the identification or characterization of anomalous coronary arteries and for monitoring coronary artery aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=see_link\">",
"     \"Congenital and pediatric coronary artery abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high spatial resolution of CMR enables accurate assessment of ventricular volumes, ventricular systolic function (ejection fraction), and myocardial mass and wall thickness. Such analysis is useful in the assessment of patients with heart failure, for the diagnostic evaluation of cardiomyopathy, for prediction of outcomes, and may frequently be the preferred diagnostic test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link&amp;anchor=H27#H27\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Cardiovascular magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Ischemic versus nonischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution evaluation of regional ventricular systolic function can help differentiate between ischemic and nonischemic cardiomyopathy. LGE, which identifies myocardial",
"    <span class=\"nowrap\">",
"     scar/fibrosis,",
"    </span>",
"    can also be used to make this distinction.",
"   </p>",
"   <p>",
"    LGE is present in most patients with ischemic cardiomyopathy (81 to 100 percent) compared to 12 to 41 percent in patients without significant obstructive coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/46,74,75\">",
"     46,74,75",
"    </a>",
"    ]. Although LGE can be seen in ischemic and nonischemic cardiomyopathies, the patterns of LGE tend to be different in the two disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic cardiomyopathy is characterized by subendocardial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transmural LGE.",
"     </li>",
"     <li>",
"      In comparison, isolated mid-wall or epicardial enhancement is strongly suggestive of a nonischemic cardiomyopathy. Mid-wall involvement in ischemic cardiomyopathy involved segments different from those showing subendocardial LGE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two studies, LGE similar to that in ischemic cardiomyopathy was seen in 9 to 13 percent of patients with unobstructed coronary arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. A possible explanation for this finding is recanalization after a myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LGE also may be seen in hypertrophic cardiomyopathy, myocarditis, sarcoidosis, and infiltrative cardiomyopathies such as amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of LGE to predict recovery of left ventricular function after revascularization in patients with ischemic cardiomyopathy and the use of CMR for infarct detection and size and for the detection of intracardiac thrombi are discussed above, while the data evaluating the use of coronary MRI is presented separately. (See",
"    <a class=\"local\" href=\"#H36992887\">",
"     'Myocardial viability'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H36992805\">",
"     'Infarct detection and sizing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H36993959\">",
"     'Intracavitary thrombus'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymmetric thickening of the interventricular septum and other patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy (HCM) can be readily detected by CMR. CMR may be of particular value in the assessment of variant types of hypertrophic cardiomyopathy sometimes not detected by TTE, including apical and lateral wall hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. It is also possible to visualize systolic anterior motion of the mitral valve and turbulence in the left ventricular outflow tract created by the dynamic obstruction in obstructive hypertrophic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, LGE techniques may be used to identify patchy mid-wall LGE, particularly at the junctions of the interventricular septum and right ventricular free wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/76,79,80\">",
"     76,79,80",
"    </a>",
"    ]. The extent of enhancement has been associated with progressive ventricular dilation and markers of sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/80\">",
"     80",
"    </a>",
"    ] but its prognostic significance has not been established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link&amp;anchor=H4#H4\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Cardiac sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis and monitoring of cardiac sarcoidosis by CMR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h4\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing body of literature on the role of CMR in patients with suspected iron overload. In the presence of myocardial iron overload, myocardial T2* (T2 star) is reduced due to inhomogeneities that are increased with iron deposition. In one study of 106 patients with thalassemia and multiple blood transfusions, there was a significant inverse correlation between liver T2* and liver iron concentration by biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/81\">",
"     81",
"    </a>",
"    ]. Increasing myocardial iron content as assessed by myocardial T2* correlated with decreasing left ventricular ejection fraction but there was no correlation between myocardial T2* and serum ferritin or liver iron content, which may relate to temporal differences in iron uptake and release between these two organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A difference in iron loading and unloading between the liver and heart was also seen in a report dealing with 66 patients (age range: 3 to 82 years) with transfusion-dependent anemias and thalassemia intermedia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/83\">",
"     83",
"    </a>",
"    ]. There was a poor correlation between hepatic and myocardial iron as assessed by T2* MRI, and a subgroup of patients was identified with increased myocardial iron without a matched degree of hepatic hemosiderosis. Left ventricular ejection fraction was insensitive for detecting elevated myocardial iron. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'CT, MRI, and SQUID techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inter-center reproducibility of the T2* technique was validated in a small multicenter study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/84\">",
"     84",
"    </a>",
"    ]. CMR also enables evaluation of response to treatment of iron overload. A meta-analysis of available studies in patients with transfusion- dependent thalassemia has concluded that iron chelators significantly reduced myocardial iron content by about 24 percent (95% CI 17-30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/85\">",
"     85",
"    </a>",
"    ]. There was no significant difference between the amount of iron reduced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    . LVEF was not significantly changed by chelation, although this meta-analysis indicated that a publication bias existed for LVEF, but not for myocardial iron.",
"   </p>",
"   <p>",
"    The prognostic value of cardiac T2* was evaluated in a study of 652 thalassemia major patients followed at 21 UK centers who underwent 1442 CMR scans at a single CMR center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/86\">",
"     86",
"    </a>",
"    ]. At one year follow-up there were 80 episodes of heart failure and 98 episodes of arrhythmia. The following associations with T2* were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac T2* &lt;10 ms was associated with heart failure with a relative risk of 160 (95% CI, 64 to 1129). Heart failure occurred in 47 percent of patients with cardiac T2* &lt;6 ms with a relative risk of 270 (95% CI, 64 to 1129). Cardiac T2* was &lt;10 ms in 98 percent of scans in patients who developed heart failure.",
"     </li>",
"     <li>",
"      Cardiac T2* &lt;20 ms was associated with arrhythmia with a relative risk of 4.6 (95% CI, 2.7 to 8). Arrhythmia occurred in 14 percent of patients with a cardiac T2* of &lt;6 ms. Cardiac T2* was &lt;20 ms in 83 percent of scans of patients who developed arrhythmias.",
"     </li>",
"     <li>",
"      Cardiac T2* was a substantially better predictor of heart failure or arrhythmia than liver T2* or serum ferritin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The availability of automated T2* CMR software may facilitate dissemination of this technique for monitoring myocardial siderosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h4\">",
"     Restrictive cardiomyopathy versus constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR is also an excellent approach to differentiate between restrictive and constrictive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the infiltrated myocardium in restrictive cardiomyopathy due to amyloidosis is easily detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/76,88,89\">",
"     76,88,89",
"    </a>",
"    ]. There is homogeneous thickening of the ventricular and atrial walls, including the interatrial septum and right atrial free wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79527 \" href=\"mobipreview.htm?23/40/24199\">",
"     image 2",
"    </a>",
"    ). These abnormalities are not seen in patients with idiopathic restrictive cardiomyopathy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63447 \" href=\"mobipreview.htm?40/55/41842\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/89\">",
"     89",
"    </a>",
"    ]. LGE imaging often demonstrates circumferential subendocardial or diffuse transmural enhancement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h4\">",
"     Chagas heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of LGE CMR in the assessment of Chagas heart disease was assessed in a series of 51 patients of varying disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/90\">",
"     90",
"    </a>",
"    ]. Myocardial fibrosis was detected in early asymptomatic stages and increased with clinical stage of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14266?source=see_link&amp;anchor=H114864684#H114864684\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\", section on 'Cardiovascular magnetic resonance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Acute myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR can be used to identify the presence of myocardial edema and myocyte damage in myocarditis. CMR evaluation of myocarditis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     VALVULAR HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The turbulence created by valvular stenosis and regurgitation is easily visualized on cine gradient echo CMR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/73,91\">",
"     73,91",
"    </a>",
"    ]. However, changes in the acquisition parameters (eg, shorter echo time, use of steady state free precession sequences) can markedly alter this effect, so that qualitative assessment of valvular lesions must be done with caution and by those familiar with the characteristics of the involved parameters. In addition, CMR determined ejection fraction and ventricular volumes can help to determine the timing of valvular surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21658413\">",
"    <span class=\"h2\">",
"     Regurgitant valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regurgitant valvular lesions produce a zone of proximal isovelocity surface area (PISA) on the side of the valve opposite from the direction of regurgitant flow with both CMR and echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/92\">",
"     92",
"    </a>",
"    ]. The amount of PISA is directly related to the amount of regurgitation.",
"   </p>",
"   <p>",
"    Phase velocity mapping enables quantification of the amount of aortic regurgitation.",
"   </p>",
"   <p>",
"    Valvular regurgitation caused by endocarditis is well seen with gradient echo images, but vegetations are only occasionally visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21658406\">",
"    <span class=\"h2\">",
"     Stenotic valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of CMR in quantifying stenotic valve disease is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial report, aortic valve planimetry by CMR correlated well with transesophageal echocardiography (TEE) planimetry in a series of 40 patients with aortic stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/94\">",
"       94",
"      </a>",
"      ]. The mean valve area was 0.91 cm2 by CMR and 0.89 cm2 by TEE; the correlation coefficient between the two methods was 0.96. However, the correlation of CMR with valve area determined by cardiac catheterization was not as good (0.44). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1208?source=see_link\">",
"       \"Aortic valve area in aortic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In two series of 39 patients with mitral stenosis, the correlation coefficients of planimetered mitral valve areas from CMR data were 0.81 and 0.86 with Doppler pressure half-time echocardiography and 0.89 with catheterization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. CMR slightly overestimated mitral valve area compared to echocardiography (by 8 percent) and catheterization (by 5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/96\">",
"       96",
"      </a>",
"      ]. Thus, a planimetered CMR mitral valve area less than 1.65 cm2 suggests mitral stenosis defined as a catheterization value of less than 1.5 cm2. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=see_link\">",
"       \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21658399\">",
"    <span class=\"h2\">",
"     Myocardial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential prognostic value of myocardial fibrosis detected by CMR late gadolinium enhancement (LGE) in patients with aortic stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link&amp;anchor=H21855299#H21855299\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Cardiovascular magnetic resonance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36993959\">",
"    <span class=\"h1\">",
"     INTRACAVITARY THROMBUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical detection of ventricular thrombi is generally performed by transthoracic echocardiography (TTE) and evaluation of atrial thrombi is generally performed by TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link\">",
"     \"Left ventricular thrombus after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, CMR appears to have greater sensitivity and similarly high specificity for detection of left ventricular thrombi in the MI population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. The largest study consisted of 160 patients with a remote prior infarction who had surgical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathological confirmation of the presence (48 patients [30 percent]) or absence of chronic left ventricular thrombus; all patients underwent CMR including LGE, TTE, and intraoperative TEE. CMR was significantly more sensitive (88 versus 23 and 40 percent with TTE and TEE, respectively); all three imaging modalities were highly specific (99 percent for CMR versus 96 percent with TTE and TEE). The patients with left ventricular thrombus had a higher incidence of recent embolic events (6.1 versus 0.8 percent).",
"   </p>",
"   <p>",
"    High LGE sensitivity for left ventricular thrombus was also noted in an analysis of 57 patients with acute or past MI or ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/99\">",
"     99",
"    </a>",
"    ]. LGE detected mural left ventricular thrombus in 12 (21 percent); only five were seen by TTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data are available for CMR imaging of left ventricular thrombus in nonischemic populations and of atrial thrombus. Although atrial thrombus can be detected by contrast and noncontrast CMR techniques, diagnostic accuracy compared to TEE is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PERIPHERAL ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to generate images of blood vessels without the administration of contrast medium coupled with the capability of producing high resolution 3D images gives CMR a particular advantage in assessing peripheral artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/9\">",
"     9",
"    </a>",
"    ]. Carotid arteries can be imaged along their entire length, identifying stenoses, resultant turbulent flow, and the presence and possibly age of arterial thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary data suggest that CMR can distinguish atherosclerotic lesions with intact, thick fibrous caps from those with a lipid-rich necrotic core and intraplaque hemorrhage or with thin and disrupted caps, which have the potential for rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. Although the number of patients who have been studied is small, patients undergoing carotid endarterectomy who have ruptured caps on CMR appear to be more likely to have had a recent transient ischemic attack or stroke than those with thick fibrous caps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=see_link\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMR can also be useful in documenting the regression of aortic and carotid atherosclerotic lesions during therapy with a statin drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/107\">",
"     107",
"    </a>",
"    ]. The iliac and femoral arteries can also be readily imaged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/108\">",
"     108",
"    </a>",
"    ]. These images permit precise planning for peripheral interventions, without exposure to iodinated contrast medium or the post-procedure recovery associated with arterial puncture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H58544732#H58544732\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Other imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     CONGENITAL HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR has many other clinically important applications for evaluation of patients with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/109\">",
"     109",
"    </a>",
"    ]. Patients with complex congenital heart disease include many who are younger and will undergo numerous imaging tests during their lifetime. Thus, a noninvasive test that does not employ ionizing radiation is preferred. Spin-echo and SSFP CMR can be readily applied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Phase velocity mapping techniques can accurately measure the pulmonary and systemic blood flows and establish the ratio associated with intracardiac shunts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/3\">",
"     3",
"    </a>",
"    ]. 3D SSFP CMR may allow simplified image acquisition and reformatting of a single set of images into any desired projection plane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LGE can also detect areas of fibrosis in patients with repaired tetralogy of Fallot, a possible marker of late adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/3/34874/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of tetralogy of Fallot\", section on 'Long-term outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8169189\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the imaging techniques employed in cardiovascular magnetic resonance (CMR) imaging, the mainstays are spin echo imaging, gradient echo imaging, late gadolinium enhancement (LGE) sequences, and flow velocity encoding. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMR uses no ionizing radiation. However, CMR is potentially problematic in patients with certain types of metallic implants. Thorough screening of all patients prior to CMRI is mandatory. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Safety'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=see_link&amp;anchor=H19#H19\">",
"       \"Principles of magnetic resonance imaging\", section on 'Precautions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"       \"Diagnostic imaging procedures during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical applications of CMR include imaging of aortic, pericardial, myocardial, valvular, peripheral artery, congenital heart disease, ischemic heart disease, and intraventricular thrombus. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMR enables assessment of cardiac structure and function and vascular structures largely without need for an exogenous contrast agent. Gadolinium-based contrast agent administration is indicated for angiography or assessment of contrast enhancement properties but should be avoided in patients with moderate to severe kidney disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Kidney disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late gadolinium enhancement (LGE) is a technique that enables identification of myocardial fibrosis including myocardial infarction and focal myocardial fibrosis in patients with hypertrophic and other cardiomyopathies. Characteristic LGE patterns are helpful for diagnosis of amyloid cardiomyopathy, myocarditis, and cardiac sarcoid. Pericardial LGE is a sign of inflammation. (See",
"      <a class=\"local\" href=\"#H36992798\">",
"       'Late gadolinium enhancement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link&amp;anchor=H2554149#H2554149\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\", section on 'Cardiovascular magnetic resonance'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pericardial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMR enables identification and quantification of myocardial iron overload, which may be helpful for diagnosis, prognosis, and treatment. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Iron overload'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/1\">",
"      Kramer CM, Barkhausen J, Flamm SD, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 2008; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/2\">",
"      Menghetti L, Basso C, Nava A, et al. Spin-echo nuclear magnetic resonance for tissue characterisation in arrhythmogenic right ventricular cardiomyopathy. Heart 1996; 76:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/3\">",
"      Beerbaum P, K&ouml;rperich H, Barth P, et al. Noninvasive quantification of left-to-right shunt in pediatric patients: phase-contrast cine magnetic resonance imaging compared with invasive oximetry. Circulation 2001; 103:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/4\">",
"      Sayad DE, Willett DL, Bridges WH, et al. Noninvasive quantitation of left ventricular wall thickening using cine magnetic resonance imaging with myocardial tagging. Am J Cardiol 1995; 76:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/5\">",
"      Hundley WG, Meshack BM, Willett DL, et al. Comparison of quantitation of left ventricular volume, ejection fraction, and cardiac output in patients with atrial fibrillation by cine magnetic resonance imaging versus invasive measurements. Am J Cardiol 1996; 78:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/6\">",
"      Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/7\">",
"      Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol 2004; 44:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/8\">",
"      Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004; 25:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/9\">",
"      Olin JW, Kaufman JA, Bluemke DA, et al. Atherosclerotic Vascular Disease Conference: Writing Group IV: imaging. Circulation 2004; 109:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/10\">",
"      Summers RM, Andrasko-Bourgeois J, Feuerstein IM, et al. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation 1998; 98:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/11\">",
"      Sechtem U, Tscholakoff D, Higgins CB. MRI of the normal pericardium. AJR Am J Roentgenol 1986; 147:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/12\">",
"      Breen JF. Imaging of the pericardium. J Thorac Imaging 2001; 16:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/13\">",
"      Gatzoulis MA, Munk MD, Merchant N, et al. Isolated congenital absence of the pericardium: clinical presentation, diagnosis, and management. Ann Thorac Surg 2000; 69:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/14\">",
"      Kojima S, Yamada N, Goto Y. Diagnosis of constrictive pericarditis by tagged cine magnetic resonance imaging. N Engl J Med 1999; 341:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/15\">",
"      White CS. MR evaluation of the pericardium and cardiac malignancies. Magn Reson Imaging Clin N Am 1996; 4:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/16\">",
"      Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 1992; 182:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/17\">",
"      Francone M, Dymarkowski S, Kalantzi M, Bogaert J. Real-time cine MRI of ventricular septal motion: a novel approach to assess ventricular coupling. J Magn Reson Imaging 2005; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/18\">",
"      Rokey R, Vick GW 3rd, Bolli R, Lewandowski ED. Assessment of experimental pericardial effusion using nuclear magnetic resonance imaging techniques. Am Heart J 1991; 121:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/19\">",
"      Smith WH, Beacock DJ, Goddard AJ, et al. Magnetic resonance evaluation of the pericardium. Br J Radiol 2001; 74:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/20\">",
"      Watanabe A, Hara Y, Hamada M, et al. A case of effusive-constructive pericarditis: an efficacy of GD-DTPA enhanced magnetic resonance imaging to detect a pericardial thickening. Magn Reson Imaging 1998; 16:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/21\">",
"      Casolo F, Biasi S, Balzarini L, et al. MRI as an adjunct to echocardiography for the diagnostic imaging of cardiac masses. Eur J Radiol 1988; 8:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/22\">",
"      Semelka RC, Shoenut JP, Wilson ME, et al. Cardiac masses: signal intensity features on spin-echo, gradient-echo, gadolinium-enhanced spin-echo, and TurboFLASH images. J Magn Reson Imaging 1992; 2:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/23\">",
"      Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/24\">",
"      Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003; 361:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/25\">",
"      Ingkanisorn WP, Rhoads KL, Aletras AH, et al. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol 2004; 43:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/26\">",
"      Thiele H, Kappl MJ, Conradi S, et al. Reproducibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging. J Am Coll Cardiol 2006; 47:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/27\">",
"      Kim RJ, Albert TS, Wible JH, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 2008; 117:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/28\">",
"      Ibrahim T, B&uuml;low HP, Hackl T, et al. Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. J Am Coll Cardiol 2007; 49:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/29\">",
"      Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998; 98:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/30\">",
"      Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/31\">",
"      Taylor AJ, Al-Saadi N, Abdel-Aty H, et al. Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging. Circulation 2004; 109:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/32\">",
"      Baks T, van Geuns RJ, Biagini E, et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006; 47:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/33\">",
"      Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 2005; 46:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/34\">",
"      Kumar A, Abdel-Aty H, Kriedemann I, et al. Contrast-enhanced cardiovascular magnetic resonance imaging of right ventricular infarction. J Am Coll Cardiol 2006; 48:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/35\">",
"      Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/36\">",
"      Fieno DS, Kim RJ, Chen EL, et al. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000; 36:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/37\">",
"      Gerber BL, Rochitte CE, Bluemke DA, et al. Relation between Gd-DTPA contrast enhancement and regional inotropic response in the periphery and center of myocardial infarction. Circulation 2001; 104:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/38\">",
"      Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002; 105:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/39\">",
"      Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001; 357:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/40\">",
"      Choi KM, Kim RJ, Gubernikoff G, et al. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 2001; 104:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/41\">",
"      Hillenbrand HB, Kim RJ, Parker MA, et al. Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Circulation 2000; 102:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/42\">",
"      Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998; 98:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/43\">",
"      Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/44\">",
"      Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004; 110:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/45\">",
"      Ichikawa Y, Sakuma H, Suzawa N, et al. Late gadolinium-enhanced magnetic resonance imaging in acute and chronic myocardial infarction. Improved prediction of regional myocardial contraction in the chronic state by measuring thickness of nonenhanced myocardium. J Am Coll Cardiol 2005; 45:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/46\">",
"      Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003; 108:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/47\">",
"      G&ouml;tte MJ, van Rossum AC, Marcus JT, et al. Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J Am Coll Cardiol 2001; 37:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/48\">",
"      Abraham TP, Nishimura RA. Myocardial strain: can we finally measure contractility? J Am Coll Cardiol 2001; 37:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/49\">",
"      Geskin G, Kramer CM, Rogers WJ, et al. Quantitative assessment of myocardial viability after infarction by dobutamine magnetic resonance tagging. Circulation 1998; 98:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/50\">",
"      Gunning MG, Anagnostopoulos C, Knight CJ, et al. Comparison of 201Tl, 99mTc-tetrofosmin, and dobutamine magnetic resonance imaging for identifying hibernating myocardium. Circulation 1998; 98:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/51\">",
"      Yan AT, Shayne AJ, Brown KA, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006; 114:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/52\">",
"      Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J 2007; 28:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/53\">",
"      Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002; 346:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/54\">",
"      Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010; 122:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/55\">",
"      Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 1990; 323:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/56\">",
"      Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation 2003; 107:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/57\">",
"      Cury RC, Shash K, Nagurney JT, et al. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation 2008; 118:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/58\">",
"      Wahl A, Paetsch I, Gollesch A, et al. Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J 2004; 25:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/59\">",
"      Hundley WG, Hamilton CA, Thomas MS, et al. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation 1999; 100:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/60\">",
"      Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 1999; 99:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/61\">",
"      Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998; 31:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/62\">",
"      Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004; 109:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/63\">",
"      Kuijpers D, Ho KY, van Dijkman PR, et al. Dobutamine cardiovascular magnetic resonance for the detection of myocardial ischemia with the use of myocardial tagging. Circulation 2003; 107:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/64\">",
"      Al-Saadi N, Nagel E, Gross M, et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation 2000; 101:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/65\">",
"      Schwitter J, Nanz D, Kneifel S, et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation 2001; 103:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/66\">",
"      Al-Saadi N, Nagel E, Gross M, et al. Improvement of myocardial perfusion reserve early after coronary intervention: assessment with cardiac magnetic resonance imaging. J Am Coll Cardiol 2000; 36:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/67\">",
"      Rieber J, Huber A, Erhard I, et al. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve. Eur Heart J 2006; 27:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/68\">",
"      Paetsch I, Jahnke C, Wahl A, et al. Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. Circulation 2004; 110:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/69\">",
"      Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol 2006; 47:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/70\">",
"      Klem I, Heitner JF, Shah DJ, et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 2006; 47:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/71\">",
"      Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012; 379:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/72\">",
"      Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 2007; 115:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/73\">",
"      Schiebler M, Axel L, Reichek N, et al. Correlation of cine MR imaging with two-dimensional pulsed Doppler echocardiography in valvular insufficiency. J Comput Assist Tomogr 1987; 11:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/74\">",
"      Soriano CJ, Ridocci F, Estornell J, et al. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. J Am Coll Cardiol 2005; 45:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/75\">",
"      McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/76\">",
"      Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/77\">",
"      Arriv&eacute; L, Assayag P, Russ G, et al. MRI and cine MRI of asymmetric septal hypertrophic cardiomyopathy. J Comput Assist Tomogr 1994; 18:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/78\">",
"      Sardanelli F, Molinari G, Petillo A, et al. MRI in hypertrophic cardiomyopathy: a morphofunctional study. J Comput Assist Tomogr 1993; 17:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/79\">",
"      Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/80\">",
"      Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/81\">",
"      Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/82\">",
"      Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008; 112:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/83\">",
"      Deborah Chirnomas S, Geukes-Foppen M, Barry K, et al. Practical implications of liver and heart iron load assessment by T2*-MRI in children and adults with transfusion-dependent anemias. Am J Hematol 2008; 83:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/84\">",
"      Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006; 91:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/85\">",
"      Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 2008; 141:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/86\">",
"      Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120:1961.",
"     </a>",
"    </li>",
"    <li>",
"     Link, K, Szczesniak, D, Lesco, N. Imaging of the valves and great vessels. In: Cardiac imaging, 2nd ed, Scorton, D, Schelbert, H, Wolf, G, Brundage, B (Eds), WB Saunders, Philadelphia 1996. p.708.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/88\">",
"      von Kemp K, Beckers R, Vandenweghe J, et al. Echocardiography and magnetic resonance imaging in cardiac amyloidosis. Acta Cardiol 1989; 44:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/89\">",
"      Celletti F, Fattori R, Napoli G, et al. Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging. Am J Cardiol 1999; 83:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/90\">",
"      Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 2005; 46:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/91\">",
"      Pflugfelder PW, Landzberg JS, Cassidy MM, et al. Comparison of cine MR imaging with Doppler echocardiography for the evaluation of aortic regurgitation. AJR Am J Roentgenol 1989; 152:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/92\">",
"      Yoshida K, Yoshikawa J, Hozumi T, et al. Assessment of aortic regurgitation by the acceleration flow signal void proximal to the leaking orifice in cinemagnetic resonance imaging. Circulation 1991; 83:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/93\">",
"      Caduff JH, Hernandez RJ, Ludomirsky A. MR visualization of aortic valve vegetations. J Comput Assist Tomogr 1996; 20:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/94\">",
"      John AS, Dill T, Brandt RR, et al. Magnetic resonance to assess the aortic valve area in aortic stenosis: how does it compare to current diagnostic standards? J Am Coll Cardiol 2003; 42:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/95\">",
"      Lin SJ, Brown PA, Watkins MP, et al. Quantification of stenotic mitral valve area with magnetic resonance imaging and comparison with Doppler ultrasound. J Am Coll Cardiol 2004; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/96\">",
"      Djavidani B, Debl K, Lenhart M, et al. Planimetry of mitral valve stenosis by magnetic resonance imaging. J Am Coll Cardiol 2005; 45:2048.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/98\">",
"      Srichai MB, Junor C, Rodriguez LL, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J 2006; 152:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/99\">",
"      Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 2002; 106:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/100\">",
"      Barkhausen J, Hunold P, Eggebrecht H, et al. Detection and characterization of intracardiac thrombi on MR imaging. AJR Am J Roentgenol 2002; 179:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/101\">",
"      Ohyama H, Hosomi N, Takahashi T, et al. Comparison of magnetic resonance imaging and transesophageal echocardiography in detection of thrombus in the left atrial appendage. Stroke 2003; 34:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/102\">",
"      Mohrs OK, Nowak B, Petersen SE, et al. Thrombus detection in the left atrial appendage using contrast-enhanced MRI: a pilot study. AJR Am J Roentgenol 2006; 186:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/103\">",
"      Corti R, Osende JI, Fayad ZA, et al. In vivo noninvasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol 2002; 39:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/104\">",
"      Hatsukami TS, Ross R, Polissar NL, Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 2000; 102:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/105\">",
"      Yuan C, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001; 104:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/106\">",
"      Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/107\">",
"      Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/108\">",
"      Rofsky NM, Adelman MA. MR angiography in the evaluation of atherosclerotic peripheral vascular disease. Radiology 2000; 214:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/109\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/110\">",
"      Simpson IA, Sahn DJ. Adult congenital heart disease: use of transthoracic echocardiography versus magnetic resonance imaging scanning. Am J Card Imaging 1995; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/111\">",
"      Hirsch R, Kilner PJ, Connelly MS, et al. Diagnosis in adolescents and adults with congenital heart disease. Prospective assessment of individual and combined roles of magnetic resonance imaging and transesophageal echocardiography. Circulation 1994; 90:2937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/112\">",
"      S&oslash;rensen TS, K&ouml;rperich H, Greil GF, et al. Operator-independent isotropic three-dimensional magnetic resonance imaging for morphology in congenital heart disease: a validation study. Circulation 2004; 110:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/3/34874/abstract/113\">",
"      Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation 2006; 113:405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5314 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34874=[""].join("\n");
var outline_f34_3_34874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8169189\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GATING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AORTIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PERICARDIAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36991928\">",
"      MYOCARDIAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36991943\">",
"      Gadolinium contrast techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36992798\">",
"      - Late gadolinium enhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36992805\">",
"      Infarct detection and sizing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36992887\">",
"      Myocardial viability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36992969\">",
"      Prediction of post-MI mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36992976\">",
"      Chest pain without significant coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36993816\">",
"      - Detection of diffuse myocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36993685\">",
"      CMR characterization of myocardial diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pharmacologic stress CMR",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dobutamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adenosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adenosine plus dobutamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CMR after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36995756\">",
"      Coronary MR angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ischemic versus nonischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Restrictive cardiomyopathy versus constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Acute myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      VALVULAR HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21658413\">",
"      Regurgitant valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21658406\">",
"      Stenotic valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21658399\">",
"      Myocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36993959\">",
"      INTRACAVITARY THROMBUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PERIPHERAL ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      CONGENITAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8169189\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5314|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/49/16144\" title=\"diagnostic image 1\">",
"      Aortic dissection on magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/40/24199\" title=\"diagnostic image 2\">",
"      Late gadolinium enhancement in myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/55/41842\" title=\"diagnostic image 3\">",
"      MRI myocardial viability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/48/40705\" title=\"diagnostic image 4A\">",
"      Dobutamine stress CMR predicts viable myocardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/20/13634\" title=\"diagnostic image 4B\">",
"      Dobutamine stress CMR predicts lack of viable myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5314|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/41/8850\" title=\"figure 1A\">",
"      Cardiac plane definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/55/26487\" title=\"figure 1B\">",
"      LV segmentation I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/9/16533\" title=\"figure 1C\">",
"      Coronary artery territories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/22/18795\" title=\"table 1\">",
"      Utility of cardiac MRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_3_34875="Prog brain mets trip-neg BC";
var content_f34_3_34875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognosis of patients with brain metastases from triple-negative breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Study",
"      </td>",
"      <td class=\"subtitle1\">",
"       Time period",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of patients",
"      </td>",
"      <td class=\"subtitle1\">",
"       Median survival after CNS recurrence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dawood et al",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td>",
"       1980-2006",
"      </td>",
"      <td>",
"       42",
"      </td>",
"      <td>",
"       2.9 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lin et al",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"      <td>",
"       2000-2006",
"      </td>",
"      <td>",
"       53",
"      </td>",
"      <td>",
"       4.9 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eichler et al",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"      <td>",
"       2001-2005",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       4.0 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nam et al",
"       <sup>",
"        [4]",
"       </sup>",
"      </td>",
"      <td>",
"       2001-2006",
"      </td>",
"      <td>",
"       47",
"      </td>",
"      <td>",
"       3.4 months",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"     1. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20:621.",
"     <br>",
"      2. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638.",
"      <br>",
"       3. Eichler AF, Kuter I, Ryan P, et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359.",
"       <br>",
"        4. Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008; 10:R20.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34875=[""].join("\n");
var outline_f34_3_34875=null;
var title_f34_3_34876="Liveborn chromosome abn rate";
var content_f34_3_34876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chromosomal abnormalities among live births",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Total livebirths",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        103,069",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Male livebirths",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        61,484",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Female livebirths",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        41,585",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Type of abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Autosomal trisomies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        47, +21",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        1/730",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        47, +18",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        1/5,424",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        47, +13",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1/17,178",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Sex chromosome abnormalities - males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        47, XXY",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        1/842",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        47, XYY",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        1/931",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Sex chromosome abnormalities - females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        47, XXX",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        1/924",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        45, X",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1/2,772",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Structural abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Balanced",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        1/490",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Unbalanced",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        1/1,516",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left indent1\" colspan=\"2\">",
"        Total abnormalities",
"       </td>",
"       <td>",
"        736",
"       </td>",
"       <td>",
"        1/140",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hsu, LYF. Prenatal diagnosis of chromosomal abnormalities through amniocentesis. In: Genetic Disorders and the Fetus, 4th ed, Milunsky, A (Ed), The Johns Hopkins University Press, Baltimore 1998. p. 180.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34876=[""].join("\n");
var outline_f34_3_34876=null;
var title_f34_3_34877="Mortality stage IA IIIB HL";
var content_f34_3_34877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Causes of death in stage IA-IIIB Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 230px; background-image: url(data:image/gif;base64,R0lGODlhJQHmAOYAAP///4CAgP+AgICZzJC5nAAAAP/MmQAzmUBAQMDAwP8AAP9AQEBms//AwMDN5sjcziAgICBzOVBQUHBwcKCz2f+ZM7CwsNDQ0DAwMKCgoBAQEPDw8ODg4BBAn/Dz+ViWa1BzuZCQkP/mzWBgYP8QEHCNxv+wsDBZrP9QUNDZ7CBNpn9MGf8wMP9gYLDA3//g4GCAv/+goP+zZv/w8P8gII85HBA5HOTu5/9wcP/Q0JCm07+MWeDm8/+QkKzLtX8AAGafdy58Rf+sWf/fwP/Zs495XP9MGf/s2UqNXv+fQMepaIKwkDyFUp7Cqf+mTf/589bl27rUwnSohIBAQL9NZv/z5lB5XP+5c/+MWf/Gjf+/gP/Tpk85HFdWKr+AgL9AQIBmTcfDm7+mjEdcTvL38wgcDhhWKgAZTIAQEMdcToicjjAyOb9yJldmOgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAlAeYAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZmCYCAiagCzja48gzLAoL5wKf6OTuxAIK4gA53y8tCy05gg34+gAmUCzoISiGNxQo9gEQkK/du4e/YihAJ2DfCxIsBJAgAaCBgowLvClAgUMegAUKaJyjAaAkingLIMrspXGighg9FLRgqKABCgUvBL34OQMAC44oBZ0DQIIlAIczo9oqSq9kSJ3dBLxIOohrUq8KnsYUK7UsLYYx+imo+NFEAxw5/3K2aNAtp0gUJ8PmzWtC4lizgF01QJlyHcBzH4MKoKGAxDccJEYWBUuPMcq/gTNr3sy5s+fPoEOLPpXgwqANGQJk2DA6Fd2sWRtsCgcgxgKF0S4EKIBgEAbeBTC0RsUQdjfZmtrRDSoNQQHegiwUkABAQgELw011iyTA4IIYORAW9blgoCDlWukh7PbihTccIQuWR2HvfXwAL+DT5xbUINVUCUAHwG4BDFhAgQAkEMCCASSQXSfbQTLRUSmd08JCO6EUA1nxNHARCTw14BE6kW1I0mJAjbhAiTNsJAA+EhHUFCsB9mZggQQKouCCCCD4oCYRPtJOh2TN0AMK6nDYU/88G3bo0TomrIUfQ4yJKGWUAuS0IX4tshAlQavUKEgIBUwAwAQFhGDIgj9uEqQjQ/ZE1lE92KUkXXI6KeWTF7EQQws9PdnRWkQOAug5/6FyAZkYJLABBwVAkAAEBXCwpo9tXvJmI3HK1k5Kb0nZaZQoDBbonmt5VCpKVq7zZA4fNRADXiPitYpzzxXgYAaUQpDBIWxmismmjHRKlkToiBoTkSVhdKqrUgLqbKuDQomYYYx940uwwlpC7Cg9NGACopzMkBIw3HZLybeiMNZWJ3b+kq66krBLLyLz3vuIvfoWkm+/iLxWHMCM/EtwIcUdd7AiBi8sCL8OC9KwwxBHPPH/whU7fPHBGS+8McEdH+KAA4Lw4AAPi6TAAAWIMFACISqzbM3HAIdsyAEHCDLAAQMs4gDPiBzAACE8DEDyzJhGTIjNheCsM9AelMAADCkI4gEMDIAANdYDGA2A0ACkMIALRZM8AAU6TO0BNDT3yzQhOHfNANAndDBA3SifcEAJMNC9d989C+1BByd48HPgB5ygwgEwsJ200g8bNgnOlPOcwt4AuHCADpc3fvjPngMtNAMdVH3410N7APYzbdNL132T5wzAzkYD/bntPJ9+Os6Lk7z70Kg7DvnSISEX+9M9d6CCA1qnMPjyJfCsOvSin3C5CoaLDvzqzrQelQNdhy/+//jkj08FFeWTf/QhTs8OdAp6qyAzBR0IDTT99gc+9M4g/C4I983w3kwGwID0GbB85ztg+NbHCQqMTGsukIkAZdK1YUlOFX07gAp6JsHHdaaCmrrg8C41GhB6S4QjJMQEswG+8RXQgpaIWSakBpEVYoOA6oNhJU6HibnV0INlMSEn3kaIw3ngbAAoWgTPRkAKpAAEIFgbBYymNgDMzQVQrBoA0gaCCAIAfFiMYhMFIbWpaVEYNryGEC8hMNhN4nQq6MAWD8AynNVNg3pr3NxgED0QWBGPGgRA9EoAQfcR7gCEqx/KNlgC5YliAr8CQAiASIk0WmON3gqJwnYItJ25oP9u/9vfAUgGNh8CQG9/FAQqCQcA1flxZ6QUpe+kVj9QbCABGBhBAhIgARtpwpLKaGH6XggkFFLidDxIHOaCB8vgmdKHz8zZ6sDWTGqOUnNdROUnApSr54yAE8BMBg4NyMAQaoKHczuAFq0Zyz86QAcH8GM0AQDBnenAfe2EJe1csDhQcCAAEOhRAELAmk2EExmYBAURRQY0AFAgcYNgpzM1KLhUptIDWuvAy/DJzFF6IH79DMUFLPWJgx4joZ9Y6CKiJ7NFmHIYGdBArnyZCZMSA3zEJIVKFdGBDqyNES8VhkwRQFQzGZSSlyxgOUOxU4howKiesOkwUOqJ1xnzMxP/+GZJkVoNqkKoeNnB1XNoigmp7kKY4cvpKJoqkwkQtajg5Gozxim+pSr0qikkoRo5uAq2QuQCv5mUmo56Q76qwq8PwYAGNJAAt8Z1GmhVayoQ+47rIEBBZL2EWWtBV6+xgrLu0EAIEGABCGj1l3I9qWFdAVpy7CZXDiKsNLzaCYEZpxtuHM5oJYCdx852taJI2G03mZ0AUIcDpPVtNGg7RLxmSgORHEFmLbHZWLRQssF1bpt0JbHpVqK6sBinXe9KMAxgwAIWeKpy5wpcnWr3R9J5jgZIilpoMNcTrQXMP0NA3/oKA63DbC8oXpNbek0Aqp0Aryg6m77xplSTxtOX/3RBoeBQ3PcU+Q1MCDTAoEj6NxgX1s57MyVWAX0YGCEuRYYBc4Fd7tI0sgWxgD874kxZIAD/hPGJawFg8WHXNbApsL7QpCsJnLamqWUFg+v6CuEKIMIA08AIGhUA71Yyyai47oxhseLN6OqyE47xLMSbiy5rBgEYgIB1BrtjVxjOBT+uhZkzcwGZBqegbc6y1PSWOJc5eBZz1kxpoorlTxDQBQ746S8CDZgNuJW3CS60J1J8lhqrq8S9zfMpKA1oS3frQADYAAasPIkKL4LTsmC0WSA9IOqIWRUl2KgwVF2WEQQUARAIKIKpK+kG0hEenhZWiceqaVI8tKWzDnZeH/9hakTE2hi01livNYHqTi97Ei7eJbCmbQktQ1vZ1+5mAbadChDAoGt/5kW0zYLnRzzHxeQ+heoUTQyrLntSAWj3IsYqgdgmiEE9QgUF/HiM4kAZcsgtgAYyvQgJBGAECifpjqrMbUqAANnAvjYhtA0J5/h7EM222gHonfEUjgDHksDlwxWu7wFVXBIDT8a6pYIrCXi4ERz4TXB0rMKXR6IEW86FbQeWVwuMQKZP7S+vT8GAdOPCyU9ettG7SWpIhBwAKjgjMGaeGVxhIAMcyMCuv+tzSMgu2RofxAgmoPRidyIFKih52jMQW/SuVxQOAN4uhk70tAf8TFWPRMgHIGv/XUA96hrnZjdd7XZOnADjTwf3wi6AAA3cWgI8L2vZG+EAOdJE8g6jO4U3z4hz+4LrnXFUi12cec2SXhHJRJnQsyLktH+Z6nc3dOMMr0nEp91fYWeQanLviQ44vcmg/z2SQfFmGJxA3cl3mLiJ/WpLUABrfD6Bn2fBd9xGf2FvDf/Yl56Jh5YA0SQHdO+Nc3DlnyKcx4a++ydxgV7CtfqTeLb8mXGDJhDAB2QACT7wAVAABR/gA7+gc9TXeI7AAF60C6gHCj4QARQYAR8ACQQQAQ9wAwTwAL9QABkwbidHfJLQdJ+3Cw9AACq4gh14CDcQAUHggVBAAAAwgB8ABFEA/wAc+ABRgIBQAAQf8AEauIM1GIQ4KAg3sAQ3mIOxoCuS4lj4JwkdIHsQ+H2jQAAfwIIq6IGG0AQRsASFAARLQABMEAE38AAwaIE3EARBgIUaiIY0KIZkaIZkwIYEIAUXGAsQsHLTQYKRcHZVuAsq6AgZSIOEwIEfUIYPgIZgCABeiIAZuIgRQIOIqIiPiISycAEXsAESIAEtR36WwAOeVwt8V3uzMIiNMIF5qINriAQ+IAVvOImCEIkAEIlw2IqvqIG0SAuiBwB2F4WQkHe3QAM7wX6CaIiNUIZZCIRoCAQPIISSaIjN+Iyx2IER4IzQCAURgAQP4ANAIAt/B4UMyP8IcGYLJuAUwYCKjXADQECBTNAEAACLQYAE1TgISwCD9BiN8YiPGggAUUCPsvgKipcrjLd8l1BtovAdw6COZUF5lkdUmOeHjwAC90QLDcARC4mMgNGLhIYJpVMLpniMZxZ4V3YJKTCKsnCRiQIMDGkWVTZ6l6ADBDcLO1EMLVkWaPJW40d2l0CRtHARK8mSGmkWJUaSzOZzH0mTF2KTQ2kxL3eSPwkUrZCCWliVVqmFWbgZusFfkWYJBEQLLbCUrICFV1mWVsmFgRGC8tV6oAhzvyYLLcIcY9mU6qIB/WYBGFCQmkcJ8QdoYjmXqVAFBmAARHAIRyADhbkM3DUgRun/CBPUl3BJAu2HCjcpCkRQAU4gBBUgBE8AAAZQASIAACJQAQbADGkWABOgXsCYCJCZapgBmKZQBZjZmVtQAVpQBTJgm0QwmlmQBTJQmgDwBAYgA1cwBKJpAEewm7xQZ8+BAZ/Ik5DQmrIgmbBQmaBQm1kgCE9QAUlwBE6wmVkwmhUgA0lQAYUpBElgAJp5BJ9ZnsDJC4PWlY8gnbFgG6FAlWa5gllpCp/5nhVQAZ4JmqJJmgAwBKR5BONpAFpAmp9pnLvAAdn2YhJZCB6gAhVZCzSgLZ9Alvm5gmiJCCIwmCI6oiRKoqFpCAZ6BYKAoEIQoKE5mqUJo6P5m4MZogK6/wuvhXurWQhfmZJZ0QLouKF0SQnDWaJGaqKIoJkGMASaaZz9KQIwOqClmQRJsJtbQASfeaK68Fqjdn/jmETGp35ZoaFCugmDuQlPoAXlKQQOWgXfeQVRGqVHcAX/6QRDkKW8sAEAJWVs6XqOAAO7l2pW2AjWOQlnmh1kMm7y6TNTCAttNKiIgJ/7mQmHOhoW4BwQwGY7KghxNlm9N5mawKEtqAkGsAPCd6qouiAf9w6vJVDDt6kUgD2xoGqFagkGsAKumqqouqqDAKHwhi9EFQmUd3OxkKMzNaFWdKFAFmSQugi1Wgm3unnGiggh6HCN4ByC8E+8+gq+mm19WpKLkP+Uh7V+vkcJ+Jmfk8oJ0aoJYgIAqWEBnThSzqFLCdJLE1BQGWCvpXUgCaCtoeZWIwBjqjFaI/Ccw3AxUEljnSCq+fmhlBCiJCoDK0B67YqpvwEBF0ApXycdEoAm1LEbDmdaQ0V3oKZYAaBYltKclHJkxzAxUTOTo1CKzVqLQ/oJRUqiYECxAoKtAPAbBuIg1rEglAIAlicIG7ABPBsgAXABZeKLaQIA0LEBJoYMBoNF8XR8mXB4oEoJz6qu7wlyOmsjPIutu+EgziF8UEtTScuvoKa0aSsIU9uyQLRB6Zddh3CuHdqh6ToKlQq2mcABjGK2ikq23EUmd/lNa8ZLCeD/HBbQYqBmebxUAKYhIHFrDP8Sq6dAYMbEsHnbsKfQtxIjrd0EAGM7bmUrMZTShxtwdJHCAemVJm4LWJESSZTbmLzwL/JzCutRroPQta0wcam6A6Z6qn83f/mCuadAArhBCFS5t7RAcboqvKm6rRqXLytzCjmAkYbAoQ77vJQEuvPnL0kzb6fQA6/ZuzXrChA7mMJ7pEUavokwLzFnCi1CpoTgu6pws6W6A+5rAFoKv+JbCBenu7ZyCPibCpV6dQSTLuRbCiZAAkGJvreQwK93bekik6MwcWgwBbq6IFZgBR0cwiI8wiQsvTxSwcsWLBjVAQ9IYQgwBjYQwzI8wzJs/wYgTMI4jKpgsAI83MM+/MM/zAbDq6oALAls4gIdEEUDlhVTMAVF0AZ5273qSqP9e6T/W8RGXCAgEHSHALwhrAZFUANizAVc0AXpy59fi8WmwCbiymwIMAU/EMdyPMdxXMZFoIVSjMBprMaksCBQ6cUj3CPClQZiXMhi3AVFsLWNsL5V3Mgj+pt8jAoLgsHQm8MJECScu4WYoL+O3MlXHMmisCA++S94q4VFUARhMJhKoASd3MoiCsmgTAwL8pH/wqFhbMhiXARKQMWu3MufHMvbsgZncMIGTAAhigVGkMzKbARYAMvA7JJlMMNWkMokusoyIANYgAVW/MyAEQBjoP+Fu2zFEcjNaJSrAWDCqfoFX5DD7NzO7vzO8BzPI0y99FLJCyIGYtDBXuAF7kxU8pzD/vzPOBzQAh3IKJwZptZsIbfQBx0YCd3QetXHEB3RCzzRfivRa2zRPecwHCcKHe3R9NwJHw3S5FzSJn3SKJ3SKq1xqKEaBtsL8RlqqbEaxAC4A1VQLU3T9/IbziEcw6AbJsbTwUEMYuXTQu3T6sKx1XEdw4ArNqLU1sFwv2ABR0spCQDVTK0uOZIjw9CuWw1qxUAp/wRqXN0tX63RoeDVZA3Ww0AmZnLW9OLWZ/K0XS0gco0mmgoMaKJVd03X3QIpkiLWPx24jxIpk1Ipw2DqHXvYIIB92G3XJrwyu0TdTbvSK8T6gd1UIJHtKyvd2Z792aAd2qI92qRd2qZ92qid2l3dr4LQYo+t2qwatYv10rCtDRtAKTf2tHqKAKzmVggQsP92AaI3WgjAdrXNDNKhsYJgsr9hGnuYmhBgIDK1chNwsiF93MKAK6bBtD0CcQXSWJVnulltHQ533dgdDO1aIwxy1dOBl+IdW6urc1J93sXQrkQLXQkQAqlxIPv6s4IwAiHQWH5N38Zg3/X3HBBA1Rc7tKc7IEi3kwQe4RI+4RRe4RZ+4Rie4Rq+4Rze4R7+4SAe4iL+e4EAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Competing causes of death in 794 patients with laparoscopically-stage IA-IIIB Hodgkin lymphoma. Deaths from Hodgkin lymphoma primarily occurred in the first five to ten years and tended to plateau after 15 years, while deaths from second malignancy primarily occur after ten years and continued to increase with time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Mauch, PM, Kalish, LA, Marcus, KC, et al, Cancer J Sci Am 1995; 1:33.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34877=[""].join("\n");
var outline_f34_3_34877=null;
var title_f34_3_34878="Drugs and photosensitivity";
var content_f34_3_34878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some agents that may cause photosensitivity reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anticancer drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dacarbazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluorouracil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flutamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vinblastine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amitriptyline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoxapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clomipramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desipramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Doxepin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Imipramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Maprotiline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenelzine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Protriptyline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trazodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimipramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antimicrobials",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ciprofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clofazimine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dapsone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Demeclocycline*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Doxycycline*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enoxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flucytosine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Griseofulvin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lomefloxacin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Minocycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nalidixic acid*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Norfloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oxytetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyrazinamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethopterin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antiparasitic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antipsychotic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorpromazine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluphenazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Haloperidol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Perphenazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prochlorperazine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thioridazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiothixene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trifluoperazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Triflupromazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetazolamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amiloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bendroflumethiazide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzthiazide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorthiazide*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Furosemide*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrochlorothiazide*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydroflumethiazide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methyclothiazide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metolazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polythiazide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimterene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trichlormethiazide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypoglycemics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetohexamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorpropamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glipizide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glyburide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tolazamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tolbutamide*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            NSAIDs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Difluisal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ibuprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Indomethacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ketoprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nabumetone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Naproxen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylbutazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Piroxicam*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulindac",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Sunscreens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aminobenzoic acids*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Avobenzone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzophenonones*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cinnamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Homosalate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menthyl anthranilate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            PABA esters*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antihistamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyproheptadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diphenhydramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anthypertensives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Captopril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diltiazem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methyldopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Minoxidil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nifedipine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Others",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alpazolam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amantadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amiodarone*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzyl peroxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bergamol oil, oils of citron, lavender, lime, sandalwood, cedar*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlordiazepoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clofibrate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desoximetasone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disopyramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Etretinate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoroscein",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gold salts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hexachlorophene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isotretinoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6-methylcoumRIN*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Musk ambrette*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Promethazine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinidine sulfate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tretinoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimeprazine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reactions which occur more frequently",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from The Medical Letter 1995; 37:35.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34878=[""].join("\n");
var outline_f34_3_34878=null;
var title_f34_3_34879="Infected dog bite";
var content_f34_3_34879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An infected dog bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the sutured hand wounds, including the puncture wound at the base of the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ludwig S. Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_3_34879=[""].join("\n");
var outline_f34_3_34879=null;
